U.S. patent application number 15/163750 was filed with the patent office on 2016-09-15 for cyclic protein tyrosine kinase inhibitors.
The applicant listed for this patent is BRISTOL-MYERS SQUIBB COMPANY. Invention is credited to Joel C. Barrish, Ping Chen, Jagabandhu Das, Arthur M.P. Doweyko, Derek Norris, Ramesh Padmanabha, John Wityak.
Application Number | 20160264537 15/163750 |
Document ID | / |
Family ID | 22440334 |
Filed Date | 2016-09-15 |
United States Patent
Application |
20160264537 |
Kind Code |
A1 |
Das; Jagabandhu ; et
al. |
September 15, 2016 |
CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
Abstract
Novel cyclic compounds and salts thereof, pharmaceutical
compositions containing such compounds, and methods of using such
compounds in the treatment of protein tyrosine kinase-associated
disorders such as immunologic and oncologic disorders.
Inventors: |
Das; Jagabandhu;
(Mercerville, NJ) ; Padmanabha; Ramesh; (Hamden,
CT) ; Chen; Ping; (Hillsborough, NJ) ; Norris;
Derek; (Pennington, NJ) ; Doweyko; Arthur M.P.;
(Long Valley, NJ) ; Barrish; Joel C.; (Richboro,
PA) ; Wityak; John; (Carlsbad, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
BRISTOL-MYERS SQUIBB COMPANY |
Princeton |
NJ |
US |
|
|
Family ID: |
22440334 |
Appl. No.: |
15/163750 |
Filed: |
May 25, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14620244 |
Feb 12, 2015 |
9382219 |
|
|
15163750 |
|
|
|
|
14226868 |
Mar 27, 2014 |
8993567 |
|
|
14620244 |
|
|
|
|
11271626 |
Nov 10, 2005 |
8716323 |
|
|
14226868 |
|
|
|
|
10378373 |
Mar 3, 2003 |
|
|
|
11271626 |
|
|
|
|
09548929 |
Apr 13, 2000 |
6596746 |
|
|
10378373 |
|
|
|
|
60129510 |
Apr 15, 1999 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 263/48 20130101;
A61P 37/00 20180101; C07D 417/06 20130101; C07D 213/82 20130101;
A61P 11/02 20180101; C07D 239/42 20130101; A61P 1/00 20180101; C07D
233/90 20130101; A61P 17/00 20180101; A61P 29/00 20180101; A61P
17/06 20180101; A61P 19/02 20180101; A61P 9/10 20180101; A61P 27/02
20180101; C07D 231/38 20130101; A61P 11/00 20180101; C07C 233/65
20130101; A61P 43/00 20180101; C07D 213/81 20130101; C07D 491/113
20130101; A61P 21/00 20180101; A61P 37/02 20180101; C07D 277/56
20130101; C07D 417/12 20130101; C07D 417/14 20130101; C07D 409/12
20130101; A61P 35/00 20180101; A61P 25/00 20180101; C07C 237/40
20130101; A61P 37/08 20180101; C07D 471/04 20130101; A61P 11/06
20180101; A61P 37/06 20180101; A61P 5/14 20180101 |
International
Class: |
C07D 277/56 20060101
C07D277/56; C07D 417/06 20060101 C07D417/06; C07D 491/113 20060101
C07D491/113; C07D 471/04 20060101 C07D471/04; C07D 213/81 20060101
C07D213/81; C07C 233/65 20060101 C07C233/65; C07D 239/42 20060101
C07D239/42; C07D 263/48 20060101 C07D263/48; C07D 213/82 20060101
C07D213/82; C07D 417/12 20060101 C07D417/12; C07D 417/14 20060101
C07D417/14 |
Claims
1. A cyclic compound of the following formula I or a salt thereof:
##STR00622## where Q is thiazole optionally substituted with
R.sub.1; Z is a single bond; X.sub.1 and X.sub.2 together form
.dbd.O; R.sub.1 is: (1) hydrogen or R.sub.6, where R.sub.6 is
alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl,
cycloalkenylalkyl, aryl, aralkyl, heterocyclo, or heterocycloalkyl,
each of which is unsubstituted or substituted with Z.sub.1, Z.sub.2
and one or more groups Z.sub.3; (2) --OH or --OR.sub.6; (3) --SH or
--SR.sub.6; (4) --C(O).sub.2H, --C(O).sub.qR.sub.6, or
--O--C(O).sub.qR.sub.6, where q is 1 or 2; (5) --SO.sub.3H or
--S(O).sub.qR.sub.6; (6) halo; (7) cyano; (8) nitro; (9)
--Z.sub.4--NR.sub.7R.sub.8; (10)
--Z.sub.4--N(R.sub.9)--Z.sub.5--NR.sub.10R.sub.11; (11)
--Z.sub.4--N(R.sub.12)--Z.sub.5--R.sub.6; (12)
--P(O)(OR.sub.6).sub.2; R.sub.2 is hydrogen, R.sub.6,
--Z.sub.4--R.sub.6 or --Z.sub.13--NR.sub.7R.sub.8; R.sub.3 is
--C(O)--NR.sub.7R.sub.8, wherein R.sup.7 is aralkyl, which is
unsubstituted or substituted with Z.sub.1, Z.sub.2 and one or more
groups Z.sub.3; R.sub.4 and R.sub.5: (1) are each independently
hydrogen or R.sub.6; (2)
--Z.sub.4--N(R.sub.9)--Z.sub.5--NR.sub.10R.sub.11; (3)
--N(R.sub.9)Z.sub.4R.sub.6; or (4) together with the nitrogen atom
to which they are attached complete a 3- to 8-membered saturated or
unsaturated heterocyclic ring which is unsubstituted or substituted
with Z.sub.1, Z.sub.2 and Z.sub.3, which heterocyclic ring may
optionally have fused to it a benzene ring itself unsubstituted or
substituted with Z.sub.1, Z.sub.2 and Z.sub.3; R.sub.8, R.sub.9,
R.sub.10, R.sub.11 and R.sub.12: (1) are each independently
hydrogen or R.sub.6; or (2) any two of R.sub.9, R.sub.10 and
R.sub.11 may together be alkylene or alkenylene completing a 3- to
8-membered saturated or unsaturated ring together with the nitrogen
atoms to which they are attached, which ring is unsubstituted or
substituted with Z.sub.1, Z.sub.2 and Z.sub.3; R.sub.13 is: (1)
cyano; (2) nitro; (3) --NH.sub.2; (4) --NHOalkyl; (5) --OH; (6)
--NHOaryl; (7) --NHCOOalkyl; (8) --NHCOOaryl; (9)
--NHSO.sub.2alkyl; (10) --NHSO.sub.2aryl; (11) aryl; (12)
heteroaryl; (13) --Oalkyl; or (14) --Oaryl; R.sub.14 is: (1)
--NO.sub.2; (2) --COOalkyl; or (3) --COOaryl; Z.sub.1, Z.sub.2 and
Z.sub.3 are each independently: (1) hydrogen or Z.sub.6, where
Z.sub.6 is (i) alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl,
alkylaryl, cycloalkylaryl, heterocyclo, or heterocycloalkyl; (ii) a
group (i) which is itself substituted by one or more of the same or
different groups (i); or (iii) a group (i) or (ii) which is
substituted by one or more of the following groups (2) to (16) of
the definition of Z.sub.1, Z.sub.2 and Z.sub.3; (2) --OH or
--OZ.sub.6; (3) --SH or --SZ.sub.6; (4) --C(O).sub.qH,
--C(O).sub.qZ.sub.6, or --O--C(O).sub.qZ.sub.6; (5) --SO.sub.3H,
--S(O).sub.qZ.sub.6; or S(O).sub.qN(Z.sub.9)Z.sub.6; (6) halo; (7)
cyano; (8) nitro; (9) --Z.sub.4--NZ.sub.7Z.sub.8; (10)
--Z.sub.4--N(Z.sub.9)--Z.sub.5--NZ.sub.7Z.sub.8; (11)
--Z.sub.4--N(Z.sub.10)--Z.sub.5--Z.sub.6; (12)
--Z.sub.4--N(Z.sub.10)--Z.sub.5--H; (13) oxo; (14)
--O--C(O)--Z.sub.6; (15) any two of Z.sub.1, Z.sub.2, and Z.sub.3
may together be alkylene or alkenylene completing a 3- to
8-membered saturated or unsaturated ring together with the atoms to
which they are attached; or (16) any two of Z.sub.1, Z.sub.2, and
Z.sub.3 may together be --O--(CH.sub.2).sub.r--O--, where r is 1 to
5, completing a 4- to 8-membered ring together with the atoms to
which they are attached; Z.sub.4 and Z.sub.5 are each
independently: (1) a single bond; (2)
--Z.sub.1--S(O).sub.q--Z.sub.12--; (3)
--Z.sub.11--C(O)--Z.sub.12--; (4) --Z.sub.11--C(S)--Z.sub.12--; (5)
--Z.sub.11--O--Z.sub.12--; (6) --Z.sub.11--S--Z.sub.12--; (7)
--Z.sub.11--O--C(O)--Z.sub.12--; or (8)
--Z.sub.11--C(O)--O--Z.sub.12--; Z.sub.7, Z.sub.8, Z.sub.9 and
Z.sub.10: (1) are each independently hydrogen or Z.sub.6; (2)
Z.sub.7 and Z.sub.8, or Z.sub.6 and Z.sub.10, may together be
alkylene or alkenylene, completing a 3- to 8-membered saturated or
unsaturated ring together with the atoms to which they are
attached, which ring is unsubstituted or substituted with Z.sub.1,
Z.sub.2 and Z.sub.3; or (3) Z.sub.7 or Z.sub.8, together with
Z.sub.9, may be alkylene or alkenylene completing a 3- to
8-membered saturated or unsaturated ring together with the nitrogen
atoms to which they are attached, which ring is unsubstituted or
substituted with Z.sub.1, Z.sub.2 and Z.sub.3; Z.sub.11 and
Z.sub.12 are each independently: (1) a single bond; (2) alkylene;
(3) alkenylene; or (4) alkynylene; and Z.sub.13 is: (1) a single
bond; (2) --Z.sub.1--S(O).sub.q--Z.sub.12--; (3)
--Z.sub.11--C(O)--Z.sub.12--; (4) --Z.sub.11--C(S)--Z.sub.12--; (5)
--Z.sub.11--O--Z.sub.12--; (6) --Z.sub.11--S--Z.sub.12--; (7)
--Z.sub.11--O--C(O)--Z.sub.12--; (8)
--Z.sub.11--C(O)--O--Z.sub.12--; (9) --C(NR.sub.13)--; (10)
--C(CHR.sub.14)--; or (11) --C(C(R.sub.14).sub.2)--. providing that
said compound is other than (a) a compound of formula (ix)
##STR00623## where R.sub.2i is hydrogen or alkyl; R.sub.3i is
--C(O)--NH-(alk); and R.sub.58 and R.sub.59 are independently
hydrogen, alkyl or halogen.
2. A compound of claim 1, wherein R.sub.1 is hydrogen, halo, alkyl,
aryl, alkoxy, alkoxycarbonyl, or aryloxycarbonyl.
3. A compound of claim 2, wherein R.sub.1 is hydrogen.
4. A compound of claim 1, wherein R.sub.2 is hydrogen.
5. A compound of claim 1, wherein R.sub.4 is hydrogen.
6. A compound of claim 1, wherein R.sub.5 is an aryl group which is
substituted with Z.sub.1, Z.sub.2 and one or more groups
Z.sub.3.
7. A compound of claim 1 wherein R.sub.1 is hydrogen or alkyl,
R.sub.2 and R.sub.4 are independently hydrogen or alkyl, and
R.sub.5 is aryl which is unsubstituted or substituted with Z.sub.1,
Z.sub.2 and one or more groups Z.sub.3.
8. A compound of formula II or salt thereof: ##STR00624## where n
is 1; X.sub.3 is oxygen; A is nitrogen; B is sulfur R.sub.1 is: (1)
hydrogen or R.sub.6, where R.sub.6 is alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl,
aralkyl, heterocyclo, or heterocycloalkyl, each of which is
unsubstituted or substituted with Z.sub.1, Z.sub.2 and one or more
(preferably, one or two) groups Z.sub.3; (2) --OH or --OR.sub.6;
(3) --SH or --SR.sub.6; (4) --C(O).sub.2H, --C(O).sub.qR.sub.6, or
--O--C(O).sub.qR.sub.6, where q is 1 or 2; (5) --SO.sub.3H or
--S(O).sub.qR.sub.6; (6) halo; (7) cyano; (8) nitro; (9)
--Z.sub.4--NR.sub.7R.sub.8; (10)
--Z.sub.4--N(R.sub.9)--Z.sub.5--NR.sub.10R.sub.11; (11)
--Z.sub.4--N(R.sub.12)--Z.sub.5--R.sub.6; (12)
--P(O)(OR.sub.6).sub.2; R.sub.2 is hydrogen, R.sub.6,
--Z.sub.4--R.sub.6 or --Z.sub.13--NR.sub.7R.sub.8; R.sub.3 is
--C(O)--NR.sub.7R.sub.8, wherein R.sup.7 is aralkyl, which is
unsubstituted or substituted with Z.sub.1, Z.sub.2 and one or more
groups Z.sub.3; R.sub.4 and R.sub.5: (1) are each independently
hydrogen or R.sub.6; (2)
--Z.sub.4--N(R.sub.9)--Z.sub.5--NR.sub.10R.sub.11; (3)
--N(R.sub.9)Z.sub.4R.sub.6; or (4) together with the nitrogen atom
to which they are attached complete a 3- to 8-membered saturated or
unsaturated heterocyclic ring which is unsubstituted or substituted
with Z.sub.1, Z.sub.2 and Z.sub.3, which heterocyclic ring may
optionally have fused to it a benzene ring itself unsubstituted or
substituted with Z.sub.1, Z.sub.2 and Z.sub.3; R.sub.8, R.sub.9,
R.sub.10, R.sub.11 and R.sub.12: (1) are each independently
hydrogen or R.sub.6; or (2) any two of R.sub.9, R.sub.10 and
R.sub.11 may together be alkylene or alkenylene completing a 3- to
8-membered saturated or unsaturated ring together with the nitrogen
atoms to which they are attached, which ring is unsubstituted or
substituted with Z.sub.1, Z.sub.2 and Z.sub.3; R.sub.13 is: (1)
cyano; (2) nitro; (3) --NH.sub.2; (4) --NHOalkyl; (5) --OH; (6)
--NHOaryl; (7) --NHCOOalkyl; (8) --NHCOOaryl; (9)
--NHSO.sub.2alkyl; (10) --NHSO.sub.2aryl; (11) aryl; (12)
heteroaryl; (13) --Oalkyl; or (14) --Oaryl; R.sub.14 is: (1)
--NO.sub.2; (2) --COOalkyl; or (3) --COOaryl; Z.sub.1, Z.sub.2 and
Z.sub.3 are each independently: (1) hydrogen or Z.sub.6, where
Z.sub.6 is (i) alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl,
alkylaryl, cycloalkylaryl, heterocyclo, or heterocycloalkyl; (ii) a
group (i) which is itself substituted by one or more of the same or
different groups (i); or (iii) a group (i) or (ii) which is
substituted by one or more of the following groups (2) to (16) of
the definition of Z.sub.1, Z.sub.2 and Z.sub.3; (2) --OH or
--OZ.sub.6; (3) --SH or --SZ.sub.6; (4) --C(O).sub.qH,
--C(O).sub.qZ.sub.6, or --O--C(O).sub.qZ.sub.6; (5) --SO.sub.3H,
--S(O).sub.qZ.sub.6; or S(O).sub.qN(Z.sub.9)Z.sub.6; (6) halo; (7)
cyano; (8) nitro; (9) --Z.sub.4--NZ.sub.7Z.sub.8; (10)
--Z.sub.4--N(Z.sub.9)--Z.sub.5--NZ.sub.7Z.sub.8; (11)
--Z.sub.4--N(Z.sub.10)--Z.sub.5--Z.sub.6; (12)
--Z.sub.4--N(Z.sub.10)--Z.sub.5--H; (13) oxo; (14)
--O--C(O)--Z.sub.6; (15) any two of Z.sub.1, Z.sub.2, and Z.sub.3
may together be alkylene or alkenylene completing a 3- to
8-membered saturated or unsaturated ring together with the atoms to
which they are attached; or (16) any two of Z.sub.1, Z.sub.2, and
Z.sub.3 may together be --O--(CH.sub.2).sub.r--O--, where r is 1 to
5, completing a 4- to 8-membered ring together with the atoms to
which they are attached; Z.sub.4 and Z.sub.5 are each
independently: (1) a single bond; (2)
--Z.sub.11--S(O).sub.q--Z.sub.12--; (3)
--Z.sub.11--C(O)--Z.sub.12--; (4) --Z.sub.11--C(S)--Z.sub.12--; (5)
--Z.sub.11--O--Z.sub.12--; (6) --Z.sub.11--S--Z.sub.12--; (7)
--Z.sub.11--O--C(O)--Z.sub.12--; or (8)
--Z.sub.11--C(O)--O--Z.sub.12--; Z.sub.7, Z.sub.8, Z.sub.9 and
Z.sub.10: (1) are each independently hydrogen or Z.sub.6; (2)
Z.sub.7 and Z.sub.8, or Z.sub.6 and Z.sub.10, may together be
alkylene or alkenylene, completing a 3- to 8-membered saturated or
unsaturated ring together with the atoms to which they are
attached, which ring is unsubstituted or substituted with Z.sub.1,
Z.sub.2 and Z.sub.3; or (3) Z.sub.7 or Z.sub.8, together with
Z.sub.9, may be alkylene or alkenylene completing a 3- to
8-membered saturated or unsaturated ring together with the nitrogen
atoms to which they are attached, which ring is unsubstituted or
substituted with Z.sub.1, Z.sub.2 and Z.sub.3; Z.sub.11 and
Z.sub.12 are each independently: (1) a single bond; (2) alkylene;
(3) alkenylene; or (4) alkynylene; and Z.sub.13 is: (1) a single
bond; (2) --Z.sub.11--S(O).sub.q--Z.sub.12--; (3)
--Z.sub.11--C(O)--Z.sub.12--; (4) --Z.sub.11--C(S)--Z.sub.12--; (5)
--Z.sub.11--O--Z.sub.12--; (6) --Z.sub.11--S--Z.sub.12--; (7)
--Z.sub.11--O--C(O)--Z.sub.12--; (8)
--Z.sub.11--C(O)--O--Z.sub.12--; (9) --C(NR.sub.13)--; (10)
--C(CHR.sub.14)--; or (11) --C(C(R.sub.14).sub.2)--. providing that
said compound is other than (a) a compound of formula (ix)
##STR00625## where R.sub.2i is hydrogen or alkyl; R.sub.3i is
--C(O)--NH-(alk); and R.sub.58 and R.sub.59 are independently
hydrogen, alkyl or halogen.
9. A compound of claim 8 wherein R.sub.1 is hydrogen or alkyl,
R.sub.2 and R.sub.4 are independently hydrogen or alkyl, and
R.sub.5 is aryl which is unsubstituted or substituted with Z.sub.1,
Z.sub.2 and one or more groups Z.sub.3.
10. A compound of claim 9, wherein R.sub.5 is aryl which is
unsubstituted or independently substituted with one or more alkyl
or halo.
11. A pharmaceutical composition, comprising a pharmaceutically
acceptable vehicle ordiluent and at least one compound of claim
1.
12. A pharmaceutical composition, comprising a pharmaceutically
acceptable vehicle ordiluent and at least one compound of claim 8.
Description
RELATED APPLICATIONS
[0001] This application is continuation of Ser. No. 14/620,244,
filed Feb. 12, 2015, now allowed, which is a continuation of Ser.
No. 14/226,868, filed Mar. 27, 2014, now U.S. Pat. No. 8,993,567,
which is a continuation of Ser. No. 11/271,626, filed Nov. 10,
2005, now U.S. Pat. No. 8,716,323, which is a continuation of
application Ser. No. 10/378,373 filed Mar. 3, 2003, which is a
continuation of application Ser. No. 09/548,929 filed Apr. 13,
2000, now U.S. Pat. No. 6,596,746, which claims priority from
provisional application No. 60/129,510 filed Apr. 15, 1999. The
entire disclosure of each of the foregoing applications is herein
incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to cyclic compounds and salts
thereof, to methods of using such compounds in treating protein
tyrosine kinase-associated disorders such as immunologic and
oncologic disorders, and to pharmaceutical compositions containing
such compounds.
BACKGROUND OF THE INVENTION
[0003] Protein tyrosine kinases (PTKs) are enzymes which, in
conjuction with ATP as a substrate, phosphorylate tyrosine residues
in peptides and proteins. These enzymes are key elements in the
regulation of cell signaling including cell proliferation and cell
differentiation. PTKs comprise, inter alia, receptor tyrosine
kinases (RPTKs), including members of the epidermal growth factor
kinase family (e.g., HER1 and HER2), platelet derived growth factor
(PDGF), and kinases that play a role in angiogenesis (Tie-2 and
KDR); and, in addition, non-receptor tyrosine kinases, including
members of the Syk, JAK and Src (e.g. Src, Fyn, Lyn, Lck and Blk)
families (see Bolen, J. B., Rowley, R. B., Spana, C., and
Tsygankov, A. Y., "The src family of tyrosine protein kinases in
hemopoietic signal transduction", FASEB J., 6, 3403-3409 (1992);
Ullrich, A. and Schlessinger, J., "Signal transduction by receptors
with tyrosine kinase activity", Cell, 61, 203-212 (1990); and Ihle,
J. N., "The Janus protein tyrosine kinases in hematopoetic cytokine
signaling", Sem. Immunol., 7, 247-254 (1995)).
[0004] Enhanced activity of PTKs has been implicated in a variety
of malignant and nonmalignant proliferative diseases. In addition,
PTKs play a central role in the regulation of cells of the immune
system. PTK inhibitors can thus impact a wide variety of oncologic
and immunologic disorders. Such disorders may be ameliorated by
selective inhibition of a certain receptor or non-receptor PTK,
such as Lck, or due to the homology among PTK classes, by
inhibition of more than one PTK by an inhibitor.
[0005] A PTK of particular interest is Lck which is found in T
cells where it is involved in phosphorylating key protein
substrates. It is required for productive antigen receptor
signaling and cell activation. In the absence of Lck activity, the
T cell receptor (TCR) zeta chain is not phosphorylated, the kinase
ZAP-70 is not activated, and Ca.sup.2+ mobilization essential for T
cell activation does not occur (see Weiss, A. and Littman, D. R.,
"Signal transduction by lymphocyte antigen receptors", Cell, 76,
263-274 (1994); Iwashima, M., Irving, B. A., van Oers, N. S. C.,
Chan, A. C., and Weiss, A., "Sequential interactions of the TCR
with two distinct cytoplasmic tyrosine kinases", Science, 263,
1136-1139 (1994); and Chan, A. C., Dalton, M., Johnson, R., Kong,
G., Wang, T., Thoma, R., and Kurosaki, T., "Activation of ZAP-70
kinase activity by phosphorylation of tyrosine 493 is required for
lymphocyte antigen receptor function", EMBO J., 14, 2499-2508
(1995)). Inhibitors of Lck are thus useful in the treatment of
T-cell mediated disorders such as chronic diseases with an
important T cell component, for example rheumatoid arthritis,
multiple sclerosis and lupus, as well as acute diseases where T
cells are known to play an essential role, for example acute
transplant rejection and delayed-type hypersensitivity (DTH)
reactions.
SUMMARY OF THE INVENTION
[0006] The present invention provides cyclic compounds of the
following formula I and salts thereof, for use as protein tyrosine
kinase inhibitors:
##STR00001##
where
Q is:
[0007] (1) a 5-membered heteroaryl ring; [0008] (2) a 6-membered
heteroaryl ring; or [0009] (3) an aryl ring; [0010] optionally
substituted with one or more groups R.sub.1;
Z is:
[0010] [0011] (1) a single bond; [0012] (2) --R.sub.15C.dbd.CH--;
or [0013] (3) --(CH.sub.2).sub.m--, where m is 1 to 2; X.sub.1 and
X.sub.2 are each hydrogen, or together form .dbd.O or .dbd.S;
R.sub.1 is:
[0013] [0014] (1) hydrogen or R.sub.6, [0015] where R.sub.6 is
alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl,
cycloalkenylalkyl, aryl, aralkyl, heterocyclo, or heterocycloalkyl,
each of which is unsubstituted or substituted with Z.sub.1, Z.sub.2
and one or more (preferably, one or two) groups Z.sub.3; [0016] (2)
--OH or --OR.sub.6; [0017] (3) --SH or --SR.sub.6; [0018] (4)
--C(O).sub.2H, --C(O).sub.qR.sub.6, or --O--C(O).sub.qR.sub.6,
where q is 1 or 2; [0019] (5) --SO.sub.3H or --S(O).sub.qR.sub.6;
[0020] (6) halo; [0021] (7) cyano; [0022] (8) nitro; [0023] (9)
--Z.sub.4--NR.sub.7R.sub.8; [0024] (10)
--Z.sub.4--N(R.sub.9)--Z.sub.5--NR.sub.10R.sub.11; [0025] (11)
--Z.sub.4--N(R.sub.12)--Z.sub.5--R.sub.6; [0026] (12)
--P(O)(OR.sub.6).sub.2; R.sub.2 and R.sub.3 are each independently:
[0027] (1) hydrogen or R.sub.6; [0028] (2) --Z.sub.4--R.sub.6; or
[0029] (3) --Z.sub.13--NR.sub.7R.sub.8; R.sub.4 and R.sub.5: [0030]
(1) are each independently hydrogen or R.sub.6; [0031] (2)
--Z.sub.4--N(R.sub.9)--Z.sub.5--NR.sub.10R.sub.11; [0032] (3)
--N(R.sub.9)Z.sub.4R.sub.6; or [0033] (4) together with the
nitrogen atom to which they are attached complete a 3- to
8-membered saturated or unsaturated heterocyclic ring which is
unsubstituted or substituted with Z.sub.1, Z.sub.2 and Z.sub.3,
which heterocyclic ring may optionally have fused to it a benzene
ring itself unsubstituted or substituted with Z.sub.1, Z.sub.2 and
Z.sub.3; R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and
R.sub.12: [0034] (1) are each independently hydrogen or R.sub.6;
[0035] (2) R.sub.7 and R.sub.8 may together be alkylene, alkenylene
or heteroalkyl, completing a 3- to 8-membered saturated or
unsaturated ring with the nitrogen atom to which they are attached,
which ring is unsubstituted or substituted with Z.sub.1, Z.sub.2
and Z.sub.3; or [0036] (3) any two of R.sub.9, R.sub.10 and
R.sub.11 may together be alkylene or alkenylene completing a 3- to
8-membered saturated or unsaturated ring together with the nitrogen
atoms to which they are attached, which ring is unsubstituted or
substituted with Z.sub.1, Z.sub.2 and Z.sub.3;
R.sub.13 is:
[0036] [0037] (1) cyano; [0038] (2) nitro; [0039] (3) --NH.sub.2;
[0040] (4) --NHOalkyl; [0041] (5) --OH; [0042] (6) --NHOaryl;
[0043] (7) --NHCOOalkyl; [0044] (8) --NHCOOaryl; [0045] (9)
--NHSO.sub.2alkyl; [0046] (10) --NHSO.sub.2aryl; [0047] (11) aryl;
[0048] (12) heteroaryl; [0049] (13) --Oalkyl; or [0050] (14)
--Oaryl;
R.sub.14 is:
[0050] [0051] (1) --NO.sub.2; [0052] (2) --COOalkyl; or [0053] (3)
--COOaryl;
R.sub.15 is:
[0053] [0054] (1) hydrogen; [0055] (2) alkyl; [0056] (3) aryl;
[0057] (4) arylalkyl; or [0058] (5) cycloalkyl; Z.sub.1, Z.sub.2
and Z.sub.3 are each independently: [0059] (1) hydrogen or Z.sub.6,
where Z.sub.6 is (i) alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl,
alkylaryl, cycloalkylaryl, heterocyclo, or heterocycloalkyl; (ii) a
group (i) which is itself substituted by one or more of the same or
different groups (i); or (iii) a group (i) or (ii) which is
substituted by one or more of the following groups (2) to (16) of
the definition of Z.sub.1, Z.sub.2 and Z.sub.3; [0060] (2) --OH or
--OZ.sub.6; [0061] (3) --SH or --SZ.sub.6; [0062] (4)
--C(O).sub.qH, --C(O).sub.qZ.sub.6, or --O--C(O).sub.qZ.sub.6;
[0063] (5) --SO.sub.3H, --S(O).sub.qZ.sub.6; or
S(O).sub.qN(Z.sub.9)Z.sub.6; [0064] (6) halo; [0065] (7) cyano;
[0066] (8) nitro; [0067] (9) --Z.sub.4--NZ.sub.7Z.sub.8; [0068]
(10) --Z.sub.4--N(Z.sub.9)--Z.sub.5--NZ.sub.7Z.sub.8; [0069] (11)
--Z.sub.4--N(Z.sub.10)--Z.sub.5--Z.sub.6; [0070] (12)
--Z.sub.4--N(Z.sub.10)--Z.sub.5--H; [0071] (13) oxo; [0072] (14)
--O--C(O)--Z.sub.6; [0073] (15) any two of Z.sub.1, Z.sub.2, and
Z.sub.3 may together be alkylene or alkenylene completing a 3- to
8-membered saturated or unsaturated ring together with the atoms to
which they are attached; or [0074] (16) any two of Z.sub.1,
Z.sub.2, and Z.sub.3 may together be --O--(CH.sub.2).sub.r--O--,
where r is 1 to 5, completing a 4- to 8-membered saturated or
unsaturated ring together with the atoms to which they are
attached; Z.sub.4 and Z.sub.5 are each independently: [0075] (1) a
single bond; [0076] (2) --Z.sub.11--S(O).sub.q--Z.sub.12--; [0077]
(3) --Z.sub.11--C(O)--Z.sub.12--; [0078] (4)
--Z.sub.11--C(S)--Z.sub.12--; [0079] (5) --Z.sub.11--O--Z.sub.12--;
[0080] (6) --Z.sub.11--S--Z.sub.12--; [0081] (7)
--Z.sub.11--O--C(O)--Z.sub.12--; or [0082] (8)
--Z.sub.11--C(O)--O--Z.sub.12--; Z.sub.7, Z.sub.8, Z.sub.9 and
Z.sub.10: [0083] (1) are each independently hydrogen or Z.sub.6;
[0084] (2) Z.sub.7 and Z.sub.8, or Z.sub.6 and Z.sub.10, may
together be alkylene or alkenylene, completing a 3- to 8-membered
saturated or unsaturated ring together with the atoms to which they
are attached, which ring is unsubstituted or substituted with
Z.sub.1, Z.sub.2 and Z.sub.3; or [0085] (3) Z.sub.7 or Z.sub.8,
together with Z.sub.9, may be alkylene or alkenylene completing a
3- to 8-membered saturated or unsaturated ring together with the
nitrogen atoms to which they are attached, which ring is
unsubstituted or substituted with Z.sub.1, Z.sub.2 and Z.sub.3;
Z.sub.11 and Z.sub.12 are each independently: [0086] (1) a single
bond; [0087] (2) alkylene; [0088] (3) alkenylene; or [0089] (4)
alkynylene; and
Z.sub.13 is:
[0089] [0090] (1) a single bond; [0091] (2)
--Z.sub.11--S(O).sub.q--Z.sub.12--; [0092] (3)
--Z.sub.11--C(O)--Z.sub.12--; [0093] (4)
--Z.sub.11--C(S)--Z.sub.12--; [0094] (5) --Z.sub.11--O--Z.sub.12--;
[0095] (6) --Z.sub.11--S--Z.sub.12--; [0096] (7)
--Z.sub.11--O--C(O)--Z.sub.12--; [0097] (8)
--Z.sub.11--C(O)--O--Z.sub.12--; [0098] (9) --C(NR.sub.13)--;
[0099] (10) --C(CHR.sub.14)--; or [0100] (11)
--C(C(R.sub.14).sub.2)--.
[0101] Compounds within formula I include compounds of the
following formula II and salts thereof:
##STR00002##
[0102] where
n is 1 or 2 A is selected from carbon and nitrogen; B is selected
from nitrogen, oxygen and sulfur; X.sub.3 is oxygen or sulfur; and
R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as described
above.
DETAILED DESCRIPTION OF THE INVENTION
[0103] The following are definitions of terms used in this
specification. The initial definition provided for a group or term
herein applies to that group or term throughout the present
specification, individually or as part of another group, unless
otherwise indicated.
[0104] The terms "alk" or "alkyl" refer to straight or branched
chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1
to 8 carbon atoms. The expression "lower alkyl" refers to alkyl
groups of 1 to 4 carbon atoms.
[0105] The term "alkenyl" refers to straight or branched chain
hydrocarbon groups of 2 to 10, preferably 2 to 4, carbon atoms
having at least one double bond. Where an alkenyl group is bonded
to a nitrogen atom, it is preferred that such group not be bonded
directly through a carbon bearing a double bond.
[0106] The term "alkynyl" refers to straight or branched chain
hydrocarbon groups of 2 to 10, preferably 2 to 4, carbon atoms
having at least one triple bond. Where an alkynyl group is bonded
to a nitrogen atom, it is preferred that such group not be bonded
directly through a carbon bearing a triple bond.
[0107] The term "alkylene" refers to a straight chain bridge of 1
to 5 carbon atoms connected by single bonds (e.g.,
--(CH.sub.2).sub.x-- wherein x is 1 to 5), which may be substituted
with 1 to 3 lower alkyl groups.
[0108] The term "alkenylene" refers to a straight chain bridge of 2
to 5 carbon atoms having one or two double bonds that is connected
by single bonds and may be substituted with 1 to 3 lower alkyl
groups. Exemplary alkenylene groups are --CH.dbd.CH--CH.dbd.CH--,
--CH.sub.2--CH.dbd.CH--, --CH.sub.2--CH.dbd.CH--CH.sub.2--,
--C(CH.sub.3).sub.2CH.dbd.CH-- and
--CH(C.sub.2H.sub.5)--CH.dbd.CH--.
[0109] The term "alkynylene" refers to a straight chain bridge of 2
to 5 carbon atoms that has a triple bond therein, is connected by
single bonds, and may be substituted with 1 to 3 lower alkyl
groups. Exemplary alkynylene groups are --C.ident.C--,
--CH.sub.2--C.ident.C--, --CH(CH.sub.3)--C.ident.C-- and
--C.ident.C--CH(C.sub.2H.sub.5)CH.sub.2--.
[0110] The terms "ar" or "aryl" refer to aromatic cyclic groups
(for example 6 membered monocyclic, 10 membered bicyclic or 14
membered tricyclic ring systems) which contain 6 to 14 carbon
atoms. Exemplary aryl groups include phenyl, naphthyl, biphenyl and
anthracene.
[0111] The terms "cycloalkyl" and "cycloalkenyl" refer to cyclic
hydrocarbon groups of 3 to 12 carbon atoms.
[0112] The terms "halogen" and "halo" refer to fluorine, chlorine,
bromine and iodine.
[0113] The term "unsaturated ring" includes partially unsaturated
and aromatic rings.
[0114] The terms "heterocycle", "heterocyclic" or "heterocyclo"
refer to fully saturated or unsaturated, including aromatic (i.e.
"heteroaryl") cyclic groups, for example, 4 to 7 membered
monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered
tricyclic ring systems, which have at least one heteroatom in at
least one carbon atom-containing ring. Each ring of the
heterocyclic group containing a heteroatom may have 1, 2, 3 or 4
heteroatoms selected from nitrogen atoms, oxygen atoms and/or
sulfur atoms, where the nitrogen and sulfur heteroatoms may
optionally be oxidized and the nitrogen heteroatoms may optionally
be quaternized. The heterocyclic group may be attached at any
heteroatom or carbon atom of the ring or ring system.
[0115] Exemplary monocyclic heterocyclic groups include
pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl,
imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl,
isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl,
isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl,
oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl,
2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl,
4-piperidonyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
tetrahydropyranyl, morpholinyl, thiamorpholinyl, thiamorpholinyl
sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and
tetrahydro-1,1-dioxothienyl, triazolyl, triazinyl, and the
like.
[0116] Exemplary bicyclic heterocyclic groups include indolyl,
benzothiazolyl, benzoxazolyl, benzodioxolyl, benzothienyl,
quinuclidinyl, quinolinyl, tetra-hydroisoquinolinyl, isoquinolinyl,
benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl,
coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl,
pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl,
furo[3,2-b]pyridinyl] or furo[2, 3-b]pyridinyl), dihydroisoindolyl,
dihydroquinazolinyl (such as 3, 4-dihydro-4-oxo-quinazolinyl),
tetrahydroquinolinyl and the like.
[0117] Exemplary tricyclic heterocyclic groups include carbazolyl,
benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl
and the like.
[0118] The term "heteroaryl" refers to aromatic heterocyclic
groups.
[0119] Exemplary heteroaryl groups include pyrrolyl, pyrazolyl,
imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl,
isothiazolyl, furyl, thienyl, oxadiazolyl, pyridinyl, pyrazinyl,
pyrimidinyl, pyridazinyl, triazolyl, triazinyl, and the like.
[0120] Where q is 1 or 2, "--C(O).sub.qH" denotes --C(O)--H or
--C(O)--OH; "--C(O).sub.qR.sub.6" or "--C(O).sub.qZ.sub.6" denote,
respectively, --C(O)--R.sub.6 or --C(O)--OR.sub.6, or
--C(O)--Z.sub.6 or --C(O)--OZ.sub.6; "--O--C(O).sub.qR.sub.6" or
"--O--C(O).sub.qZ.sub.6" denote, respectively, --O--C(O)--R.sub.6
or --O--C(O)--OR.sub.6, or --O--C(O)--Z.sub.6 or
--O--C(O)--OZ.sub.6; and "--S(O).sub.qR.sub.6" or
"--S(O).sub.qZ.sub.6" denote, respectively, --SO--R.sub.6 or
--SO.sub.2--R.sub.6, or --SO--Z.sub.6 or --SO.sub.2--Z.sub.6.
[0121] Compounds of the formula I may in some cases form salts
which are also within the scope of this invention. Reference to a
compound of the formula I herein is understood to include reference
to salts thereof, unless otherwise indicated. The term "salt(s)",
as employed herein, denotes acidic and/or basic salts formed with
inorganic and/or organic acids and bases. Zwitterions (internal or
inner salts) are included within the term "salt(s)" as used herein
(and may be formed, for example, where the R substituents comprise
an acid moiety such as a carboxyl group). Also included herein are
quaternary ammonium salts such as alkylammonium salts.
Pharmaceutically acceptable (i.e., non-toxic, physiologically
acceptable) salts are preferred, although other salts are useful,
for example, in isolation or purification steps which may be
employed during preparation. Salts of the compounds of the formula
I may be formed, for example, by reacting a compound I with an
amount of acid or base, such as an equivalent amount, in a medium
such as one in which the salt precipitates or in an aqueous medium
followed by lyophilization.
[0122] Exemplary acid addition salts include acetates (such as
those formed with acetic acid or trihaloacetic acid, for example,
trifluoroacetic acid), adipates, alginates, ascorbates, aspartates,
benzoates, benzenesulfonates, bisulfates, borates, butyrates,
citrates, camphorates, camp horsulfonates, cyclopentanepropionates,
digluconates, dodecylsulfates, ethanesulfonates, fumarates,
glucoheptanoates, glycerophosphates, hemisulfates, heptanoates,
hexanoates, hydrochlorides, hydrobromides, hydroiodides,
2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates,
2-nap hthalenesulfonates, nicotinates, nitrates, oxalates,
pectinates, persulfates, 3-phenylpropionates, phosphates, picrates,
pivalates, propionates, salicylates, succinates, sulfates (such as
those formed with sulfuric acid), sulfonates (such as those
mentioned herein), tartrates, thiocyanates, toluenesulfonates,
undecanoates, and the like.
[0123] Exemplary basic salts (formed, for example, where the R
substituents comprise an acidic moiety such as a carboxyl group)
include ammonium salts, alkali metal salts such as sodium, lithium,
and potassium salts, alkaline earth metal salts such as calcium and
magnesium salts, salts with organic bases (for example, organic
amines) such as benzathines, dicyclohexylamines, hydrabamines,
N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and
salts with amino acids such as arginine, lysine and the like. The
basic nitrogen-containing groups may be quaternized with agents
such as lower alkyl halides (e.g. methyl, ethyl, propyl, and butyl
chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl,
diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g.
decyl, lauryl, myristyl and stearyl chlorides, bromides and
iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and
others.
[0124] Prodrugs and solvates of the compounds of the invention are
also contemplated herein. The term "prodrug", as employed herein,
denotes a compound which, upon administration to a subject,
undergoes chemical conversion by metabolic or chemical processes to
yield a compound of the formula I, or a salt and/or solvate
thereof. Solvates of the compounds of formula I are preferably
hydrates.
[0125] All stereoisomers of the present compounds, such as those
which may exist due to asymmetric carbons on the R substituents of
the compound of the formula I, including enantiomeric and
diastereomeric forms, are contemplated within the scope of this
invention. Individual stereoisomers of the compounds of the
invention may, for example, be substantially free of other isomers,
or may be admixed, for example, as racemates or with all other, or
other selected, stereoisomers. The chiral centers of the present
invention can have the S or R configuration as defined by the IUPAC
1974 Recommendations.
[0126] Throughout the specification, groups and substituents
thereof are chosen to provide stable moieties and compounds.
Preferred Compounds
[0127] Preferred compounds of the present invention are compounds
of the formula I, and salts thereof, wherein Q is thiazole and
wherein one or more, and especially all, of Z, X.sub.1, X.sub.2
R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are selected from
the following definitions:
[0128] Z is a single bond;
[0129] R.sub.1 is selected from hydrogen, halo, alkyl, aryl,
alkoxy, alkoxycarbonyl, or aryloxycarbonyl and is more preferably
hydrogen;
[0130] X.sub.1 and X.sub.2 together form .dbd.O or .dbd.S and more
preferably form .dbd.O;
[0131] R.sub.2 is hydrogen;
[0132] R.sub.3 is selected from --Z.sub.4--R.sub.6 or
--Z.sub.13--NR.sub.7R.sub.8 and is more preferably
--Z.sub.4--R.sub.6 wherein Z.sub.4 is a single bond and R.sub.6 is
aryl or heteroaryl which is unsubstituted or substituted with
Z.sub.1, Z.sub.2 and one or more (preferably, one or two) groups
Z.sub.3;
[0133] R.sub.4 is hydrogen; and
[0134] R.sub.5 is selected from aryl groups or heteroaryl groups
which are substituted with Z.sub.1, Z.sub.2 and one or more (such
as one or two) groups Z.sub.3.
Methods of Preparation
[0135] The compounds of the formula I may be prepared by methods
such as those illustrated in the following Schemes A through E and
I through XI. Solvents, temperatures, pressures, and other reaction
conditions may readily be selected by one of ordinary skill in the
art. All documents cited are incorporated herein by reference in
their entirety. Starting materials are commercially available or
readily prepared by one of ordinary skill in the art. Constituents
of compounds are as defined elsewhere in the specification or as
specifically defined in a scheme.
[0136] The methods described herein may be carried out with
starting materials and/or reagents in solution or alternatively,
where appropriate, with one or more starting materials or reagents
bound to a solid support (see (1) Thompson, L. A., Ellman, J. A.,
Chemical Reviews, 96, 555-600 (1996); (2) Terrett, N. K., Gardner,
M., Gordon, D. W., Kobylecki, R. J., Steele, J., Tetrahedron, 51,
8135-8173 (1995); (3) Gallop, M. A., Barrett, R. W., Dower, W. J.,
Fodor, S. P. A., Gordon, E. M., Journal of Medicinal Chemistry, 37,
1233-1251 (1994); (4) Gordon, E. M., Barrett, R. W., Dower, W. J.,
Fodor, S. P. A., Gallop, M. A., Journal of Medicinal Chemistry, 37,
1385-1401 (1994); (5) Balkenhohl, F., von dem Bussche-Hunnefeld,
Lansky, A., Zechel, C., Angewandte Chemie International Edition in
English, 35, 2288-2337 (1996); (6) Balkenhohl, F., von dem
Bussche-Hunnefeld, Lansky, A., Zechel, C., Angewandte Chemie, 108,
2436-2487 (1996); and (7) Sofia, M. J., Drugs Discovery Today, 1,
27-34 (1996)).
##STR00003##
[0137] Scheme A illustrates a general method for forming compound
Ia, which is a compound of the formula I where X.sub.1 and X.sub.2
together form .dbd.O. As shown in Scheme A, compound Ia where
R.sub.2 and R.sub.3 are hydrogen may be formed by saponification of
i, (R* is a carboxyl protecting group such as alkyl or arylalkyl)
followed by reaction with amine iii by methods known in the art.
Alternatively i may be reacted with R.sub.2L, where L is a leaving
group such as halogen (for example, in equimolar portions),
optionally followed by reaction with R.sub.3L (for example, in
equimolar portions) to form ii. Also alternatively, i may be
subjected to reductive amination using the appropriate aldehyde or
ketone to form ii. The compound ii may then be saponified and
reacted with amine iii, under conditions known to those skilled in
the art, to form Ia where R.sub.2 and/or R.sub.3 are other than
hydrogen.
[0138] Methods for preparing preferred substituents on the
compounds I are illustrated in the following Schemes I to XI.
##STR00004##
[0139] Scheme B illustrates a general method for forming compound
Ib, which is a compound of formula I where Z is --CH.dbd.CH-- and
X.sub.1 and X.sub.2 together form .dbd.O. As shown in Scheme B, a
2-halo-compound vi can be prepared by reacting an appropriately
substituted 2-amino-compound ia with copper (ii) halide and an
alkyl nitrite such as tert-butyl nitrite in an aprotic solvent such
as acetonitrile to form 2-halo-compound iv (see J. Het. Chem. 22,
1621 (1985)). Compound iv can be reduced with a reducing agent such
as sodium borohydride in ethanol or aqueous tetrahydrofuran to form
an alcohol, which can be oxidized with an oxidizing agent such as
pyridinium chlorochromate or pyridinium dichromate to form aldehyde
v. Compound v can be reacted with an
alkyl(triphenylphosphorylidene) acetate to form carboxylate vi.
Compound vi can be saponified and then reacted with an amine iii by
methods known to those skilled in the art to form vii. Compound vii
can be reacted with an amine R.sub.2R.sub.3NH to form Ib where Z is
--CH.dbd.CH-- and X.sub.1, X.sub.2 together form .dbd.O.
Alternatively, compounds of formula Ib where R.sub.2 and R.sub.3
are H, can be formed by reacting compound vii with an appropriately
substituted benzyl amine such as 4-methoxybenzyl amine to form
compound ix, which can be hydrogenolyzed or treated with an acid
such as trifluoromethanesulfonic acid and trifluoroacetic acid in
the presence of anisole to form Ib where R.sub.2 and R.sub.3 are
hydrogen.
[0140] Methods for preparing preferred substituents on the
compounds I are illustrated in the following Schemes I to XI.
##STR00005##
[0141] Scheme C illustrates a general method for forming compound
Ic, which is a compound of formula I where Z is
--R.sub.15C.ident.CH-- and X.sub.1 and X.sub.2 together form
.dbd.O. As shown in Scheme C, a 2-amino-compound ia can be reacted
with a chloroformate or dicarbonate to form x, which can be
saponified and treated with an organolithium reagent to form
compound xi. Compound xi may be reacted with an
alkyl(triphenylphosphorylidene)acetate, followed by deprotection of
the carbamate protecting group to form xii. Alternatively, compound
Ic where R.sub.2 and R.sub.3 are hydrogen may be formed by
saponification of xii followed by reaction with an amine
R.sub.4R.sub.5NH by methods known to those skilled in the art.
Alternatively, compound xii may be reacted with R.sub.2L where L is
a leaving group such as halogen (for example, in equimolar
portions), optionally followed by reaction with R.sub.3L (for
example, in equimolar portions) to form xiii, which may be
saponified and reacted with an amine R.sub.4R.sub.5NH by methods
known to those skilled in the art to form Ia where R.sub.2 and/or
R.sub.3 are other than hydrogen.
[0142] Methods for preparing preferred substituents on the
compounds I are illustrated in the following Schemes I to XI.
##STR00006##
[0143] Scheme D illustrates a general method for forming compound
Id, which is a compound of the formula I where X.sub.1 and X.sub.2
together form .dbd.S. The compounds of the formula Ia obtained in
Scheme A may be converted into the corresponding thioamide Id using
a reagent such as Lawesson's reagent (2, 4-bis(4-methoxyphenyl)-1,
3-dithia-2, 4-diphosphetane-2, 4-disulfide (see Bull. Soc. Chim.
Belg., 87, 223 (1978)).
[0144] Methods for preparing preferred substituents on the
compounds I are illustrated in the following Schemes I to XI.
##STR00007##
[0145] Scheme E illustrates a general method for forming compound
Ie, which is a compound of the formula I where X.sub.1 and X.sub.2
are each hydrogen. As shown in Scheme E, the compound of the
formula Id obtained in Scheme D may be converted into the
corresponding amine Ie by reduction, for example, by reaction with
Raney nickel.
[0146] Methods for preparing preferred substituents on the
compounds I are illustrated in the following Schemes I to XI.
##STR00008##
[0147] As shown in Scheme I, carboxylate i can be reacted with a
chloroformate or dicarbonate to form 1. Compound 1 can be treated
with a base such as sodium hydride, sodium/potassium
hexamethyldisilazide, or lithium diisopropylamide (LDA), and an
alkylating agent R.sub.2X where X is halogen and R.sub.2 is
preferably alkyl, arylalkyl, or cycloalkylalkyl, and then
saponified with an aqueous base such as potassium hydroxide to give
2. Alternatively, 1 can the subjected to reductive amination using
the appropriate aldehyde or ketone and saponified with an aqueous
base such as potassium hydroxide to give 2. Compound 1 may,
alternatively, be simply saponified with an aqueous base such as
potassium hydroxide to give 3 where R.sub.2 is hydrogen.
[0148] Acid 2 may be reacted with an amine iii using reaction
conditions well known in the art for peptide bond synthesis (see,
for example, Bodanszky and Bodanszky, The Practice of Peptide
Chemistry, Springer-Verlag, 1984; Bodanszky, Principles of Peptide
Synthesis, Springer-Verlag, 1984) to give the compound Id which a
compound of the formula I where X.sub.1 and X.sub.2 together form
.dbd.O, R.sub.3 is COOR.sub.6, and, since 2 is the starting
material, R.sub.2 is preferably alkyl, arylalkyl or
cycloalkylalkyl. For example, reagents which activate the carboxyl
group of 2 for reaction with the amine iv include
bis-(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP chloride),
benzotriazol-1-yloxy-tris(dimethylamino)phosphonium
hexafluorophosphate (BOP reagent),
[O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium]hexafluorophosphat-
e (HATU), and carbodiimides such as dicyclohexylcarbodiimide (DCC)
or 3-ethyl-3'-(dimethylamino)propylcarbodiimide (EDCI) either alone
or in combination with a hydroxybenzotriazole. Alternatively, the
activated ester intermediate can be isolated and then treated with
the appropriate amine iv in a nonprotic solvent such as
tetrahydrofuran (THF) or dimethylformamide (DMF) in the presence of
a base, for example, an organic base such as sodium/potassium
hexamethyldisilazide, triethylamine, diisopropylethylamine or
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), or an inorganic base such
as sodium, potassium or cesium carbonate or sodium or potassium
hydride. Alternatively, the acid halide of 2 may be prepared, for
example, by reaction with thionyl chloride or oxalyl chloride,
followed by subsequent reaction with amine iii to provide compound
If, which is a compound of the formula I where R.sub.3 is
COOR.sub.6, X.sub.1 and X.sub.2 together form .dbd.O, and R.sub.2
is alkyl, arylalkyl or chycloalkylalkyl.
[0149] Similar reactions as employed above for the conversion of 2
to If may be used to convert 3 to If where R.sub.3 is COOR.sub.6,
X.sub.1 and X.sub.2 together form .dbd.O, and R.sub.2 is
hydrogen.
##STR00009##
[0150] As shown in Scheme II, acid 4 where R.sub.2 and R.sub.3 are
not hydrogen and are selected such that the nitrogen to which they
are attached is non-basic, is reduced to the aldehyde 5 by methods
well know in the art (see March, Advanced Organic Chemistry, Wiley,
1985). For example, the acid 4 may be converted to its
corresponding ester followed by reduction with diisobutylaluminum
hydride. Alternatively, the acid 4 may be reduced to the
corresponding primary alcohol, for example, by treatment with
borane/THF, LiAlH.sub.4, or via reduction of a mixed anhydride,
followed by subsequent oxidation to the aldehyde 5 using Cr(VI)
(e.g., pyridinium chlorochromate, "PCC") or under Swern or Moffatt
conditions (e.g., (COCl).sub.2/dimethylsulfoxide). The starting
acid 4 may be obtained, for example, by saponification of ii.
[0151] Reductive amination (see Hudlicky, Reductions in Organic
Chemistry, Wiley, 1984) of aldehyde 5 with amine iii in the
presence of a reducing agent such as NaBH.sub.3CN, NaBH(OAc).sub.3
(Ac=acetyl) or hydrogen and a palladium catalyst produces the amine
compound Ig, which is a compound of the formula I where X.sub.1 and
X.sub.2 are each hydrogen and R.sub.2 and R.sub.3 are each not
hydrogen.
##STR00010##
[0152] As shown in Scheme III, reduction of the acid 4 to a primary
alcohol (for example, by treatment with borane/tetrahydrofuran,
LiAlH.sub.4, or via reduction of a mixed anhydride), followed by
conversion by methods well known in the art (see March, Advanced
Organic Chemistry, Wiley, 1985), provides 6 which contains a
leaving group such as a halide, tosylate (OTs), mesylate (OMs) or
triflate (OTf). The groups R.sub.2 and R.sub.3 are selected such
that the resulting nitrogen to which they are attached is
non-basic. Compound 6 can then be converted into compound Ih, which
is a compound of the formula I where X.sub.1 and X.sub.2 are each
hydrogen and R.sub.2 and R.sub.3 are each not hydrogen, by a
displacement reaction with amine iii, preferably where amine iii is
used in excess.
##STR00011##
[0153] Scheme IV illustrates methods which may be used for the
preparation of compounds Ij, Ik, Il, Im and In. Ij, Ik, It, Im and
In are compounds of the formula I where R.sub.2 is any group as
defined, R.sub.3 is an acyl or thioacyl group, X.sub.1 and X.sub.2
are not hydrogen, and R.sub.1 is not a primary or secondary amine.
Ij, Ik, Il, Im and In have other particular substituents which are
specified in this Scheme and below. The starting compound Ii can be
prepared by suitable methods described in Schemes A and D.
[0154] Amide Ij can be prepared by treatment of amine compound Ii
with a carboxylic acid 7 in the presence of reagents which activate
the carboxyl group for reaction as described above, for example BOP
reagent, HATU, and carbodiimides such as DCC or EDCI either alone
or in combination with a hydroxybenztriazole. Alternatively, the
acid halide 8 may be reacted with amine compound Ii in the presence
of an acid scavenger such as diisopropylethylamine. The
corresponding thioamide Ik can be prepared by the treatment of
amide Ii (where X.sub.1, X.sub.2.noteq.O) with Lawesson's reagent
as described above.
[0155] Carbamate II can be prepared by treatment of amine compound
Ii with a chloroformate 9 or dicarbonate 10 in the presence of an
acid scavenger such as diisopropylethylamine.
[0156] The urea Im may be prepared by treatment of amine compound
Ii with either: 1) a chloroformate 9, such as phenylchloroformate,
followed by reaction with an amine 11; 2) a carbamoyl chloride 12
in the presence of an acid scavenger such as diisopropylethylamine;
or 3) reaction with an isocyanate 13a (where R.sub.c in Im=H). The
corresponding thiourea In may be prepared by treatment of amine
compound Ii with a thioisocyanate 13b.
[0157] R.sub.a is selected from those groups included in the
definition of R.sub.6 such that the group --C(=A)-R.sub.a is an
acyl or thioacyl group within the definition of R.sub.3. Rb and Re
are selected from those groups included in the definitions of
R.sub.7 and R.sub.8, such that the group
--C(=A)-N(R.sub.b)(R.sub.c) is an acyl or thioacyl group within the
definition of R.sub.3.
##STR00012##
[0158] Scheme V illustrates a method which can be used for the
preparation of Ip, which is a compound of the formula I where
R.sub.2 is any group as defined other than acyl, and which is
selected such that the nitrogen to which it is attached is basic,
R.sub.3 is alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenylalkyl,
aralkyl, or saturated heterocycle, and X.sub.1 and X.sub.2 are not
hydrogen. The starting compounds Io and Iq can be prepared by
suitable methods described in Schemes A and D.
[0159] As shown in Scheme V, amine compound Io is reacted with an
aldehyde or ketone 14 under reductive amination conditions
described above to give the amine Ip. Compound Ip may also be
prepared by treatment of an amine compound Iq, where R.sub.2 and
R.sub.3 are hydrogen, with t-butyl nitrite or sodium nitrite in the
presence of a copper (II) halide to give the halo-substituted
compound 15, followed by displacement with amine 16 in the presence
of a base such as sodium or potassium hydride or the like (see Lee
et al., J. Heterocyclic Chemistry, 22, 1621 (1985)).
[0160] R.sub.d and R.sub.e are independently selected from
hydrogen, alkyl, aryl, cycloalkyl or cycloalkenyl, or together are
alkylene or alkenylene completing a 3- to 8-membered saturated or
unsaturated ring, such that the group --CH(R.sub.d)(R.sub.e) is a
group within the definition of R.sub.3.
##STR00013##
[0161] As shown in Scheme VI, when R.sub.2 is any group as defined
other than acyl, and is selected such that the nitrogen to which it
is attached is basic, R.sub.3 is aryl or heteroaryl, and X.sub.1
and X.sub.2 are not hydrogen, amine compound Ir may be reacted with
a halophenyl or haloheteroaromatic group 17 in the presence of a
palladium (0) catalyst (see J. Am. Chem. Soc., 118, 7215 (1996)) to
give amine Is, which is a compound of the formula I having the
particular substituents described in this Scheme. The starting
compound Ir can be prepared by suitable methods described in
Schemes A and D.
##STR00014##
[0162] As shown in Scheme VII, when R.sub.2 is any group as defined
and R.sub.3 is a heteroaromatic group, amine compound It may be
reacted, in the presence of a base if needed, with a
2-halosubstituted heteroaromatic compound 17 where Q.sub.1,
together with atoms to which is bonded, forms a 5- or 6-membered
monocyclic or 10- to 12-membered bicyclic heteroaromatic group
(such as forming 2-chloropyridine or 2-chloropyrimidine) to give
the amine Iu, where Iu is a compound of the formula I having the
particular substituents described in this Scheme. The starting
compound It can be prepared by suitable methods described in
Schemes A and D.
##STR00015##
[0163] As shown in Scheme VIII, thiourea compound In (where X.sub.1
and X.sub.2 are not hydrogen) may be reacted with the appropriate
amine in the presence of bis-(2-oxo-3-oxazolidinyl)phosphinic
chloride (BOP chloride)
benzotriazol-1-yloxy-tris(dimethylamino)phosphonium
hexafluorophosphate (BOP-reagent),
[O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium]hexafluorophosphat-
e (HATU) and carbodiimide, such as dicyclohexyl carbodiimide (DCC)
or 3-ethyl-3'-(dimethylamino)propyl carbodiimide (EDCI) or
diisopropyl carbodiimide (DIC) in the presence of an organic base
such as triethylamine, diisopropylethylamine or
dimethylaminopyridine in solvents such as dimethylformamide,
dichloromethane or tetrahydrofuran to form compound Iv, which is a
compound of the formula I having the particular substituents
described in this Scheme.
[0164] Alternatively, Compound In can be reacted with the
appropriate amine in the presence of a mercury (II) salt such as
mercuric chloride, or by other methods known in the literature, to
form Iv.
##STR00016##
[0165] As shown in Scheme IX, amine Ir (where X.sub.1 and X.sub.2
are not hydrogen) can be reacted with diphenylcyanocarbonimidate
either alone or in the presence of a base such as sodium hydride,
sodium hexamethyldisilazide or dimethylaminopyridine in
acetonitrile, tetrahydrofuran, or dimethylformamide at room
temperature or elevated temperature to form intermediate compound
Iw. Compound Iw can be reacted with an amine R.sub.7R.sub.8NH to
form compound Iv, which is a compound of the formula I having the
particular substituents described in this Scheme.
##STR00017##
[0166] As shown in Scheme X, compound Ir (where X.sub.1 and X.sub.2
hydrogen) can be reacted with 18 or 19 either alone or in the
presence of a base such as sodium hydride, sodium hexamethyl
disilazide or dimethylaminopyridine in dimethyl formamide or
tetrahydrofuran at room temperature or at higher temperature to
form compounds Ix or Iy respectively, which can be reacted with an
amine R.sub.7R.sub.8NH at room temperature or elevated temperature
to form compounds Iz or Iz* respectively. Compound Iz is a compound
of the formula I having the particular substituents described in
this Scheme. Compound Iz* is a compound of the formula I having the
particular substituents described in this Scheme.
##STR00018##
[0167] As shown in Scheme XI, compounds of formula I can also be
prepared from 15 by treatment with the defined amine in the
presence of an acid catalyst (for example, see: Gunzenhauser et
al., Helv. Chim. Acta, 71, 33 (1988)).
Utility
[0168] The compounds of the present invention inhibit protein
tyrosine kinases, especially Src-family kinases such as Lck, Fyn,
Lyn, Src, Yes, Hck, Fgr and Blk, and are thus useful in the
treatment, including prevention and therapy, of protein tyrosine
kinase-associated disorders such as immunologic and oncologic
disorders. The compounds inhibit also receptor tyrosine kinases
including HER1 and HER2 and are therefore useful in the treatment
of proliferative disorders such as psoriasis and cancer. The
ability of these compounds to inhibit HER1 and other receptor
kinases will also permit their use as anti-angiogenic agents to
treat disorders such as cancer and diabetic retinopathy. "Protein
tyrosine kinase-associated disorders" are those disorders which
result from aberrant tyrosine kinase activity, and/or which are
alleviated by the inhibition of one or more of these enzymes. For
example, Lck inhibitors are of value in the treatment of a number
of such disorders (for example, the treatment of autoimmune
diseases), as Lck inhibition blocks T cell activation. The
treatment of T cell mediated diseases, including inhibition of T
cell activation and proliferation, is a particularly preferred
embodiment of the present invention. Compounds which selectively
block T cell activation and proliferation are preferred. Compounds
of the present invention which block the activation of endothelial
cell PTK by oxidative stress, thereby limiting surface expression
of adhesion molecules that induce neutrophil binding, and which
inhibit PTK necessary for neutrophil activation are useful, for
example, in the treatment of ischemia and reperfusion injury.
[0169] The present invention thus provides methods for the
treatment of protein tyrosine kinase-associated disorders,
comprising the step of administering to a subject in need thereof
at least one compound of the formula I in an amount effective
therefor. Other therapeutic agents such as those described below
may be employed with the inventive compounds in the present
methods. In the methods of the present invention, such other
therapeutic agent(s) may be administered prior to, simultaneously
with or following the administration of the compound(s) of the
present invention.
[0170] Use of the compounds of the present invention in treating
protein tyrosine kinase-associated disorders is exemplified by, but
is not limited to, treating a range of disorders such as:
transplant (such as organ transplant, acute transplant or
heterograft or homograft (such as is employed in burn treatment))
rejection; protection from ischemic or reperfusion injury such as
ischemic or reperfusion injury incurred during organ
transplantation, myocardial infarction, stroke or other causes;
transplantation tolerance induction; arthritis (such as rheumatoid
arthritis, psoriatic arthritis or osteoarthritis); multiple
sclerosis; chronic obstructive pulmonary disease (COPD), such as
emphysema; inflammatory bowel disease, including ulcerative colitis
and Crohn's disease; lupus (systemic lupus erythematosis); graft
vs. host disease; T-cell mediated hypersensitivity diseases,
including contact hypersensitivity, delayed-type hypersensitivity,
and gluten-sensitive enteropathy (Celiac disease); psoriasis;
contact dermatitis (including that due to poison ivy); Hashimoto's
thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such
as Graves' Disease; Addison's disease (autoimmune disease of the
adrenal glands); Autoimmune polyglandular disease (also known as
autoimmune polyglandular syndrome); autoimmune alopecia; pernicious
anemia; vitiligo; autoimmune hypopituatarism; Guillain-Barre
syndrome; other autoimmune diseases; cancers, including cancers
where Lck or other Src-family kinases such as Src are activated or
overexpressed, such as colon carcinoma and thymoma, and cancers
where Src-family kinase activity facilitates tumor growth or
survival; glomerulonephritis; serum sickness; uticaria; allergic
diseases such as respiratory allergies (asthma, hayfever, allergic
rhinitis) or skin allergies; scleracierma; mycosis fungoides; acute
inflammatory responses (such as acute respiratory distress syndrome
and ishchemia/reperfusion injury); dermatomyositis; alopecia
areata; chronic actinic dermatitis; eczema; Behcet's disease;
Pustulosis palmoplanteris; Pyoderma gangrenum; Sezary's syndrome;
atopic dermatitis; systemic schlerosis; and morphea. The present
invention also provides a method for treating the aforementioned
disorders such as atopic dermatitis by administration of any
compound capable of inhibiting protein tyrosine kinase.
[0171] Src-family kinases other than Lck, such as Hck and Fgr, are
important in the Fc gamma receptor responses of monocytes and
macrophages. Compounds of the present invention inhibit the Fc
gamma dependent production of TNF alpha in the monocyte cell line
THP-1 that does not express Lck. The ability to inhibit Fc gamma
receptor dependent monocyte and macrophage responses results in
additional anti-inflammatory activity for the present compounds
beyond their effects on T cells. This activity is especially of
value, for example, in the treatment of inflammatory diseases such
as arthritis or inflammatory bowel disease. In particular, the
present compounds are of value for the treatment of autoimmune
glomerulonephritis and other instances of glomerulonephritis
induced by deposition of immune complexes in the kidney that
trigger Fc gamma receptor responses leading to kidney damage.
[0172] In addition, Src family kinases other than Lck, such as Lyn
and Src, are important in the Fc epsilon receptor induced
degranulation of mast cells and basophils that plays an important
role in asthma, allergic rhinitis, and other allergic disease. Fc
epsilon receptors are stimulated by IgE-antigen complexes.
Compounds of the present invention inhibit the Fc epsilon induced
degranulation responses, including in the basophil cell line RBL
that does not express Lck. The ability to inhibit Fc epsilon
receptor dependent mast cell and basophil responses results in
additional anti-inflammatory activity for the present compounds
beyond their effect on T cells. In particular, the present
compounds are of value for the treatment of asthma, allergic
rhinitis, and other instances of allergic disease.
[0173] The combined activity of the present compounds towards
monocytes, macrophages, T cells, etc. may be of value in the
treatment of any of the aforementioned disorders.
[0174] In a particular embodiment, the compounds of the present
invention are useful for the treatment of the aforementioned
exemplary disorders irrespective of their etiology, for example,
for the treatment of transplant rejection, rheumatoid arthritis,
multiple sclerosis, chronic obstructive pulmonary disease,
inflammatory bowel disease, lupus, graft v. host disease, T-cell
mediated hypersensitivity disease, psoriasis, Hashimoto's
thyroiditis, Guillain-Barre syndrome, cancer, contact dermatitis,
allergic disease such as allergic rhinitis, asthma, ischemic or
reperfusion injury, or atopic dermatitis whether or not associated
with PTK.
[0175] By virtue of their ability to inhibit HER1 and HER2 kinases,
compounds of the present invention can also be used for the
treatment of proliferative diseases, including psoriasis and
cancer. The HER1 receptor kinase has been shown to be expressed and
activated in many solid tumors including non-small cell lung,
colorectal, and breast cancer. Similarly, the HER2 receptor kinase
has been shown to be overexpressed in breast, ovarian, lung and
gastric cancer. Monoclonal antibodies that downregulate the
abundance of the HER2 receptor or inhibit signaling by the HER1
receptor have shown anti-tumor effficacy in preclincal and clinical
studies. It is therefore expected that inhibitors of the HER1 and
HER2 kinases will have efficacy in the treatment of tumors that
depend on signaling from either of the two receptors. These
compounds are expected to have efficacy either as single agent or
in combination with other chemotherapeutic agents such as
placlitaxel (Taxol), doxorubicin hydrochloride (adriamycin), and
cisplatin (Platinol). See the following documents and references
cited therein: Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert,
N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V.,
Shak, S., Lieberman, G., and Slamon, D. J., "Multinational study of
the efficacy and safety of humanized anti-HER2 monoclonal antibody
in women who have HER2-overexpressing metastatic breast cancer that
has progressed after chemotherapy for metastatic disease", J. of
Clin. Oncol. 17(9), p. 2639-2648 (1999); Baselga, J., Pfister, D.,
Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G.,
Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V.,
Waksal, H., and Mendelsohn, J., "Phase I studies of anti-epidermal
growth factor receptor chimeric antibody C225 alone and in
combination with cisplatin", J. Clin. Oncol. 18(4), p. 904-914
(2000).
[0176] The present invention also provides pharmaceutical
compositions comprising at least one of the compounds of the
formula I capable of treating a protein tyrosine kinase-associated
disorder in an amount effective therefor, and a pharmaceutically
acceptable vehicle or diluent. The compositions of the present
invention may contain other therapeutic agents as described below,
and may be formulated, for example, by employing conventional solid
or liquid vehicles or diluents, as well as pharmaceutical additives
of a type appropriate to the mode of desired administration (for
example, excipients, binders, preservatives, stabilizers, flavors,
etc.) according to techniques such as those well known in the art
of pharmaceutical formulation.
[0177] The compounds of the formula I may be administered by any
suitable means, for example, orally, such as in the form of
tablets, capsules, granules or powders; sublingually; buccally;
parenterally, such as by subcutaneous, intravenous, intramuscular,
or intrasternal injection or infusion techniques (e.g., as sterile
injectable aqueous or non-aqueous solutions or suspensions);
nasally such as by inhalation spray; topically, such as in the form
of a cream or ointment; or rectally such as in the form of
suppositories; in dosage unit formulations containing non-toxic,
pharmaceutically acceptable vehicles or diluents. The present
compounds may, for example, be administered in a form suitable for
immediate release or extended release. Immediate release or
extended release may be achieved by the use of suitable
pharmaceutical compositions comprising the present compounds, or,
particularly in the case of extended release, by the use of devices
such as subcutaneous implants or osmotic pumps. The present
compounds may also be administered liposomally.
[0178] Exemplary compositions for oral administration include
suspensions which may contain, for example, microcrystalline
cellulose for imparting bulk, alginic acid or sodium alginate as a
suspending agent, methylcellulose as a viscosity enhancer, and
sweeteners or flavoring agents such as those known in the art; and
immediate release tablets which may contain, for example,
microcrystalline cellulose, dicalcium phosphate, starch, magnesium
stearate and/or lactose and/or other excipients, binders,
extenders, disintegrants, diluents and lubricants such as those
known in the art. The present compounds may also be delivered
through the oral cavity by sublingual and/or buccal administration.
Molded tablets, compressed tablets or freeze-dried tablets are
exemplary forms which may be used. Exemplary compositions include
those formulating the present compound(s) with fast dissolving
diluents such as mannitol, lactose, sucrose and/or cyclodextrins.
Also included in such formulations may be high molecular weight
excipients such as celluloses (avicel) or polyethylene glycols
(PEG). Such formulations may also include an excipient to aid
mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy
propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose
(SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to
control release such as polyacrylic copolymer (e.g., Carbopol 934).
Lubricants, glidants, flavors, coloring agents and stabilizers may
also be added for ease of fabrication and use.
[0179] Exemplary compositions for nasal aerosol or inhalation
administration include solutions in saline which may contain, for
example, benzyl alcohol or other suitable preservatives, absorption
promoters to enhance bioavailability, and/or other solubilizing or
dispersing agents such as those known in the art.
[0180] Exemplary compositions for parenteral administration include
injectable solutions or suspensions which may contain, for example,
suitable non-toxic, parenterally acceptable diluents or solvents,
such as mannitol, 1,3-butanediol, water, Ringer's solution, an
isotonic sodium chloride solution, or other suitable dispersing or
wetting and suspending agents, including synthetic mono- or
diglycerides, and fatty acids, including oleic acid.
[0181] Exemplary compositions for rectal administration include
suppositories which may contain, for example, a suitable
non-irritating excipient, such as cocoa butter, synthetic glyceride
esters or polyethylene glycols, which are solid at ordinary
temperatures, but liquify and/or dissolve in the rectal cavity to
release the drug.
[0182] Exemplary compositions for topical administration include a
topical carrier such as Plastibase (mineral oil gelled with
polyethylene).
[0183] The effective amount of a compound of the present invention
may be determined by one of ordinary skill in the art, and includes
exemplary dosage amounts for an adult human of from about 0.1 to
100 mg/kg of body weight of active compound per day, which may be
administered in a single dose or in the form of individual divided
doses, such as from 1 to 4 times per day. It will be understood
that the specific dose level and frequency of dosage for any
particular subject may be varied and will depend upon a variety of
factors including the activity of the specific compound employed,
the metabolic stability and length of action of that compound, the
species, age, body weight, general health, sex and diet of the
subject, the mode and time of administration, rate of excretion,
drug combination, and severity of the particular condition.
Preferred subjects for treatment include animals, most preferably
mammalian species such as humans, and domestic animals such as
dogs, cats and the like, subject to protein tyrosine
kinase-associated disorders.
[0184] The compounds of the present invention may be employed alone
or in combination with each other and/or other suitable therapeutic
agents useful in the treatment of protein tyrosine
kinase-associated disorders such as PTK inhibitors other than those
of the present invention, antiinflammatories, antiproliferatives,
chemotherapeutic agents, immunosuppressants, anticancer agents and
cytotoxic agents.
[0185] Exemplary such other therapeutic agents include the
following: cyclosporins (e.g., cyclosporin A), CTLA4-Ig, antibodies
such as anti-ICAM-3, anti-IL-2 receptor (Anti-Tac), anti-CD45RB,
anti-CD2, anti-CD3 (OKT-3), anti-CD4, anti-CD80, anti-CD86,
monoclonal antibody OKT3, agents blocking the interaction between
CD40 and gp39, such as antibodies specific for CD40 and/or gp39
(i.e., CD154), fusion proteins constructed from CD40 and gp39
(CD40Ig and CD8gp39), inhibitors, such as nuclear translocation
inhibitors, of NF-kappa B function, such as deoxyspergualin (DSG),
non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen,
steroids such as prednisone or dexamethasone, gold compounds,
antiproliferative agents such as methotrexate, FK506 (tacrolimus,
Prograf), mycophenolate mofetil, cytotoxic drugs such as
azathiprine and cyclophosphamide, TNF-.alpha. inhibitors such as
tenidap, anti-TNF antibodies or soluble TNF receptor such as
etanercept (Enbrel), rapamycin (sirolimus or Rapamune), leflunimide
(Arava), and cyclooxygenase-2 (COX-2) inhibitors such as celecoxib
(Celebrex) and rofecoxib (Vioxx), or derivatives thereof, and the
PTK inhibitors disclosed in the following U.S. patent applications,
incorporated herein by reference in their entirety: Ser. No.
60/056,770, filed Aug. 25, 1997 (Attorney Docket No. QA202*), Ser.
No. 60/069,159, filed Dec. 9, 1997 (Attorney Docket No. QA202a*),
Ser. No. 09/097,338, filed Jun. 15, 1998 (Attorney Docket No.
QA202b), Ser. No. 60/056,797, filed Aug. 25, 1997 (Attorney Docket
No. QA205*), Ser. No. 09/094,797, filed Jun. 15, 1998 (Attorney
Docket No. QA205a), Ser. No. 60/065,042, filed Nov. 10, 1997
(Attorney Docket No. QA207*), Ser. No. 09/173,413, filed Oct. 15,
1998, (Attorney Docket No. QA207a), Ser. No. 60,076,789, filed Mar.
4, 1998 (Attorney Docket No. QA208*), and Ser. No. 09,262,525,
filed Mar. 4, 1999 (Attorney Docket No. QA208a). See the following
documents and references cited therein: Hollenbaugh, D.,
Douthwright, J., McDonald, V., and Aruffo, A., "Cleavable CD40Ig
fusion proteins and the binding to sgp39", J. Immunol. Methods
(Netherlands), 188(1), p. 1-7 (Dec. 15 1995); Hollenbaugh, D.,
Grosmaire, L. S., Kullas, C. D., Chalupny, N. J., Braesch-Andersen,
S., Noelle, R. J., Stamenkovic, I., Ledbetter, J. A., and Aruffo,
A., "The human T cell antigen gp39, a member of the TNF gene
family, is a ligand for the CD40 receptor: expression of a soluble
form of gp39 with B cell co-stimulatory activity", EMBO J
(England), 11(12), p 4313-4321 (December 1992); and Moreland, L. W.
et al., "Treatment of rheumatoid arthritis with a recombinant human
tumor necrosis factor receptor (p75)-Fc fusion protein, New England
J. of Medicine, 337(3), p. 141-147 (1997).
[0186] Exemplary classes of anti-cancer agents and cytotoxic agents
include, but are not limited to: alkylating agents, such as
nitrogen mustards, alkyl sulfonates, nitrosoureas, ethylenimines,
and triazenes; antimetabolites, such as folate antagonists, purine
analogues, and pyrimidine analogues; antibiotics, such as
anthracyclines, bleomycins, mitomycin, dactinomycin, and
plicamycin; enzymes, such as L-asparaginase; farnesyl-protein
transferase inhibitors; hormonal agents, such as glucocorticoids,
estrogens/antiestrogens, androgens/antiandrogens, progestins, and
luteinizing hormone-releasing hormone anatagonists, octreotide
acetate; microtubule-disruptor agents, such as ecteinascidins or
their analogs and derivatives; microtubule-stabilizing agents such
as paclitaxel (Taxol.RTM.), docetaxel (Taxotere.RTM.), and
epothilones A-F or their analogs or derivatives; plant-derived
products, such as vinca alkaloids, epipodophyllotoxins, taxanes;
and topoisomerase inhibitors; prenyl-protein transferase
inhibitors; and miscellaneous agents such as, hydroxyurea,
procarbazine, mitotane, hexamethylmelamine, platinum coordination
complexes such as cisplatin and carboplatin; and other agents used
as anti-cancer and cytotoxic agents such as biological response
modifiers, growth factors; immune modulators, and monoclonal
antibodies. The compounds of the invention may also be used in
conjunction with radiation therapy.
[0187] Representative examples of these classes of anti-cancer and
cytotoxic agents include, but are not limited to, mechlorethamine
hydrochlordie, cyclophosphamide, chlorambucil, melphalan,
ifosfamide, busulfan, carmustin, lomustine, semustine,
streptozocin, thiotepa, dacarbazine, methotrexate, thioguanine,
mercaptopurine, fludarabine, pentastatin, cladribin, cytarabine,
fluorouracil, doxorubicin hydrochloride, daunorubicin, idarubicin,
bleomycin sulfate, mitomycin C, actinomycin D, safracins,
saframycins, quinocarcins, discodermolides, vincristine,
vinblastine, vinorelbine tartrate, etoposide, teniposide,
paclitaxel, tamoxifen, estramustine, estramustine phosphate sodium,
flutamide, buserelin, leuprolide, pteridines, diyneses, levamisole,
aflacon, interferon, interleukins, aldesleukin, filgrastim,
sargramostim, rituximab, BCG, tretinoin, irinotecan hydrochloride,
betamethosone, gemcitabine hydrochloride, altretamine, and topoteca
and any analogs or derivatives thereof.
[0188] Preferred members of these classes include, but are not
limited to paclitaxel, cisplatin, carboplatin, doxorubicin,
carminomycin, daunorubicin, aminopterin, methotrexate, methopterin,
mitomycin C, ecteinascidin 743, porfiromycin, 5-fluorouracil,
6-mercaptopurine, gemcitabine, cytosine arabinoside,
podophyllotoxin or podophyllotoxin derivatives such as etoposide,
etoposide phosphate or teniposide, melphalan, vinblastine,
vincristine, leurosidine, vindesine, and leurosine.
[0189] Examples of anti-cancer and other cytotoxic agents include
the following: epothilone derivatives as found in U.S. Ser. No.
09/506,481 filed Feb. 17, 2000 (Attorney Docket No. LD186); German
Patent No. 4138042.8; WO 97/19086, WO 98/22461, WO 98/25929, WO
98/38192, WO 99/01124, WO 99/02224, WO 99/02514, WO 99/03848, WO
99/07692, WO 99/27890, WO 99/28324, WO 99/43653, WO 99/54330, WO
99/54318, WO 99/54319, WO 99/65913, WO 99/67252, WO 99/67253, and
WO 00/00485; cyclin dependent kinase inhibitors as found in WO
99/24416; and prenyl-protein transferase inhibitors as found in WO
97/30992 and WO 98/54966.
[0190] The above other therapeutic agents, when employed in
combination with the compounds of the present invention, may be
used, for example, in those amounts indicated in the Physicians'
Desk Reference (PDR) or as otherwise determined by one of ordinary
skill in the art.
[0191] The following assays can be employed in ascertaining the
degree of activity of a compound ("test compound") as a PTK
inhibitor. Compounds described in the following Examples have been
tested in one or more of these assays, and have shown activity.
Enzyme Assay Using Lck, Fyn, Lyn, Hck, Fgr, Src, Blk or Yes
[0192] The following assay has been carried out using the protein
tyrosine kinases Lck, Fyn, Lyn, Hck, Fgr, Src, Blk and Yes.
[0193] The protein tyrosine kinase of interest is incubated in
kinase buffer (20 mM MOPS, pH7, 10 mM MgCl.sub.2) in the presence
of the test compound.
[0194] The reaction is initiated by the addition of substrates to
the final concentration of 1 .mu.M ATP, 3.3 .mu.Ci/ml [33P]
gamma-ATP, and 0.1 mg/ml acid denatured enolase (prepared as
described in Cooper, J. A., Esch, F. S., Taylor, S. S., and Hunter,
T., "Phosphorylation sites in enolase and lactate dehydrogenase
utilized by tyrosine protein kinases in vivo and in vitro", J.
Biol. Chem., 259, 7835-7841 (1984)). The reaction is stopped after
10 minutes by the addition of 10% trichloroacetic acid, 100 mM
sodium pyrophosphate followed by 2 mg/ml bovine serum albumin. The
labeled enolase protein substrate is precipitated at 4 degrees,
harvested onto Packard Unifilter plates and counted in a Topcount
scintillation counter to ascertain the protein tyrosine kinase
inhibitory activity of the test compound (activity inversely
proportional to the amount of labeled enolase protein obtained).
The exact concentration of reagents and the amount of label can be
varied as needed.
[0195] This assay is advantageous as it employs an exogenous
substrate (enolase) for more accurate enzyme kinetics, and can be
conducted in a 96-well format that is readily automated. In
addition, His-tagged protein tyrosine kinases (described below)
offer much higher production yields and purity relative to
GST-protein tyrosine kinase fusion protein.
[0196] The protein tyrosine kinase may be obtained from commercial
sources or by recombinant methods described herewith. For the
preparation of recombinant Lck, human Lck was prepared as a
His-tagged fusion protein using the Life Technologies (Gibco)
baculovirus vector pFastBac Hta (commercially available) in insect
cells. A cDNA encoding human Lck isolated by PCR (polymerase chain
reaction) was inserted into the vector and the protein was
expressed using the methods described by the manufacturer. The Lck
was purified by affinity chromatography. For the production of Lck
in insect cells using baculovirus, see Spana, C., O'Rourke, E. C.,
Bolen, J. B., and Fargnoli, J., "Analysis of the tyrosine kinase
p561ck expressed as a glutathione S-transferase protein in
Spodoptera frugiperda cells," Protein expression and purification,
Vol. 4, p. 390-397 (1993). Similar methods may be used for the
recombinant production of other Src-family kinases.
[0197] Enzyme Assay Using HER1 or HER2 Compounds of interest were
assayed in a kinase buffer that contained 20 mM Tris.HCl, pH 7.5,
10 mM MnCl.sub.2, 0.5 mM dithiothreitol, bovine serum albumin at
0.1 mg/ml, poly(glu/tyr, 4:1) at 0.1 mg/ml, 1 .mu.M ATP, and 4
.mu.Ci/ml [gamma-.sup.33P]ATP. Poly(glu/tyr, 4:1) is a synthetic
polymer that serves as a phosphoryl acceptor and is purchased from
Sigma Chemicals. The kinase reaction is initiated by the addition
of enzyme and the reaction mixtures were incubated at 26.degree. C.
for 1 h. The reaction is terminated by the addition of EDTA to 50
mM and proteins are precipitated by the addition of trichloroacetic
acid to 5%. The precipitated proteins are recovered by filtration
onto Packard Unifilter plates and the amount of radioactivity
incorporated is measured in a Topcount scintillation counter.
[0198] For the preparation of recombinant HER1, the cytoplasmic
sequence of the receptor were expressed in insect cells as a GST
fusion protein, which was purified by affinity chromatography as
described above for Lck. The cytoplasmic sequence of HER2 was
subcloned into the baculovirus expression vector pBlueBac4
(Invitrogen) and was expressed as an untagged protein in insect
cells. The recombinant protein was partially purified by
ion-exchange chromatography.
[0199] Cell Assays
(1) Cellular Tyrosine Phosphorylation
[0200] Jurkat T cells are incubated with the test compound and then
stimulated by the addition of antibody to CD3 (monoclonal antibody
G19-4). Cells are lysed after 4 minutes or at another desired time
by the addition of a lysis buffer containing NP-40 detergent.
Phosphorylation of proteins is detected by anti-phosphotyrosine
immunoblotting. Detection of phosphorylation of specific proteins
of interest such as ZAP-70 is detected by immunoprecipitation with
anti-ZAP-70 antibody followed by anti-phosphotyrosine
immunoblotting. Such procedures are described in Schieven, G. L.,
Mittler, R. S., Nadler, S. G., Kirihara, J. M., Bolen, J. B.,
Kanner, S. B., and Ledbetter, J. A., "ZAP-70 tyrosine kinase, CD45
and T cell receptor involvement in UV and H.sub.2O.sub.2 induced T
cell signal transduction", J. Biol. Chem., 269, 20718-20726 (1994),
and the references incorporated therein. The Lck inhibitors inhibit
the tyrosine phosphorylation of cellular proteins induced by
anti-CD3 antibodies.
[0201] For the preparation of G19-4, see Hansen, J. A., Martin, P.
J., Beatty, P. G., Clark, E. A., and Ledbetter, J. A., "Human T
lymphocyte cell surface molecules defined by the workshop
monoclonal antibodies," in Leukocyte Typing I, A. Bernard, J.
Boumsell, J. Dausett, C. Milstein, and S. Schlossman, eds. (New
York: Springer Verlag), p. 195-212 (1984); and Ledbetter, J. A.,
June, C. H., Rabinovitch, P. S., Grossman, A., Tsu, T. T., and
Imboden, J. B., "Signal transduction through CD4 receptors:
stimulatory vs. inhibitory activity is regulated by CD4 proximity
to the CD3/T cell receptor", Eur. J. Immunol., 18, 525 (1988).
(2) Calcium Assay
[0202] Lck inhibitors block calcium mobilization in T cells
stimulated with anti-CD3 antibodies. Cells are loaded with the
calcium indicator dye indo-1, treated with anti-CD3 antibody such
as the monoclonal antibody G19-4, and calcium mobilization is
measured using flow cytometry by recording changes in the
blue/violet indo-1 ratio as described in Schieven, G. L., Mittler,
R. S., Nadler, S. G., Kirihara, J. M., Bolen, J. B., Kanner, S. B.,
and Ledbetter, J. A., "ZAP-70 tyrosine kinase, CD45 and T cell
receptor involvement in UV and H.sub.2O.sub.2 induced T cell signal
transduction", J. Biol. Chem., 269, 20718-20726 (1994), and the
references incorporated therein.
(3) Proliferation Assays
[0203] Lck inhibitors inhibit the proliferation of normal human
peripheral blood T cells stimulated to grow with anti-CD3 plus
anti-CD28 antibodies. A 96 well plate is coated with a monoclonal
antibody to CD3 (such as G19-4), the antibody is allowed to bind,
and then the plate is washed. The antibody bound to the plate
serves to stimulate the cells. Normal human peripheral blood T
cells are added to the wells along with test compound plus
anti-CD28 antibody to provide co-stimulation. After a desired
period of time (e.g., 3 days), the [3H]-thymidine is added to the
cells, and after further incubation to allow incorporation of the
label into newly synthesized DNA, the cells are harvested and
counted in a scintillation counter to measure cell
proliferation.
[0204] The following Examples illustrate embodiments of the present
invention, and are not intended to limit the scope of the claims.
Abbreviations employed in the Examples are defined below. Compounds
of the Examples are identified by the example and step in which
they are prepared (for example, "IA" denotes the title compound of
step A of Example 1), or by the example only where the compound is
the title compound of the example (for example, "2" denotes the
title compound of Example 2).
ABBREVIATIONS
[0205] aq.=aqueous [0206] conc.=concentrated [0207]
DMSO=dimethylsulfoxide [0208] EtOAc=ethyl acetate [0209]
Et.sub.2O=diethyl ether [0210] h=hours [0211]
HATU=N-[dimethylamino-1H-1,2,3-triazolo-[4,5-b]pyridin-1-yl
methylene]-N-methyl methanaminium hexafluorophosphate N-oxide
[0212] MeOH=methanol [0213] MOPS=4-morpholine-propanesulfonic acid
[0214] MS=mass spectrometry [0215] Ret Time=retention time [0216]
RT=room temperature [0217] satd.=saturated [0218]
TFA=trifluoroacetic acid [0219] THF=tetrahydrofuran [0220]
DMF=N,N-dimethylformamide
Example 1
Preparation of
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-methyl-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
##STR00019##
[0221] A.
Ethyl-2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxyl-
ate
[0222] A suspension of
ethyl-2-amino-4-methyl-thiazole-5-carboxylate (18.6 g, 100 mmol),
di-t-butyldicarbonate (26.2 g, 120 mmol) and
4-dimethylaminopyridine (800 mg, 6.55 mmol) in dry tetrahydrofuran
(300 mL) was stirred under nitrogen for 18 h. The solvent was
evaporated in vacuo. The residue was suspended in dichloromethane
(1 L) and filtered through a pad of celite. The filtrate was washed
with 1 N aqueous HCl solution (300 mL, 2.times.), water and brine,
dried (MgSO.sub.4), and concentrated in vacuo. The residue was
triturated with hexanes. The solid was filtered and dried in vacuo
to obtain the title compound (20 g, 72%) as a tan solid.
B. 2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxylic
acid
[0223] A stirred solution of
ethyl-2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxylate
(10 g, 34.95 mmol) in tetrahydrofuran-ethanol (250 mL, 2:3) was
treated with a 6N KOH solution (250 mL). The mixture was heated to
55.degree. C. overnight. The solution was cooled to 0.degree. C.
and acidified with concd. HCl to pH 1. The solvent was evaporated
in vacuo. The residue was washed with water, diethyl ether, dried
in vacuo over anhydrous phosphorous pentoxide to obtain the title
acid (6 g, 89%) as a white solid.
C. 2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxylic
acid chloride
[0224] A 2 M solution of oxalyl chloride in dichloromethane (22.5
mL, 45 mmol) was added dropwise to a stirred suspension of
2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxylic acid
(10 g, 38.72 mmol) in dichloromethane (150 mL) and N,N-dimethyl
formamide (150 .mu.L) at 00.degree. C. The suspension gradually
became homogenous after addition was complete. The solution was
allowed to warm to room temperature and stirred at rt for 1.5 h.
The solvent was evaporated in vacuo and the residue was
coevaporated with toluene (300 mL, 2.times.) and then dried in
vacuo to obtain the title acid chloride (10.7 g, 99%) as a tan
solid.
D.
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-methyl-2-thiazolyl]carbam-
ic acid, 1,1-dimethylethyl ester
[0225] 2,4,6-Trimethyl aniline (6.3 mL, 38.66 mmol) was added
dropwise to a stirred solution of
2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxylic acid
chloride (10.7 g, 38.66 mmol) in dichloromethane (150 mL) at
0.degree. C. After 20 min, diisopropylethylamine (8.8 mL, 44.88
mmol) was added dropwise. The solution was allowed to warm to rt
and stirred for an additional 2 h. The solvent was evaporated in
vacuo. The residue was suspended in EtOAc (700 mL), washed with 1 N
aq. HCl solution (300 mL, 2.times.), water, and brine; dried
(MgSO.sub.4), filtered and concentrated. The residue was triturated
with ether to obtain the title compound (12.5 g, 86%) as a tan
solid.
Example 2
Preparation of
2-Amino-N-(2,4,6-trimethylphenyl)-4-methyl-5-thiazolecarboxamide
##STR00020##
[0227] A solution of
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-methyl-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester (10 g, 26.63 mmol) in trifluoroacetic
acid (100 mL) was stirred at rt for 3 h. The solution was
concentrated under reduced pressure and the residue was diluted
with EtOAc (700 mL), washed with 5% aq. KHCO.sub.3 solution (400
mL, 2.times.), water, and brine; dried (MgSO.sub.4), filtered and
concentrated. The residue was washed with ether (200 mL) and
acetonitrile (100 mL) to obtain the title compound (6.7 g, 91%) as
a white solid.
Example 3
Preparation of
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-trifluoromethyl-2-thiazolyl-
]carbamic acid, 1,1-dimethylethyl ester
##STR00021##
[0228] A.
Ethyl-2-tert-butoxycarbonyloxyamino-4-trifluoromethyl-thiazole-5-
-carboxylate
[0229] A suspension of
ethyl-2-amino-4-trifluoromethyl-thiazole-5-carboxylate (5.05 g,
21.02 mmol), di-t-butyldicarbonate (4.82 g, 22.07 mmol) and
4-dimethylaminopyridine (260 mg, 2.1 mmol) in dichloromethane (209
mL) was stirred under nitrogen for 1.5 h. The solvent was
evaporated in vacuo. The residue was chromatographed on a silica
gel column. Elution with 5% EtOAc in hexanes, followed by 15% EtOAc
in hexanes afforded the title compound (6.57 g, 92%) as a white
solid.
B.
2-Tert-butoxycarbonyloxyamino-4-trifluoromethyl-thiazole-5-carboxylic
acid
[0230] A stirred solution of
ethyl-2-tert-butoxycarbonyloxyamino-4-trifluoromethyl-thiazole-5-carboxyl-
ate (6.5 g, 19.1 mmol) in methanol (100 mL) was treated with a 1N
aq. NaOH solution (573 mL). The mixture was stirred at rt
overnight. The solution was cooled to 0.degree. C. and acidified
with a 6 M aq. HCl solution to pH 1 and extracted with chloroform
(150 mL, 6.times.). The chloroform extracts were combined, dried
(Na.sub.2SO.sub.4), filtered and concentrated under reduced
pressure and in vacuo to obtain the title acid (5.75 g, 96%) as a
white solid.
C.
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-trifluoromethyl-2-thiazol-
yl]carbamic acid, 1,1-dimethylethyl ester
[0231] 4-Methylmorpholine (40 .mu.L, 0.39 mmol) was added to a
mixture of
2-tert-butoxycarbonyloxyamino-4-trifluoromethyl-thiazole-5-carboxylic
acid (100 mg, 0.32 mmol), 2,4,6-trimethylaniline (45 .mu.L, 0.32
mmol), and benzotriazol-1-yloxy-tris-(dimethylamino)phosphonium
hexafluorophosphate (BOP reagent, 380 mg, 0.4 mmol) in DMF (2 mL).
The solution was stirred at rt for 72 h, diluted with
dichloromethane and washed with 0.25 M aq. KHSO.sub.4 solution
followed by satd. aq. KHCO.sub.3 solution. The dichloromethane
extract was separated, dried (Na.sub.2SO.sub.4), filtered and
concentrated. The residue was chromatographed on a silica gel
column and eluted with 5% EtOAc in hexanes followed by 10% EtOAc in
hexanes to obtain the title compound (90 mg, 65%) as a white
solid.
Example 4
Preparation of
2-Amino-N-(2,4,6-trimethylphenyl)-4-trifluoromethyl-5-thiazolecarboxamide-
, trifluoroacetate (1:1)
##STR00022##
[0233] A solution of
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-trifluoromethyl-2-thiazolyl-
]carbamic acid, 1,1-dimethylethyl ester (120 mg, 0.28 mmol) in
trifluoroacetic acid (5 mL) was stirred at 0.degree. C. for 1 h.
The solution was concentrated under reduced pressure and the
residue was coevaporated with ether to obtain a yellow solid which
was triturated with hexanes to obtain the title compound (96 mg,
76%) as a light yellow solid.
Example 5
Preparation of
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-phenyl-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
##STR00023##
[0234] A.
Ethyl-2-tert-butoxycarbonyloxyamino-4-phenyl-thiazole-5-carboxyl-
ate
[0235] Compound 5A was prepared by an analogous method as that of
3A, except using ethyl-2-amino-4-phenyl-thiazole-5-carboxylate to
give the title compound 5A as a white solid (90.5%).
B. 2-Tert-butoxycarbonyloxyamino-4-phenyl-thiazole-5-carboxylic
acid
[0236] Compound 5B was prepared by an analogous method as that of
3B, except using 5A to give the title compound 5B as a white solid
(99%).
C. 2-Tert-butoxycarbonyloxyamino-4-phenyl-thiazole-5-carboxylic
acid chloride
[0237] Compound 5C was prepared by an analogous method as that of
IC, except using 5B to give the title compound 5C as a white solid
(90%).
D.
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-phenyl-2-thiazolyl]carbam-
ic acid, 1,1-dimethylethyl ester
[0238] Compound 5D was prepared by an analogous method as that of
ID, except using 5C to give the title compound 5D as a light yellow
solid (93%).
Example 6
Preparation of
2-Amino-N-(2,4,6-trimethylphenyl)-4-phenyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00024##
[0240] Compound 6 was prepared by an analogous method as that of 4,
except using 5D to give the title compound 6 as a white solid
(68%).
Example 7
Preparation of
[5-[[Phenylamino]carbonyl]-4-methyl-2-thiazolyl]carbamic acid,
1,1-dimethylethyl ester
##STR00025##
[0242] Compound was prepared by an analogous method as that of ID,
except using aniline in place of 2,4,6-trimethylaniline and
triethylamine in place of diisopropylethylamine to give the title
compound 7 as an off-white solid (76%).
Example 8
Preparation of 2-Amino-N-(phenyl)-4-methyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00026##
[0244] Compound 8 was prepared by an analogous method as that of 4,
except using 7 to give the title compound 8 as a white solid
(68%).
Example 9
Preparation of
[5-[[(2,4-Dichlorophenyl)amino]carbonyl]-4-methyl-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
##STR00027##
[0246] Compound 9 was prepared by an analogous method as that of
ID, except using 2,4-dichloroaniline to give the title compound 9
as a white solid (28%).
Example 10
Preparation of 2-Amino-N-(2,
4-dichlorophenyl)-4-methyl-5-thiazolecarboxamide, trifluoroacetate
(1:1)
##STR00028##
[0248] Compound 10 was prepared by an analogous method as that of
4, except using 9 to give the title compound 8 as a white solid
(100%).
Example 11
Preparation of
5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
##STR00029##
[0249] A.
Ethyl-2-tert-butoxycarbonyloxyamino-thiazole-5-carboxylate
[0250] Compound 11A was prepared by an analogous method as that of
3A, except using ethyl-2-amino-thiazole-5-carboxylate to give the
title compound 11A as a white solid (79.5%).
B. 2-Tert-butoxycarbonyloxyamino-thiazole-5-carboxylic acid
[0251] Compound 11B was prepared by an analogous method as that of
3B, except using 11A to give the title compound 11B as a white
solid (95.5%).
C. 2-Tert-butoxycarbonyloxyamino-thiazole-5-carboxylic acid
chloride
[0252] Compound 11C was prepared by an analogous method as that of
IC, except using 11B to give the title compound 11C.
D. [5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
[0253] Compound 11D was prepared by an analogous method as that of
ID, except using 11C to give the title compound 11D as an off-white
solid (70%).
Example 12
Preparation of
2-Amino-N-(2,4,6-trimethylphenyl)-4-phenyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00030##
[0255] Compound 12 was prepared by an analogous method as that of
4, except using 11D to give the title compound 12 as a light yellow
solid (88%).
Examples 13 to 53
General Procedure
[0256] Compounds 13 to 53 were prepared following the procedure
described below. Appropriate amines (0.40 mmol) and
diisopropylethylamine (70 .mu.L, 0.40 mmol) were added to a
suspension of 1C (100 mg, 0.36 mmol) in dichloromethane (3 mL). The
solution was stirred mechanically in a sealed tube at rt for 16 h.
The reaction mixtures were diluted with methanol (200 .mu.L) and
loaded in Varian SCX ion exchange columns (2 g/6 cc) pretreated
with methanol-dichloromethane (8 mL, 1:1) followed by
dichloromethane (8 mL). SCX Column filtration were performed using
a Gilson robot unit. The column was washed sequentially with
dichloromethane (9 mL), dichloromethane-methanol (9 mL, 4:1),
dichloromethane-methanol (9 mL, 1:1), methanol (9 mL), 0.01 M
ammonium hydroxide in methanol (9 mL) and 0.05 M ammonium hydroxide
in methanol (9 mL). The elutes were collected separately by the
robot and then concentrated using a speed vac. Fractions containing
the products were combined.
[0257] "HPLC Ret Time" is the HPLC retention time under the
following conditions: YMC S5 ODS 4.6.times.50 mm Ballastic Column,
4 min gradient starting from 100% solvent A (10% MeOH, 90%
H.sub.2O, 0.2% H.sub.3PO.sub.4) to 100% solvent B (90% MeOH, 10%
H.sub.2O, 0.2% H.sub.3PO.sub.4), flow rate 4 mL/min, .lamda.=220
nM.
TABLE-US-00001 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 13 ##STR00031## [5-[[(2-Methoxy-6- methylphenyl)amino]-
carbonyl]-4-methyl-2- thiazolyl]carbamic acid 1,1-dimethylethyl
ester 3.79 14 ##STR00032## [4-Methyl-5-[[[3- methyl-4-(1-methyl-
ethyl)phenyl]amino]- carbonyl]-2- thiazolyl]-carbamic acid
1,1-dimethylethyl ester 4.51 15 ##STR00033## [5-[[(4-Bromo-2,6-di-
methylphenyl)amino]- carbonyl]-4-methyl-2- thiazolyl]carbamic acid
1,1-dimethyl- ethyl ester 4.24 16 ##STR00034## [4-Methyl-5-[[[2-
methyl-6-(1- methylethyl)phenyl]- amino]cabonyl]-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 4.17 17
##STR00035## [5-[[(2,4- Dimethylphenyl)amino] carbonyl]-4-methyl-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 4.05 18
##STR00036## [4-Methyl-5-[[(2- methylphenyl)amino]car- bonyl]-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.87 19
##STR00037## [5-[[(2-Chloro-6- methylphenyl)amino]car-
bonyl]-4-methyl-2- thiazolyl]carbamic acid 1,1-dimethylethyl ester
3.86 20 ##STR00038## [5-[[[2-(1,1- Dimethylethyl)-4-
methylphenyl]amino]car- bonyl]-4-methyl-2- thiaozlyl]carbamic acid
1,1-dimethylethyl ester 4.30 21 ##STR00039## [5-[[(2-
Furanylmethyl)amino]car- bonyl]-4-methyl-2- thiazolyl]carbamic acid
1,1-dimethylethyl ester 3.54 22 ##STR00040## [5-[[[3-Methoxy-5-
(trifluoromethyl)phenyl] amino]carbonyl]-4- methyl-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 4.43 23
##STR00041## [5-[[(4- Cyclohexylphenyl)amino] carbonyl]-4-methyl-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 4.78 24
##STR00042## [5-[[(Cyclohexyl methyl)amino]carbonyl]-
4-methyl-2-thiazolyl] carbamic acid 1,1- dimethylethyl ester 4.21
25 ##STR00043## [5-[[(2,3-Dihydro-1H- indenyl)amino]carbonyl]-
4-methyl-2- thiazolyl]carbamic acid 1,1-dimethylethyl ester 4.30 26
##STR00044## [5-[(2,5-Dihydro-1H- pyrrol-1-yl)carbonyl]-
4-methyl-2- thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.56 27
##STR00045## [5-[(2,5-Dihydro-2,5- dimethyl-1H-pyrrol-1-
yl)carbonyl]-4-methyl- 2-thiazolyl]carbamic acid 1,1-dimethylethyl
ester 3.86 28 ##STR00046## 1-[[2-[[(1,1- Dimethylethoxy)carbonyl]
amino]-4-methyl-5- thiazolyl]carbonyl]-L- prolinamide 2.96 29
##STR00047## [5-[(4-Formyl-1- piperazinyl)carbonyl]- 4-methyl-2-
thiaozlyl]carbamic acid 1,1-dimethylethyl ester 2.90 30
##STR00048## [5-(1,4-Dioxa-8- azaspiro[4.5]decan-8-
ylcarbonyl)-4-methyl- 2-thiazolyl]carbamic acid 1,1-dimethylethyl
ester 3.54 31 ##STR00049## [5-[[3-[(Diethylamino) carbonyl]-1-
piperidinyl] carbonyl]-4-methyl-2- thiazolyl]carbamic acid
1,1-dimethylethyl ester 3.66 32 ##STR00050## [4-Methyl-5-
[(octahydro-1- quinolinyl)carbonyl]- 2-thiazolyl]carbamic acid
1,1-dimethylethyl ester 4.37 33 ##STR00051## 2-[[(1,1-
Dimethylethoxy) carbonyl]amino]-4- methyl-5- thiazolecarboxylic
acid 2-[(1,1- dimethylethoxy) carbonyl]hydrazide 3.50 34
##STR00052## [5-[[(4-Methoxyphenyl) amino]carbonyl]-4- methyl-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.83 35
##STR00053## [4-Methyl-5-[[(4- methylphenyl)amino]car- bonyl]-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 4.07 36
##STR00054## [5-[[(1,2- Dimethylpropyl) amino]carbonyl]-4-
methyl-2- thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.87 37
##STR00055## [5-[[(2,2- Dimethylpropyl) amino]carbonyl]-4-
methyl-2- thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.97 38
##STR00056## [4-Methyl-5-[(2- propynylamino)carbonyl]-
2-thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.22 39
##STR00057## [4-Methyl-5-[(2- propenylamino)carbonyl]-
2-thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.41 40
##STR00058## [4-Methyl-5- [(methylphenylamino) carbonyl]-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.75 41
##STR00059## [4-Methyl-5-[[(3,4,5- trimethoxyphenyl)amino]
carbonyl]-2- thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.84
42 ##STR00060## [5-[[[2,6,8-Bis(1- methylethyl)phenyl]ami-
no]carbonyl]-4-methyl- 2-thiazolyl]carbamic acid 1,1-dimethylethyl
ester 4.40 43 ##STR00061## [5-[[[3-(1H-Imidazol- 1-
yl)propyl]amino]carbonyl]- 4-methyl-2- thiazolyl]carbamic acid
1,1-dimethylethyl ester 2.45 44 ##STR00062## [5-[[[(3,4-
Difluorophenyl)methyl] amino]carbonyl]-4- methyl-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.97 45
##STR00063## N-[[2-[[(1,1- Dimethylethoxy)carbonyl]
amino]-4-methyl-5- thiazolyl]carbonyl]-L- leucine methyl ester 3.99
46 ##STR00064## 5-[[[2-[[(1,1- Dimethylethoxy)carbonyl]
amino]-4-methyl-5- thiazolyl]carbonyl]ami- no]-4-oxopentanoic acid
methyl ester 3.27 47 ##STR00065## [5-[[[2-(Ethylthio)
ethyl]amino]carbonyl]- 4-methyl-2-thiazolyl] carbamic acid 1,1-
dimethylethyl ester 3.75 48 ##STR00066## [5-[[Bis(3-
methylbutyl)amino]carbo- nyl]-4-methyl-2- thiazolyl]carbamic acid
1,1-dimethylethyl ester 4.67 49 ##STR00067## [5-[[Ethyl(1-
methylethyl)amino]carbo- nyl]-4-methyl-2- thiazolyl]carbamic acid
1,1-dimethylethyl ester 3.84 50 ##STR00068## 2-[[(1,1-
Dimethylethoxy)carbonyl] amino]-4-methyl-5- thiazolecarboxylic acid
2-[[(3,5- dichlorophenyl)amino]thi- oxomethyl]hydrazide 4.66 51
##STR00069## [5-[[Bis(2- ethoxyethyl)amino]carbo- nyl]-4-methyl-2-
thiazolyl]carbamic acid 1,1-dimethylethyl ester 3.83 52
##STR00070## [4-Methyl-5-[[3- [(trifluoroacetyl)amino]- 1-
pyrrolidinyl]carbonyl]- 2-thiazolyl]carbamic acid 1,1-dimethylethyl
ester 3.47 53 ##STR00071## [5-[[(2,6- Dimethylphenyl)amino]
carbonyl]-4-methyl-2- thiazolyl]carbamic acid 1,1-dimethylethyl
ester 3.87
Examples 54 to 129
General Procedure
[0258] Compounds 54 to 129 were prepared following the procedure
described below. Diisopropylethyl amine (60 .mu.L, 0.34 mmol) was
added to a mixture of amine 2 (30 mg, 0.11 mmol), appropriate
carboxylic acid (0.13 mmol), 1-hydroxy-7-azabenzotriazole (19.5 mg,
0.14 mmol), and ethyl-3-(3-dimethylamino)-propyl carbodiimide
hydrochloride (26.8 mg, 0.14 mmol) in THF (0.4 mL). The mixture was
heated in a sealed tube under argon at 45.degree. C. for 24 h. The
reaction mixture was diluted with dichloromethane (4 mL) and washed
with 2 N aq. HCl solution (2 mL, 3.times.). The dichloromethane
solution was passed through a Varian SCX cation exchange column (2
g, 6 cc) on a Gilson robot. The column was eluted sequentially with
acetonitrile-methanol (10 mL, 4:1), methanol-2M methanolic ammonia
(3 mL, 4:1), and 2 M methanolic ammonia solution (3 mL, 4.times.).
The fractions were collected separately using the Gilson robot.
Fraction containing the product was concentrated and dried in
vacuo. "HPLC Ret Time" is the HPLC retention time under the
following conditions: YMC S5 ODS 4.6.times.50 mm Ballastic Column,
4 min gradient starting from 100% solvent A (10% MeOH, 90%
H.sub.2O, 0.2% H.sub.3PO.sub.4) to 100% solvent B (90% MeOH, 10%
H.sub.2O, 0.2% H.sub.3PO.sub.4), flow rate 4 mL/min, .lamda.=220 nM
for compounds 54-127. For compounds 128-129 HPLC conditions are:
Zorbax S8-C18 4.5 mm.times.7.5 cm short column, 8 min gradient
starting from 100% solvent A (10% MeOH, 90% H.sub.2O, 0.2%
H.sub.3PO.sub.4) to 100% solvent B (90% MeOH, 10% H.sub.2O, 0.2%
H.sub.3PO.sub.4), flow rate 2.5 mL/min, .lamda.=217 nM.
TABLE-US-00002 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 54 ##STR00072## 2-[[(2,2-Dichloro-1-methyl-
cyclopropyl)carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.22 55 ##STR00073##
2-[(Cyclohexylacetyl)amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.47 56 ##STR00074## 2-[(2,5-Difluoro-
benzoyl)amino]-4-methyl-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 4.15 57 ##STR00075## 2-[(5-Bromo-2-chloro-
benzoyl)amino]-4-methyl- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.37 58 ##STR00076##
2-[(3-Cyano-benzoyl)amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.06 59 ##STR00077## 2-[[4-(Acetylamino)-
benzoyl]amino]-4-methyl- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.60 60 ##STR00078##
4-Methyl-2-[[3-(trifluoro- methyl)benzoyl]amino]-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.45 61
##STR00079## 4-Methyl-2-[[2-(2-phenyl- ethyl)benzoyl]-amino]-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.64 62
##STR00080## 2-[(3,5-Dimethyl- benzoyl)amino]-4-methyl-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.49 63
##STR00081## 2-[(4-Ethenyl- benzoyl)amino]-4-methyl-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 64 ##STR00082##
2-[(4-Butyl- benzoyl)amino]-4-methyl- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.58 65 ##STR00083## 4-Methyl-2-[(4-pentyl-
benzoyl)amino]-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide
4.76 66 ##STR00084## 4-Methyl-2-[(2-methyl- 1-oxohexyl)amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.41 67 ##STR00085##
4-Methyl-2-[(1-oxo-3- phenoxypropyl)amino]-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.21 68
##STR00086## 4-Methyl-2-[(1-oxo-3- phenylpropyl)amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.26 69 ##STR00087##
2-[[3-(2-Methoxy- phenyl)-1-oxopropyl]- amino]-4-methyl-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.31 70 ##STR00088##
4-Methyl-2-[(2-naphthalenyl- acetyl)-amino]-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.43 71 ##STR00089##
2-[(Diphenyl-acetyl)amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.13 72 ##STR00090## 2-[[(2-Chloro-6-fluoro-
phenyl)acetyl]-amino]-4- methyl-N-(2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 4.17 73 ##STR00091##
4-Methyl-2-[[(2-methyl- phenyl)-acetyl]amino]-N-
(2,4,6-trimethylphenyl)-5- thiazolecarboxamide 3.95 74 ##STR00092##
2-[[(3-Methoxy- phenyl)acetyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.11 75 ##STR00093##
2-[[(3,4-Dimethoxy- phenyl)acetyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 3.90 76 ##STR00094##
2-[[(4-Chloro- phenyl)acetyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.34 77 ##STR00095##
2-[([1,1'-Biphenyl]-4- ylacetyl)amino]-4-methyl-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.60 78
##STR00096## 4-Methyl-2-[(1-oxo-4- phenylbutyl)amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.40 79 ##STR00097##
4-Methyl-2-[(1- oxooctyl)amino]-N-(2,4,6- trimethylphenyl)-
5-thiazolecarboxamide 4.65 80 ##STR00098## 2-[(2-Hydroxy-2-phenyl-
1-oxopropyl)amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.13 81 ##STR00099## 2-[(2-Hydroxy-1-
oxohexyl)amino] -4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.14 82 ##STR00100## 4-Methyl-2-[[1-oxo-4-(2-
thienyl)-butyl]amino]-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.32 83 ##STR00101## 4-Methyl-2-[(3-thienyl-
carbonyl)amino]-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide
4.04 84 ##STR00102## 2-[(2-Benzofuranyl- carbonyl)amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.37 85
##STR00103## N-[4-Methyl-5- [[(2,4,6-trimethyl-
phenyl)amino]carbonyl]- 2-thiazolyl]-4-pyridine- carboxamide,
N-oxide 3.50 86 ##STR00104## 6-Chloro-N-[4-methyl-
5-[[(2,4,6-trimethyl- phenyl)amino]carbonyl]- 2-thiazolyl]-3-
pyridinecarboxamide 4.08 87 ##STR00105## N-[4-Methyl-5-[[(2,4,6-
trimethylphenyl)amino] carbonyl]-2-thiazolyl]-3-
pyridinecarboxamide 3.56 88 ##STR00106## N-[4-Methyl-5-
[[(2,4,6-trimethyl- phenyl)amino]carbonyl]- 2-thiazolyl]-3-
quinolinecarboxamide 4.11 89 ##STR00107## 4-Methyl-2-[[(4-
nitrophenyl)acetyl]- amino]-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.08 90 ##STR00108## 4-Methyl-2-[(2,4,6-
trichlorobenzoyl)amino]- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.45 91 ##STR00109## 4-Methyl-2-[[2-[[3-
(trifluoromethyl)- phenyl]amino]benzoyl]- amino]-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.86 92 ##STR00110##
4-Methyl-2-[[4-(4- nitrophenyl)-1- oxobutyl]amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.28 93 ##STR00111##
4-Methyl-2-[[4- (methyl-sulfonyl)- benzoyl]-amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 3.79 94 ##STR00112##
2-[(4-Heptylbenzoyl) amino]-4-methyl-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 95 ##STR00113## 2-[[(2,4-Difluoro-
phenyl)acetyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.15 96 ##STR00114##
(S)-2-[[2-(Dipropylamino)-1- oxopropyl]amino]-4-methyl-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 3.20 97
##STR00115## 2-[(2-Biphenyl- enecarbonyl)amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.64 98 ##STR00116##
2-[[3-(3- Methoxyphenyl)-1- oxopropyl]amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.26 99 ##STR00117##
4-Methyl-N-(2,4,6- trimethylphenyl)-2- [[(2,4,6-trimethyl-
phenyl)acetyl]amino]- 5-thiazolecarboxamide 4.52 100 ##STR00118##
4-Methyl-2-[(1-oxo-6- heptenyl)amino]-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.47 101 ##STR00119## 2-[[(1,3-Benzodioxol-
5-yl)acetyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.07 102 ##STR00120## 4-Methyl-2-[[[2-
(phenylmethoxy)phenyl] acetyl]amino]-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.46 103 ##STR00121##
4-Methyl-2-[[(3-phenoxy- phenyl)acetyl]amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.56 104
##STR00122## 2-[(3,5-Dimethoxy- phenyl)acetyl]amino]-
4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.13 105
##STR00123## 2-[[4-[4-[Bis(2-chloro- ethyl)amino]phenyl]-1-
oxobutyl]amino]-4-methyl- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.75 106 ##STR00124##
4-[[4-[[[4-methyl-5-[[(2,4,6- trimethylphenyl)amino]
carbonyl]-2-thiazolyl]- amino]-carbonyl]phenyl]-
amino]-4-oxobutanoic acid methyl ester 4.03 107 ##STR00125##
4-Methyl-2-[[(phenyl- sulfonyl)acetyl]amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 3.77 108
##STR00126## 2-[[2-(Acetylamino)-1- oxohexyl]amino]-4-methyl-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 3.99 109
##STR00127## 2-[[4-[(Dipropyl-amino) sulfonyl]benzoyl]amino]-
4-methyl-N-(2,4,6- trimethylphenyl)- 5-thiazolecarboxamide 4.51 110
##STR00128## 2-[(4-Cyclohexyl- benzoyl)amino]-4-methyl-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.94 111
##STR00129## 2-[(4-Bromo-3-methyl- benzoyl)amino]-4-methyl-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.80 112
##STR00130## 2-[[(2,3-Difluoro- phenyl)acetyl]amino]-
4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.14 113
##STR00131## 4-Methyl-2-[[[4-(1-methyl- ethyl)phenyl]acetyl]amino]-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.56 114
##STR00132## 2-[[[4-(1,1-Dimethyl- ethyl)cyclohexyl]carbonyl]
amino]-4-methyl-N-(2,4,6- trimethylphenyl)- 5-thiazolecarboxamide
4.85 115 ##STR00133## N,N-Dimethyl-N'-[4-
methyl-5-[[(2,4,6-trimethyl- phenyl)amino]carbonyl]-
2-thiazolyl]butanediamide 3.50 116 ##STR00134## 2-[(1,6-Dioxo-
hexyl)amino]-4-methyl- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.40 117 ##STR00135## 2-[(Benzo[b]thiophen-
2-ylcarbonyl)amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.53 118 ##STR00136## 2-[(1-Adamantyl-
carbonyl)amino]-4-methyl- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.66 119 ##STR00137## 4-Methyl-2-[[(4-methyl-
cyclohexyl)carbonyl]amino]- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.48 120 ##STR00138## 2-[(1,7-Dioxooctyl)-
amino]-4-methyl-N-(2,4,6- trimethylphenyl)- 5-thiazolecarboxamide
3.88 121 ##STR00139## 2-[[2-(Acetylamino)-4-
(ethylthio)-1-oxobutyl] amino]-4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 3.93 122 ##STR00140##
1,5-Dimethyl-N-[4-methyl- 5-[[(2,4,6-trimethyl-
phenyl)amino]carbonyl]- 2-thiazolyl]-1H- pyrazole-3-carboxamide
3.91 123 ##STR00141## 2-[[[4-methyl-5-[[(2,4,6-
trimethylphenyl)amino] carbonyl]-2-thiazolyl] amino]carbonyl]
benzoic acid 3.70 124 ##STR00142## N-[4-Methyl-5-
[[(2,4,6-trimethyl- phenyl)amino]carbonyl]- 2-thiazolyl]-6-benzo-
thiazolecarboxamide 4.18 125 ##STR00143## 1-Ethyl-4-methyl-N-[4-
methyl-5-[[(2,4,6-trimethyl- phenyl)-amino]carbonyl]-
2-thiazolyl]-1H- pyrazole-3-carboxamide 4.09 126 ##STR00144##
4-Methyl-2-[[3-[(3H-1,2,3- triazolo[4,5-b]pyridin-3-
yloxy)methyl]benzoyl] amino]-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.15 127 ##STR00145## 2-[(2-Furanyl-
carbonyl)amino]-4-methyl- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.45 128 ##STR00146## 2-[(4-Chloro-
benzoyl)amino]-4-methyl- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 8.85 129 ##STR00147## 2-[(2,2-Dimethyl-1-
oxopropyl)amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 8.30
Example 130
Preparation of
[4-Methyl-5[[(2-nitrophenyl)amino]carbonyl]-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
##STR00148##
[0260] 2-Nitroaniline (55 mg, 0.4 mmol) and diisopropylethylamine
(70 .mu.L, 0.4 mmol) were added dropwise to a stirred solution of
2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxylic acid
chloride 1C (100 mg, 0.36 mmol) in dichloromethane (3 mL). After 16
h at rt, 4-N,N-dimethylaminopyridine (22 mg, 0.18 mmol) was added
and the mixture was stirred for additional 3.5 h. The solvent was
evaporated in vacuo. The residue was chromatographed on a silica
gel column. Elution with 5% EtOAc in hexanes followed by 20% EtOAc
in hexanes afforded the title compound (15 mg, 11%) as a yellow
solid.
Example 131
Preparation of
[4-Methyl-5[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic
acid, phenylmethyl ester
##STR00149##
[0261] A.
Ethyl-2-benzyloxycarbonyloxyamino-4-methyl-thiazole-5-carboxylat-
e
[0262] A 3 M aq. NaHCO.sub.3 solution (10 mL, 30 mmol) was added to
a stirred solution of ethyl-2-amino-4-methyl-thiazole-5-carboxylate
(372 mg, 2 mmol) in THF (20 mL) at 0-5.degree. C. Benzyl
chloroformate (500 .mu.L) was added. After 2 h, additional benzyl
chloroformate (500 .mu.L) and the biphasic solution was stirred for
an additional 2 h at 0-5.degree. C. The mixture was diluted with
dichloromethane (50 mL) and water (30 mL). The organic layer was
separated, dried (MgSO.sub.4), filtered and concentrated. The
residue was chromatographed on a silica gel column. Elution with
10% EtOAc in hexanes followed by 20% and 30% EtOAc in hexanes
afforded the title compound (310 mg, 48%) as a white solid.
B. 2-Benzyloxycarbonyloxyamino-4-methyl-thiazole-5-carboxylic
acid
[0263] Compound 131B was prepared by an analogous method as that of
3B, except using 131A to give the title compound 131B as a white
powder (77%).
C.
[4-Methyl-5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-2-thiazolyl]carbam-
ic acid, phenylmethyl ester
[0264] Diisopropylethylamine (70 .mu.L, 0.41 mmol) was added to a
solution of 131B (100 mg, 0.34 mmol), 2,4,6-trimethylaniline (60
.mu.L, 0.41 mmol), and
[O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium]hexafluorophosphat-
e (HATU, 160 mg, 0.41 mmol). The mixture was stirred at rt for 24
h, diluted with EtOAc (20 mL) and washed with 2 N Aq. HCl solution
(3.times.), brine, dried (Na.sub.2SO.sub.4), filtered and
concentrated. The residue was triturated with ether (40 mL) to
obtain the title compound (100 mg, 77%) as an off-white solid.
Example 132
Preparation of
Methyl[4-methyl-5-[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-thiazolyl]ca-
rbamic acid, 1,1-dimethylethyl ester
##STR00150##
[0266] Compound 132 was prepared by an analogous method as that of
1, except using
ethyl-2-tert-butoxycarbonyloxyaminomethyl-4-methyl-thiazole-5-carboxylate
to give the title compound 132 as a tan solid.
Example 133
Preparation of
4-Methyl-2-(methylamino)-N-(2,4,6-trimethylphenyl)-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00151##
[0268] Compound 133 was prepared by an analogous method as that of
4, except using 132 to give the title compound 133 as a white solid
(91%).
Example 134
Preparation of
[4-Methyl-5-[[methyl(2,4,6-trimethylphenyl)amino]carbonyl]-2-thiazolyl]ca-
rbamic acid, 1,1-dimethylethyl ester
##STR00152##
[0270] Compound 134 was prepared by an analogous method as that of
1, except using N-methyl-2,4,6-trimethylaniline to give the title
compound 134 as a white solid (60%).
Example 135
Preparation of 2-Amino-N,
4-dimethyl-N-(2,4,6-trimethylphenyl)-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00153##
[0272] Compound 135 was prepared by an analogous method as that of
4, except using 134 to give the title compound 135 as a white solid
(97%).
Example 136
Preparation of
[4-Methyl-5[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic
acid, methyl ester
##STR00154##
[0274] A mixture of 2 (100 mg, 0.36 mmol), pyridine (87 .mu.L, 1.08
mmol), methyl chloroformate (111 .mu.L, 1.44 mmol) in
dichloromethane (3 mL) was stirred at rt for 1.5 h. The solution
was diluted with dichloromethane and washed with aq. NaHCO.sub.3
solution (20 mL, 2.times.), brine; dried (MgSO.sub.4), filtered and
concentrated. The residue was triturated with ether to obtain the
title compound (88 mg, 82%) as a white solid.
Example 137
Preparation of
[4-Ethyl-5[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
##STR00155##
[0276] Compound 137 was prepared by an analogous method as that of
1, except using methyl-2-amino-4-ethyl-thiazole-5-carboxylate to
give the title compound 137 as a white solid (70%).
Example 138
Preparation of
2-Amino-4-ethyl-N-(2,4,6-trimethylphenyl)-5-thiazolecarboxamide,
trifluoroacetate
##STR00156##
[0278] Compound 138 was prepared by an analogous method as that of
4, except using 137 to give the title compound 138 as a white solid
(89%).
Example 139
Preparation of
[5-[[(2,6-Dichlorophenyl)amino]carbonyl]-4-methyl-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
##STR00157##
[0280] A 1 M solution of sodium bis-trimethylsilyl amide (290
.mu.L, 0.29 mmol) was added to a stirred solution of
2,6-dichloroaniline (13.4 mg, 0.08 mmol) in THF (1 mL). After 30
min, the mixture was cooled to 0.degree. C. and 1C (30 mg, 0.11
mmol) was added in one portion. The mixture was allowed to warm to
rt and stirred for 16 h. The solution was diluted with
dichloromethane and washed with 2 N aq. HCl solution (2 mL,
3.times.), dried (MgSO.sub.4), filtered and concentrated. The
residue was chromatographed on a silica gel column and eluted with
30% EtOAc in hexanes to obtain the title compound (20 mg, 45%) as a
light yellow solid.
Example 140
Preparation of 2-Amino-N-(2,
6-dimethylphenyl)-4-methyl-5-thiazolecarboxamide, trifluoroacetate
(1:1)
##STR00158##
[0282] Compound 140 was prepared by an analogous method as that of
4, except using 53 to give the title compound 140 as a light tan
solid (100%).
Example 141
Preparation of
2-Amino-N-(2-methoxy-6-methylphenyl)-4-methyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00159##
[0284] Compound 141 was prepared by an analogous method as that of
4, except using 13 to give the title compound 141 as an off-white
solid (100%).
Example 142
Preparation of
2-Amino-N-(2-methylphenyl)-4-methyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00160##
[0286] Compound 142 was prepared by an analogous method as that of
4, except using 18 to give the title compound 142 as a light tan
solid (90%).
Example 143
Preparation of 2-Amino-N-(2,
6-dimethyl-4-bromophenyl)-4-methyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00161##
[0288] Compound 143 was prepared by an analogous method as that of
4, except using 15 to give the title compound 143 as a light tan
solid (70%).
Example 144
Preparation of
2-Amino-N-(2-chloro-6-methylphenyl)-4-methyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00162##
[0290] Compound 144 was prepared by an analogous method as that of
4, except using 19 to give the title compound 144 as a light tan
solid (81%).
Example 145
Preparation of
2-Amino-N-(2,4-dimethylphenyl)-4-methyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00163##
[0292] Compound 145 was prepared by an analogous method as that of
4, except using 17 to give the title compound 145 as a light tan
solid (68%).
Example 146
Preparation of
2-Amino-N-(2-methyl-6-isopropylphenyl)-4-methyl-5-thiazolecarboxamide,
trifluoroacetate (1:1)
##STR00164##
[0294] Compound 146 was prepared by an analogous method as that of
4, except using 16 to give the title compound 146 as a light tan
solid (100%).
Example 147
Preparation of
2-(Acetylamino)-4-methyl-N-(2,4,6-trimethylphenyl)-5-thiazolecarboxamide
##STR00165##
[0296] A mixture of 2 (54 mg, 0.2 mmol), acetic anhydride (22
.mu.L, 0.23 mmol), dimethylaminopyridine (3 mg) in dichloromethane
(4.5 mL) was stirred at rt for 4.5 h. The mixture was diluted with
dichloromethane (65 mL) and washed with 1 N aq. HCl solution (20
mL), water; dried (MgSO.sub.4), filtered and concentrated. The
residue was chromatographed on a silica gel column and eluted with
35% EtOAc in hexanes to obtain the title compound (43 mg, 69%) as a
white solid.
Example 148
Preparation of
2-(Benzoylamino)-4-methyl-N-(2,4,6-trimethylphenyl)-5-thiazolecarboxamide
##STR00166##
[0298] A solution of 2 (100 mg, 0.36 mmol) and benzoic anhydride
(226 mg, 1 mmol) in dichloromethane (10 mL) and pyridine (2 mL) was
stirred at rt overnight. The mixture was diluted with
dichloromethane (50 mL) and washed with 2 N aq. HCl solution (15
mL, 2.times.), 10% aq. NaHCO.sub.3 solution (20 mL, 2.times.);
dried (MgSO.sub.4), filtered and concentrated. The residue was
chromatographed on a silica gel column and eluted with 30% EtOAc in
hexanes followed by 50% EtOAc in hexanes to obtain the title
compound contaminated with benzoic acid. The solid was dissolved in
EtOAc (40 mL) and washed with satd. KHCO.sub.3 solution (15 mL,
4.times.), dried (MgSO.sub.4), filtered and concentrated to obtain
the title compound (110 mg, 80%) as a white solid.
Example 149
Preparation of
4-methyl-2-[(1-oxopropyl)amino]-N-(2,4,6-trimethylphenyl)-5-thiazolecarbo-
xamide
##STR00167##
[0300] A mixture of 2 (100 mg, 0.36 mmol), propionic anhydride (332
.mu.L, 2.58 mmol) in dichloromethane (10 mL) and pyridine (4 mL)
was stirred at rt for 3 h. Dimethylaminopyridine (122 mg, 1 mmol)
was added and the mixture was stirred for additional 1.5 h. The
mixture was diluted with dichloromethane and washed with 1 N aq.
HCl solution (25 mL, 3.times.), aq. NaHCO3 solution (20 mL,
2.times.), water (20 mL), brine; dried (MgSO.sub.4), filtered and
concentrated. The residue was chromatographed on a silica gel
column and eluted with 20% EtOAc in hexanes to obtain the title
compound (81 mg, 68%) as a white solid.
Example 150
Preparation of
4-methyl-2-[(1-oxobutyll)amino]-N-(2,4,6-trimethylphenyl)-5-thiazolecarbo-
xamide
##STR00168##
[0302] Compound 150 was prepared by an analogous method as that of
149, except using butyric anhydride to give the title compound 150
as a white solid (76%).
Example 151
Preparation of
4-methyl-2-[(1-oxopentyl)amino]-N-(2,4,6-trimethylphenyl)-5-thiazolecarbo-
xamide
##STR00169##
[0304] Compound 151 was prepared by an analogous method as that of
149, except using valeric anhydride to give the title compound 151
as a white solid (77%).
Example 152
Preparation of
4-methyl-2-[(1-oxohexyl)amino]-N-(2,4,6-trimethylphenyl)-5-thiazolecarbox-
amide
##STR00170##
[0306] Compound 152 was prepared by an analogous method as that of
149, except using hexanoic anhydride to give the title compound 152
as a white solid (75%).
Example 153
Preparation of
4-Methyl-2-[(phenylcetyl)amino]-N-(2,4,6-trimethylphenyl)-5-thiazolecarbo-
xamide
##STR00171##
[0308] A solution of amine 2 (50 mg, 0.18 mmol),
diisopropylethylamine (101 .mu.L, 0.58 mmol), phenylacetic acid
(27.2 mg, 0.20 mmol), 1-hydroxy-7-azabenzotriazole (29.4 mg, 0.22
mmol), and ethyl-3-(3-dimethylamino)-propyl carbodiimide
hydrochloride (42.2 mg, 0.22 mmol) in dichloromethane (0.62 mL) was
mechanically stirred in a sealed vial for 16 h. The reaction
mixture was passed through a Varian SCX ion exchange column (2 g/6
cc) and eluted with acetonitrile-methanol (10 mL, 4:1) followed by
2 M methanolic ammonia solution (9 mL). Fractions containing the
product were combined and then concentrated. The residue was
dissolved in dichloromethane and washed with 2 N aq. HCl solution
(3.times.), dried (Na.sub.2SO.sub.4), filtered and concentrated to
obtain the title compound (39 mg, 55%) as a tan solid.
Example 154
Preparation of
2-[[(Acetylamino)acetyl]amino]-4-methyl-N-(2,4,6-trimethylphenyl)-6-thiaz-
olecarboxamide
##STR00172##
[0310] A solution of amine 2 (50 mg, 0.18 mmol),
diisopropylethylamine (400 .mu.L, 2.3 mmol), N-acetylglycine (42
mg, 0.36 mmol), 1-hydroxy-7-azabenzotriazole (49 mg, 0.36 mmol),
and ethyl-3-(3-dimethylamino)-propyl carbodiimide hydrochloride (72
mg, 0.36 mmol) in THF (5 mL) was heated to 50.degree. C. overnight.
The mixture was cooled, diluted with dichloromethane (60 mL) and
washed with 2 N aq. HCl solution (20 mL), satd. aq. KHCO.sub.3
solution (20 mL), dried (MgSO.sub.4), filtered and concentrated.
The crude solid was triturated with ether (10 mL), filtered, and
washed with ether (5 mL, 3.times.) to obtain the title compound (40
mg, 59%) as an off-white solid.
Example 155
Preparation of
2-Amino-4-methyl-N-(2,4,6-trimethylphenyl)-5-thiazolecarbothioamide
##STR00173##
[0312] A suspension of 2 (50 mg, 0.18 mmol) and Lawesson reagent
(44 mg, 0.11 mmol) in toluene (0.23 mL) was heated to 100.degree.
C. for 4 h. Additional Lawesson reagent (44 mg, 0.11 mmol) was
added and the mixture was heated for additional 3.5 h. The crude
mixture was chromatographed on a silica gel column and eluted with
50% EtOAc in hexanes followed by 70% EtOAc in hexanes to obtain a
yellow solid which was triturated with hexanes (6 mL) to obtain the
title compound (11 mg, 21%) as a yellow solid.
Examples 156 to 170
General Procedure
[0313] Compounds 156 to 170 were prepared following the procedure
described below. Diisopropylethyl amine (60 .mu.L, 0.34 mmol) was
added to a mixture of amine 2 (30 mg, 0.11 mmol), appropriate
carboxylic acid (0.13 mmol), 1-hydroxy-7-azabenzotriazole (19.5 mg,
0.14 mmol), and ethyl-3-(3-dimethylamino)-propyl carbodiimide
hydrochloride (26.8 mg, 0.14 mmol) in THF (1 mL). The mixture was
heated in a sealed tube under argon at 45.degree. C. for 24 h. The
reaction mixture was diluted with dichloromethane (4 mL) and washed
with 2 N aq. HCl solution (2 mL, 3.times.), dried
(Na.sub.2SO.sub.4) and concentrated using a speedvac. The crude
products were either triturated with dichloromethane-ether (5 mL,
1:1) or purified by silica gel chromatography (elution solvent: 50%
EtOAC in hexanes and EtOAc). "HPLC Ret Time" is the HPLC retention
time under the following conditions: YMC S5 ODS 4.6.times.50 mm
Ballastic Column, 4 min gradient starting from 100% solvent A (10%
MeOH, 90% H.sub.2O, 0.2% H.sub.3PO.sub.4) to 100% solvent B (90%
MeOH, 10% H.sub.2O, 0.2% H.sub.3PO.sub.4), flow rate 4 mL/min,
.lamda.=220 nM.
TABLE-US-00003 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 156 ##STR00174## 2-[(4-Bromo- benzoyl)amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 5.03 157
##STR00175## 4-Methyl-2-[(4- nitrobenzoyl)amino]- N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.87 158 ##STR00176##
2-[(4-Cyano- benzoyl)amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.70 159 ##STR00177## 4-Methyl-2-[[(5-
nitro-2-furanyl) carbonyl]amino]-N- (2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.63 160 ##STR00178## 4-Methyl-2-[(2-
thienylcarbonyl) amino]-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.60 161 ##STR00179## 4-[[[4-Methyl-5-[[(2,4,6-
trimethylphenyl)amino] carbonyl]-2- thiazolyl]amino]carbonyl]
benzoic acid methyl ester 4.99 162 ##STR00180## 2-[(5-Isoxazolyl-
carbonyl)amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.87 163 ##STR00181## 2-[(3-Furanylcarbonyl)
amino]-4-methyl-N- (2,4,6-trimethylphenyl)- 5-thiazolecarboxamide
4.54 164 ##STR00182## 2-[[(2,4-Dimethyl-5- thiazolyl)carbonyl]
amino]-4-methyl-N- (2,4,6-trimethylphenyl)- 5-thiazolecarboxamide
4.74 165 ##STR00183## 2-[[(4-Methoxy-3- thienyl)carbonyl]amino]-
4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.75 166
##STR00184## 4-Methyl-2-[[(5-nitro-3- thienyl)carbonyl]amino]-
N-(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.78 167
##STR00185## 2-[[[4-[(4- Chlorophenyl)thio]-3-
thienyl]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 5.27 168 ##STR00186## 2-[[(5-Chloro-4-methoxy-
3-thienyl)carbonyl] amino]-4-methyl-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 5.04 169 ##STR00187##
2-[[[2-(4,5-Dihydro-4,4- dimethyl-2-oxazolyl)-3-
thienyl]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 5.13 170 ##STR00188## 2-[[(2-Acetyl-3-
thienyl)carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.54
Examples 171 to 180
General Procedure
[0314] Compounds 171 to 180 were prepared following the procedure
described below.
[0315] A mixture of 2 (80 mg, 0.29 mmol), appropriate isocyanate
(0.87 mmol) and pyridine (2 mL) in THF (3.5 mL) was stirred at rt
overnight. In some cases the reaction mixture was heated to
60-700.degree. C. for 5 h. Some of these reactions were carried out
at rt overnight in the presence of catalytic
N,N-dimethylaminopyridine. The reaction mixture was diluted with
dichloromethane and washed with 1 N aq. HCl solution (3.times.),
water, brine; dried (MgSO.sub.4), filtered and concentrated. The
crude product was purified either by trituration with ether or
ether-hexanes mixture, or by chromatography on a silica gel column
(elution solvent 20-40% EtOAc in hexanes) followed by trituration
or by passing through Varian cation exchange SCX cartridge and
sequentially eluted with methanol (5 mL), dichloromethane (5 mL),
acetonitrile-methanol (10 mL, 4:1) and methanol-2 M methanolic
ammonia (10 mL, 4:1) to obtain the title compound. "HPLC Ret Time"
is the HPLC retention time under the following conditions: For
compounds 171-172, 175, and 177 HPLC conditions are: Zorbax S8-C18
4.5 mm.times.7.5 cm short column, 30 min gradient starting from
100% solvent A (10% MeOH, 90% H.sub.2O, 0.2% H.sub.3PO.sub.4) to
100% solvent B (90% MeOH, 10% H.sub.2O, 0.2% H.sub.3PO.sub.4), flow
rate 2.5 mL/min, .lamda.=217 nM. For the other compounds HPLC
conditions are: Zorbax S8-C18 4.5 mm.times.7.5 cm short column, 8
min gradient starting from 100% solvent A (10% MeOH, 90% H.sub.2O,
0.2% H.sub.3PO.sub.4) to 100% solvent B (90% MeOH, 10% H.sub.2O,
0.2% H.sub.3PO.sub.4), flow rate 2.5 mL/min, .lamda.=217 nM.
TABLE-US-00004 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 171 ##STR00189## 4-Methyl-2-[[(methyl-
amino)carbonyl]amino]- N-(2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 24.48 172 ##STR00190## 4-Methyl-2-[[(phenyl-
amino)carbonyl]amino]-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 30.45 173 ##STR00191## 4-Methyl-2-[[[(4-
methylphenyl)amino]- carbonyl]amino]-N- (2,4,6-trimethylphenyl)-
5-thiazole-carboxamide 8.81 174 ##STR00192## 4-Methyl-2-[[[(phenyl-
methyl)amino]carbonyl] amino]-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 8.52 175 ##STR00193## 2-[[(Butylamino)
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 30.49 176 ##STR00194## 4-Methyl-2-[[(propyl-
amino)carbonyl]amino]- N-(2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 7.41 177 ##STR00195## 2-[[(Cyclohexylamino)
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 27.21 178 ##STR00196## 2-[[[(2-Chloro-
phenyl)amino]carbonyl] amino]-4-methyl-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 8.99 179 ##STR00197## 2-[[[(3-Fluorophenyl)
amino]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 8.87 180 ##STR00198## 2-[[[(2,6-Dimethyl-
phenyl)amino]carbonyl] amino]-4-methyl-N-(2,4,6- trimethylphenyl)-
5-thiazolecarboxamide 8.92
Example 181
Preparation of
[5-[[(2,4,6-Trimethylphenyl)amino]carbonyl]-4-methyl-2-thiazolyl]carbamic
acid, phenyl ester
##STR00199##
[0317] A 10% aq. KHCO.sub.3 solution (170 mL) was added to a
stirred solution of 2 (1.02 g, 3.7 mmol) in THF (130 mL).
Phenylchloroformate (1.39 mL, 11.1 mmol) was added dropwise. The
biphasic mixture was stirred at rt overnight, diluted with
dichloromethane (200 mL) and washed with water (50 mL, 2.times.)
and brine. The organic extract was separated, dried (MgSO.sub.4),
filtered and concentrated. The residue was chromatographed on a
silica gel column and eluted with 10% EtOAc in hexanes to obtain
the title compound (980 mg, 69%) as a solid.
Examples 182 to 236
General Procedure
[0318] Compounds 182 to 236 were prepared following the procedure
described below.
[0319] A solution of phenylcarbamate 181 (20 mg, 0.054 mmol) and
the appropriate amine (0.08 mmol) in THF-acetonitrile (3 mL, 1:1)
was stirred at rt overnight. Some of the reactions required heating
to 60.degree. C. for 4 h to overnight. The mixture was diluted with
dichloromethane (4 mL) and washed with 1 N aq. HCl solution (1.5
mL, 2.times.), 1 N aq. NaOH solution (1.5 mL, 2.times.). The
dichloromethane extract was separated, dried (MgSO.sub.4), filtered
and concentrated to obtain the title product.
[0320] "HPLC Ret Time" is the HPLC retention time under the
following conditions: For compounds 182-192 HPLC conditions are:
Zorbax SB-C18 4.5 mm.times.7.5 cm short column, 8 min gradient
starting from 100% solvent A (10% MeOH, 90% H.sub.2O, 0.2%
H.sub.3PO.sub.4) to 100% solvent B (90% MeOH, 10% H.sub.2O, 0.2%
H.sub.3PO.sub.4), flow rate 2.5 mL/min, .lamda.=217 nM. For
compounds 193-236 HPLC conditions are: YMC S5 ODS 4.6.times.50 mm
Ballastic Column, 4 min gradient starting from 100% solvent A (10%
MeOH, 90% H.sub.2O, 0.2% H.sub.3PO.sub.4) to 100% solvent B (90%
MeOH, 10% H.sub.2O, 0.2% H.sub.3PO.sub.4), flow rate 4 mL/min,
.lamda.=220 nM.
TABLE-US-00005 HPLC Ret EX. Time NO. Compound Structure Compound
Name (min) 182 ##STR00200## 4-Methyl-2-[[[(2- phenylethyl)amino]-
carbonyl]amino]-N- (2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 8.83 183 ##STR00201## 2-[[(Hexylamino)
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 9.01 184 ##STR00202## 2-[[[(1,1-Dimethyl-
ethyl)amino]carbon- yl]amino]-4-methyl- N-(2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 8.48 185 ##STR00203##
2-[[[(3-Fluoro-4- methylphenyl)amino]- carbonyl]amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 8.92 186
##STR00204## 2-[[[(4-Methoxyphenyl) amino]carbonyl]amino]-
4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 8.57 187
##STR00205## 2-[[(Diethylamino) carbonyl]amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 8.19 188 ##STR00206##
2-[[[Bis(1-methyl- ethyl)amino]carbonyl]- amino]-4-methyl-N-
(2,4,6-trimethyl- phenyl)-5-thiazole- carboxamide 8.90 189
##STR00207## 4-Methyl-2-[[[methyl- (phenylmethyl)amino]-
carbonyl]amino]-N- (2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 8.56 190 ##STR00208## 4-Methyl-2-[[(methyl-
phenylamino)carbon- yl]amino]-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 8.39 191 ##STR00209## 2-[[(Cyclohexylmethyl
amino)carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 8.84 192 ##STR00210## 4-Methyl-2-[[[(1-
phenylethyl)amino]- carbonyl]amino]-N- (2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 8.47 193 ##STR00211##
2-[[[(Cyclopropyl- methyl) propylamino]- carbonyl]amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.36 194
##STR00212## 4-Methyl-2-[[[(2- methylcyclohexyl)ami-
no]carbonyl]amino]-N- (2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 4.42 195 ##STR00213## 4-Methyl-2-[[[(4-
methylcyclohexyl)- amino]carbonyl]amino]- N-(2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 4.49 196 ##STR00214##
2-[[[(Cyclohexyl- methyl) amino]- carbonyl]amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.49 197
##STR00215## 2-[[[(2,3-Dihydro-1H- inden-1-yl)amino]
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.35 198 ##STR00216## 4-Methyl-2-[[[(1-
naphthalenylmethyl)ami- no]carbonyl]amino]-N- (2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 4.43 199 ##STR00217##
2-[[[Bis(phenylmethyl) amino]carbonyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.66 200 ##STR00218##
2,6-Dimethyl-N-[4- methyl-5-[[(2,4,6- trimethylphenyl)-
amino]carbonyl]-2- thiazolyl]-4- morpholinecarboxamide 3.97 201
##STR00219## 2-Ethyl-N-[4-methyl-5- [[(2,4,6-trimethyl-
phenyl)amino]carbonyl]- 2-thiazolyl]-1- piperidinecarboxamide 4.29
202 ##STR00220## 1-[[[4-Methyl-5- [[(2,4,6-trimethyl-
phenyl)amino]carbonyl]- 2-thiazolyl]- amino]carbonyl]-3-
piperidinecarboxylic acid ethyl ester 4.10 203 ##STR00221##
3,3-Dimethyl-N-[4- methyl-5-[[(2,4,6- trimethylphenyl)amino]
carbonyl]-2-thiazolyl]-1- piperidinecarboxamide 4.32 204
##STR00222## 1-[[[4-Methyl-5- [[(2,4,6-trimethyl-
phenyl)amino]carbonyl]- 2-thiazolyl]- amino]carbonyl]-4-
piperidinecarboxylic acid ethyl ester 4.06 205 ##STR00223##
4-Methyl-2-[[[(3- methyl-2-pyridinyl)- amino] carbonyl]-
amino]-N-(2,4,6- trimethyl-phenyl)-5- thiazolecarboxamide 3.51 206
##STR00224## 4-Methyl-2-[[[1- (phenylmethyl)-4- piperidinyl]amino]-
carbonyl]amino]-N- (2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 3.28 207 ##STR00225## Octahydro-N-[4-methyl-
5-[[(2,4,6-trimethyl- phenyl)amino]carbonyl]- 2-thiazolyl]-1(2H)-
quinolinecarboxamide 4.55 208 ##STR00226## 3,4-Dihydro-N-[4-
methyl-5-[[(2,4,6- trimethylphenyl)- amino] carbonyl]-2-
thiazolyl]-2(1H)- isoquinoline carboxamide 4.35 209 ##STR00227##
2-[[[(1,5-Dimethyl- hexyl)amino]carbonyl]- amino]-4-methyl-N-
(2,4,6-trimethyl- phenyl)-5-thiazole- carboxamide 4.72 210
##STR00228## 4-Methyl-2-[[[(1- methylheptyl)amino]-
carbonyl]amino]-N- (2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 4.74 211 ##STR00229## 2-[[[[(2-Fluoro-
phenyl)methyl]amino]- carbonyl]amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.17 212 ##STR00230##
2-[[[[(2-Methoxy- phenyl)methyl]amino]- carbonyl]amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.22 213
##STR00231## 2-[[[[(2-Ethoxy- phenyl)methyl]amino]
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.36 214 ##STR00232## 2-[[[[(3-Methoxy-
phenyl)methyl]amino]- carbonyl]amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.13 215 ##STR00233##
2-[[[[(4-Chloro- phenyl)methyl]amino]- carbonyl]amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.36 216
##STR00234## 2-[[[[(4-Methoxy- phenyl)methyl]amino]-
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.12 217 ##STR00235## 2-[[[(2,2-Diphenyl-
ethyl)amino]carbonyl]- amino]-4-methyl-N- (2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 4.57 218 ##STR00236##
2-[[[(2-Aminoethyl) phenylamino]carbonyl]- amino]-4-methyl-N-
(2,4,6-trimethyl- phenyl)-5-thiazole- carboxamide 3.70 219
##STR00237## 2-[[[[2-(3-Methoxy- phenyl)ethyl]amino]-
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.26 220 ##STR00238## 2-[[[[2-(3,4-
Dimethoxyphenyl)ethyl] amino]carbonyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.05 221 ##STR00239##
2-[[[[2-(4-Methoxy- phenyl)ethyl]amino]- carbonyl]amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.25 222
##STR00240## 4-Methyl-2-[[[(3- phenylpropyl)amino]-
carbonyl]amino]-N- (2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 4.40 223 ##STR00241## 2-[[[[2-(Cyclohex-1-
en-1-yl)ethyl]- amino]carbonyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.11 224 ##STR00242##
2-[[[[4-(1,1- Dimethylethyl)cyclo- hexyl]amino]carbonyl]-
amino]-4-methyl-N- (2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 4.85 225 ##STR00243## 2-[[[(3-Butoxypropyl)
amino]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.33 226 ##STR00244## 2-[[[[2-(2-Methoxy-
phenyl)ethyl]amino]- carbonyl]amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.46 227 ##STR00245##
2-[[[[(2-Chloro-4- fluorophenyl)methyl]- amino]carbonyl]amino]-
4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.39 228
##STR00246## 2-[[(Hexylmethylamino) carbonyl]amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.65 229
##STR00247## 2-[[[[1-(4-Chloro- phenyl)ethyl]amino]-
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.42 230 ##STR00248## 2-[[[[2-(3-Chloro-
phenyl)ethyl]amino]car- bonyl]amino]-4-methyl- N-(2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 4.44 231 ##STR00249##
4-Methyl-2-[[[[2-(2- thienyl)ethyl]amino]- carbonyl]amino]-N-
(2,4,6-trimethyl- phenyl)-5-thiazole- carboxamide 4.18 232
##STR00250## 2-[[[[2-(2-Fluoro- phenyl)ethyl]amino]-
carbonyl]amino]-4- methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 5.85 233 ##STR00251## 4-Methyl-2-[[[[2-(2-
pyridinyloxy)ethyl]- amino]carbonyl]amino]- N-(2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 4.28 234 ##STR00252##
2-[[[[(2-Bromo-4,5- dimethoxyphenyl)meth- yl]methylamino]carbon-
yl]amino]-4-methyl-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 3.87 235 ##STR00253## (E)-2-[[[(3,7-
Dimethyl-2,6-octa- dienyl) amino]-car- bonyl]amino]-4-methyl-
N-(2,4,6-trimethyl- phenyl)-5-thiazole- carboxamide 4.34 236
##STR00254## 2-[[[[(2,3-Dihydro- 1,4-benzodioxin-2-
yl)methyl]amino]car- bonyl]amino]-4-methyl- N-(2,4,6-trimethyl-
phenyl)-5-thiazole- carboxamide 4.27
Examples 237 to 285
General Procedure
[0321] Compounds 237 to 285 were prepared following the procedure
described below.
[0322] A solution of phenylcarbamate 181 (20 mg, 0.054 mmol) and
the appropriate amine (0.08 mmol) in THF-acetonitrile (3 mL, 1:1)
was stirred at rt overnight. The mixture was diluted with
dichloromethane (4 mL) and washed with 1 N aq. HCl solution (1.5
mL, 2.times.), 1 N aq. NaOH solution (1.5 mL, 2.times.). The
dichloromethane extract was separated, dried (MgSO.sub.4), filtered
and concentrated to obtain the title product.
[0323] "HPLC Ret Time" is the HPLC retention time under the
following conditions: For compounds 237-278 HPLC conditions are:
YMC S5 ODS 4.6.times.50 mm Ballastic Column, 4 min gradient
starting from 100% solvent A (10% MeOH, 90% H.sub.2O, 0.2%
H.sub.3PO.sub.4) to 100% solvent B (90% MeOH, 10% H.sub.2O, 0.2%
H.sub.3PO.sub.4), flow rate 4 mL/min, .lamda.=220 nM. For compounds
279-285 HPLC conditions are: Zorbax S8-C18 4.5 mm.times.7.5 cm
short column, 8 min gradient starting from 100% solvent A (10%
MeOH, 90% H.sub.2O, 0.2% H.sub.3PO.sub.4) to 100% solvent B (90%
MeOH, 10% H.sub.2O, 0.2% H.sub.3PO.sub.4), flow rate 2.5 mL/min,
.lamda.=217 nM.
TABLE-US-00006 HPLC Ret EX. Time NO. Compound Structure Compound
Name (min) 237 ##STR00255## 2-[[[[3-Methoxy-5-
(trifluoromethyl)phenyl] amino]carbonyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 5.36 238 ##STR00256##
2-[[[(4-Cyclohexyl- phenyl) amino]carbonyl]- amino]-4-methyl-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.73 239
##STR00257## 4-Methyl-2-[[[(5,6,7,8- tetrahydro-1-
naphthalenyl)amino]- carbonyl]amino]-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 5.38 240 ##STR00258## 2-[[(1-
Anthracenylamino) carbonyl]amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.82 241 ##STR00259##
2-[[[(4-Chloro-1- naphthalenyl)amino]- carbonyl]amino]-4-
methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.76 242
##STR00260## 4-Methyl-2-[[(2- naphthalenylamino)-
carbonyl]amino]-N- (2,4,6-trimethylphenyl)- 5-thiazolecarboxamide
5.28 243 ##STR00261## 2-[[(1H-Indol-5- ylamino)carbonyl]ami-
no]-4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 5.00
244 ##STR00262## 2-[[(1,3-Benzodioxol-5- ylamino)carbonyl]ami-
no]-4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.76
245 ##STR00263## 4-Methyl-2-[[(2-pyra- zinylamino)carbonyl]ami-
no]-N-(2,4,6-trimethyl- phenyl)-5-thiazole- carboxamide 3.84 246
##STR00264## 2-[[[(5-Chloro-2- pyridinyl)amino]carbonyl]
amino]-4-methyl-N- (2,4,6-trimethylphenyl)- 5-thiazolecarboxamide
4.38 247 ##STR00265## 4-Methyl-2-[[[(6-methyl- 2-pyridinyl) amino]-
carbonyl]amino]-N- (2,4,6-trimethylphenyl)- 5-thiazolecarboxamide
4.44 248 ##STR00266## 4-Methyl-2-[[[(2-methyl- 4-quinolinyl)amino]
carbonyl]amino]-N- (2,4,6-trimethylphenyl)- 5-thiazolecarboxamide
5.23 249 ##STR00267## 2-[[[(2,3-Dihydro-1,4- benzodioxin-6-
yl)amino]carbonyl]ami- no]-4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.72 250 ##STR00268## 2-[[([1,1'-Biphenyl]-2-
ylamino)carbonyl]ami- no]-4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 5.29 251 ##STR00269## 2-[[[(4-Methoxy-2-
methylphenyl)amino]car- bonyl]amino]-4-methyl- N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.80 252 ##STR00270##
4-Methyl-N-(2,4,6- trimethylphenyl)-2- [[[(2,4,6-
trimethylphenyl)amino]- carbonyl]amino]-5- thiazolecarboxamide 5.06
253 ##STR00271## 2-[[[[2-(2-Hydroxy- ethyl)phenyl]amino]car-
bonyl]amino]-4-methyl- N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.02 254 ##STR00272## 2-[[[(3-Methoxyphenyl)
amino]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.86 255 ##STR00273## 2-[[[(4-Methoxy[1,1'-
biphenyl]-3- yl)amino]carbonyl]- amino]-4-methyl-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.81 256
##STR00274## 2-[[[(3-Acetylphenyl) amino]carbonyl]amino]-
4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.12 257
##STR00275## 2-[[[(4-Cyanophenyl) amino]carbonyl]amino]-
4-methyl-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.15 258
##STR00276## 2-[[[[4-Fluoro-2- (trifluoromethyl)phenyl]
amino]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.99 259 ##STR00277## 2-[[[(4-Hexyloxyphenyl)
amino]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.42 260 ##STR00278## 4-[[[[4-Methyl-5-
[[(2,4,6-trimethyl- phenyl) amino]carbonyl]- 2-thiazolyl]-amino]-
carbonyl]amino]benzoic acid ethyl ester 4.26 261 ##STR00279##
2-[[[(4-Decylphenyl)- amino]carbonyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 262 ##STR00280##
4-Methyl-2-[[[(4- propylphenyl)amino]- carbonyl]amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 4.71 263
##STR00281## 4-Methyl-2-[[[(3,4,5- trimethoxyphenyl)ami-
no]-carbonyl]amino]-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.67 264 ##STR00282## 4-Methyl-2-[[[[4-[[(5-
methyl-3-isoxazolyl) amino]sulfonyl]phenyl]- amino]carbonyl]amino]-
N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.27 265
##STR00283## 4-[[[[4-Methyl-5- [[(2,4,6-trimethyl
phenyl)amino]carbonyl]- 2-thiazolyl]- amino]carbonyl]-
amino]-benzoic acid butyl ester 4.75 266 ##STR00284##
2-[[(1-Isoquinolinyl amino)carbonyl]amino]- 4-methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 3.81 267 ##STR00285##
4-Methyl-2-[[[[2- [(phenyl-methyl)thio]- phenyl]amino]carbonyl]-
amino]-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide 4.42 268
##STR00286## 4-Methyl-2-[[[[4-[(5- phenoxypentyl)oxy]phen-
yl]amino]carbonyl]ami- no]-N-(2,4,6-trimethyl- phenyl)-5-thiazole-
carboxamide 4.96 269 ##STR00287## 2-[[[[5-(1,1-Dimethyl-
propyl)-2-methoxy- phenyl]amino]carbonyl]- amino]-4-methyl-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 5.76 270
##STR00288## 2-[[[(1,2-Dihydro-5- acenaphthylenyl)amino]
carbonyl]amino]-4- methyl-N-(2,4,6- trimethyl-phenyl)-5-
thiazole-carboxamide 4.70 271 ##STR00289## 4-Methyl-2-[[[(3-
phenoxyphenyl)amino]- carbonyl]amino]-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.70 272 ##STR00290## 4-Methyl-2-[[[[2-(4-
morpholinyl)phenyl]- amino]carbonyl]amino]- N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 5.01 273 ##STR00291##
4-Methyl-2-[[[[2-(1- piperidinyl)phenyl]amino] carbonyl]amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 5.55 274
##STR00292## 2-[[[(1-Acetyl-2,3- dihydro-1H-indol-6-
yl)amino]carbonyl]ami- no]-4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.08 275 ##STR00293## 2-[[[(2-Bromo-5-
methoxyphenyl)ami- no]carbonyl]amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 4.55 276 ##STR00294##
2-[[[(2,3-Dimethyl-1H- indol-5-yl)amino] carbonyl]amino]-4-
methyl-N-(2,4,6- trimethyl phenyl)-5- thiazolecarboxamide 4.30 277
##STR00295## 4-Methyl-2-[[[[2-[[(1- methylethyl)amino]car-
bonyl]phenyl]amino]car- bonyl]amino]-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 4.82 278 ##STR00296## 2-[[[(3-Bromo-2-methyl-
phenyl)amino]carbonyl]- amino]-4-methyl-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 4.60 279 ##STR00297## 2-[[[(4-Methoxybutyl)
amino]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 7.62 280 ##STR00298## 2-[[[(3,3-Dimethyl-
butyl)amino]carbonyl]- amino]-4-methyl-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 9.13 281 ##STR00299## 4-Methyl-2[[[(2-
methylbutyl)amino]- carbonyl]amino]-N- (2,4,6-trimethylphenyl)-
5-thiazolecarboxamide 8.90 282 ##STR00300## 4-Methyl-2-[[[(3-
methylbutyl)amino]car- bonyl]amino]-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 8.98 283 ##STR00301## 2-[[[(2-Methoxyethyl)-
amino]carbonyl]amino]- 4-methyl-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 7.30 284 ##STR00302## 2-[[[[2-(Dimethyl-
amino)ethyl]amino]- carbonyl]amino]-4- methyl-N-(2,4,6-
trimethylphenyl)-5- thiazolecarboxamide 5.73 285 ##STR00303##
4-Methyl-2-[[[[2- (methylthio)ethyl]amino] carbonyl]amino]-N-
(2,4,6-trimethylphenyl)- 5-thiazolecarboxamide 8.19
Examples 286 to 311
General Procedure
[0324] Compounds 286 to 311 with the exception of compound 307 were
prepared following the procedure described below.
[0325] A solution of
2-[[(Butylamino)carbonyl]amino]-4-methyl-5-thiazole carboxylic acid
chloride (30 mg, 0.11 mmol), appropriate amine (0.12 mmol) in THF
(1 mL) was treated with diisopropylethyl amine (22.6 .mu.L, 0.13
mmol). The mixture was purged with argon and stirred mechanically
in a vial for 22 h, diluted with dichloromethane (4 mL) and washed
with 2 N aq. HCl solution (3.times.). The organic extract was
separated, dried (Na.sub.2SO.sub.4), filtered and concentrated. The
crude products were purified either by truturation with
dichloromethane-ether (1:1) or by silica gel chromatography
(elution solvent: 80% EtOAc in hexanes followed by EtOAc) or by
automatic preparative HPLC (conditions: YMC S5 ODS A 20.times.100
mm Column, 10 min gradient starting from 30% solvent B (90% MeOH,
10% H.sub.2O, 0.1% TFA) and 70% solvent A (10% MeOH, 90% H.sub.2O,
0.1% TFA) to 100% solvent B, flow rate 20 mL/min, .lamda.=220 nM.
Compound 307 was prepared following the procedure described below.
A suspension solution of
2-[[(Butylamino)carbonyl]amino]-4-methyl-5-thiazole carboxylic acid
(100 mg, 0.36 mmol), and HATU (170 mg, 0.44 mmol) in DMF (3 mL) was
treated with diisopropylethyl amine (62 mL, 0.44 mmol). The mixture
was heated to 60.degree. C. for 2 h, cooled, diluted with
dichloromethane (12 mL), washed with 8M aq. Urea solution in 2 N
aq. HCl (6 mL, 3.times.), 5% aq. KHCO.sub.3 solution (6 mL,
3.times.), dried (Na.sub.2SO.sub.4), filtered and concentrated. The
residue was triturated with EtOAc-ether to obtain the mixed
anhydride intermediate (102 mg, 74%) as a white solid. A 1 M
solution of sodium bis(trimethylsilylamide) in THF (170 .mu.L, 0.17
mmol) was added dropwise to a stirred solution of
2,6-dichloroaniline (19.4 mg, 0.12 mmol) in THF (1 mL). After 15
min, the mixed anhydride intermediate (41.3 mg, 0.11 mmol) was
added in one portion. A few drops of DMF was added and the solution
was stirred for 16 h. Additional 1 M solution of sodium
bis(trimethylsilylamide) (110 .mu.L) was added and the mixture was
stirred for additional 2 h. The mixture was diluted with
dichloromethane (4 mL) and washed with 2 N aq. HCl solution (2 mL,
3.times.), satd. aq. KHCO.sub.3 solution (3.times.), dried
(Na.sub.2SO.sub.4), filtered and concentrated. The solid was washed
with hexanes (2.times.) and the residue was chromatographed on a
silica gel column. Elution with 80% EtOAc in hexanes followed by
EtOAc afforded 307 (12 mg, 27%) as a light tan solid. "HPLC Ret
Time" is the HPLC retention time under the following conditions:
YMC S5 ODS 4.6.times.50 mm Ballastic Column, 4 min gradient
starting from 100% solvent A (10% MeOH, 90% H.sub.2O, 0.2%
H.sub.3PO.sub.4) to 100% solvent B (90% MeOH, 10% H.sub.2O, 0.2%
H.sub.3PO.sub.4), flow rate 4 mL/min, .lamda.=220 nM.
TABLE-US-00007 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 286 ##STR00304## 2-[[(Butylamino)
carbonyl]amino]-N-(2,3- dihydro-1H-inden-5-yl)-
4-methyl-5-thiazole- carboxamide 4.20 287 ##STR00305##
2-[[(Butylamino) carbonyl]amino]-N-2- naphthalenyl-4-methyl-
5-thiazolecarboxamide 4.20 288 ##STR00306## 2-[[(Butylamino)
carbonyl]amino]-N-(3- hydroxy-2-naphtha- lenyl)-4-methyl-5-
thiazolecarboxamide 4.24 289 ##STR00307## 2-[[(Butylamino)
carbonyl]amino]-N-(2- fluoro-5-methylphenyl)- 4-methyl-5-
thiazolecarboxamide 3.95 290 ##STR00308## 2-[[(Butylamino)
carbonyl]amino]-N-(2,6- dimethylphenyl)-4- methyl-5-thiazole-
carboxamide 3.78 291 ##STR00309## N-(4-Bromo-2- methylphenyl)-2-
[[(butylamino)carbonyl] amino]-4-methyl-5- thiazolecarboxamide 4.12
292 ##STR00310## N-(3-Bromo-2,4,6- trimethylphenyl)-2-
[[(butylamino)carbonyl] amino]-4-methyl-5- thiazolecarboxamide 4.28
293 ##STR00311## 2-[[(Butylamino) carbonyl]amino]-N-[2,6-
dimethyl-3-(1- methylethyl)phenyl]-4- methyl-5- thiazolecarboxamide
4.28 294 ##STR00312## N-(2-Bromo-4,6- dimethylphenyl)-2-
[[(butylamino)carbonyl] amino]-4-methyl-5- thiazolecarboxamide 4.00
295 ##STR00313## 3-[[[2-[[(Butylamino) carbonyl]amino]-4-
methyl-5-thiazolyl]- carbonyl]amino]-4- methyl-2-thiophene-
carboxylic acid methyl ester 3.83 296 ##STR00314## 2-[[(Butylamino)
carbonyl]amino]-4- methyl-N-(2-methyl-6- quinolinyl)-5-
thiazolecarboxamide 2.98 297 ##STR00315## 2-[[(Butylamino)
carbonyl]amino]-N-(2,6- dimethoxyphenyl)-4- methyl-5-thiazolecar-
boxamide 3.39 298 ##STR00316## 2-[[(Butylamino)
carbonyl]amino]-N-(4- methoxy-2-naphtha- lenyl)-4-methyl-5-
thiazolecarboxamide 4.31 299 ##STR00317## 2-[[(Butylamino)
carbonyl]amino]-N-(2- methyl-1-naphthalenyl)- 4-methyl-5-thiazole-
carboxamide 3.92 300 ##STR00318## 2-[[(Butylamino)
carbonyl]amino]-N-[4- (dimethylamino)- 2,3,5,6-tetramethyl-
phenyl]-4-methyl-5- thiazolecarboxamide 3.14 301 ##STR00319##
2-[[(Butylamino) carbonyl]amino]-N-(6- methyl-5-quinolinyl)-4-
methyl-5- thiazolecarboxamide 3.13 302 ##STR00320##
2-[[(Butylamino) carbonyl]amino]-N-[2- (2-hydroxyethyl)-6-
methylphenyl]-4-methyl- 5-thiazolecarboxamide 3.50 303 ##STR00321##
2-[[(Butylamino) carbonyl]amino]-N-(2,6- dimethyl-3-
nitrophenyl)-4-methyl- 5-thiazolecarboxamide 3.75 304 ##STR00322##
N-(2-Bromo-3,4,6- trimethylphenyl)-2- [[(butylamino)carbonyl]
amino]-4-methyl-5- thiazolecarboxamide 4.12 305 ##STR00323##
N-(2-Acetyl-6- hydroxyphenyl)-2- [[(butylamino)carbonyl]
amino]-4-methyl-5- thiazolecarboxamide 3.75 306 ##STR00324##
[4-[[[2-[[(Butylamino) carbonyl]amino]-4- methyl-5-thiazolyl]-
carbonyl]amino]- 2,3,5,6-tetramethyl- phenyl]carbamic acid
1,1-dimethylethyl ester 4.10 307 ##STR00325## 2-[[(Butylamino)
carbonyl]amino]-N-(2,6- dichlorophenyl)-4- methyl-5-
thiazolecarboxamide 4.42 308 ##STR00326## N-(4-Amino-2,3,5,6-
tetramethylphenyl)-2- [[(butylamino)carbonyl] amino]-4-methyl-5-
thiazolecarboxamide 3.15 309 ##STR00327## N-[5-(Acetylamino)-2,4-
dimethylphenyl]-2- [[(butylamino)carbonyl] amino]-4-methyl-5-
thiazolecarboxamide 3.52 310 ##STR00328## N-(4-Bromo-2,6-
dimethylphenyl)-2- [[(butylamino)carbonyl] amino]-4-methyl-5-
thiazolecarboxamide 4.93 311 ##STR00329## 2-[[(Butylamino)
carbonyl]amino]-N-(2- chloro-6-methylphenyl)- 4-methyl-5-
thiazolecarboxamide 4.51
Example 312
Preparation of
4-Methyl-2-[(methylsulfonyl)amino]-N-(2,4,6-trimethylphenyl)-5-thiazoleca-
rboxamide
##STR00330##
[0326] A.
Ethyl-2-[(methylsulfonyl)amino]-4-methyl-thiazole-5-carboxylate
[0327] A stirred solution of
ethyl-2-amino-4-methyl-thiazole-5-carboxylate (558 mg, 3 mmol) in
dichloromethane (15 mL) and pyridine (5 mL) was treated with
methanesulfonyl chloride (687 mg, 6 mmol) at rt overnight. The
solution was diluted with dichloromethane (50 mL) and washed with
2N aq. HCl solution (15 mL, 3.times.), dried (MgSO.sub.4), filtered
and concentrated. The crude residue was diluted with ether (25 mL)
and the solid was filtered, washed with 1:1 ether:hexane mixture
(10 mL, 3.times.), and dried in vacuo to obtain the title compound
(687 mg, 87%) as an off-white solid.
B. 2-[(Methylsulfonyl)amino]-4-methyl-thiazole-5-carboxylic
acid
[0328] A stirred solution of
Ethyl-2-[(methylsulfonyl)amino]-4-methyl-thiazole-5-carboxylate
(300 mg, 1.14 mmol) in methanol (9 mL) was treated with a 1N NaOH
solution (28.4 mL, 28.4 mmol). The mixture was stirred at rt
overnight. The solution was cooled to 0.degree. C. and acidified
with 6N aq. HCl solution to pH 1. The solution was extracted with
dichloromethane-chloroform mixture. The organic extract was dried
(MgSO4), filtered and concentrated in vacuo to obtain the title
acid (148 mg, 55%).
C.
4-Methyl-2-[(methylsulfonyl)amino]-N-(2,4,6-trimethylphenyl)-5-thiazole-
carboxamide
[0329] Diisopropylethylamine (87 .mu.L, 0.5 mmol) was added to a
solution of 312 B (99 mg, 0.42 mmol), 2,4,6-trimethylaniline (68
.mu.L, 0.5 mmol), and
[O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium]hexafluorophos-
phate (HATU, 191 mg, 0.5 mmol) in DMF (3 mL). The mixture was
stirred at rt overnight, diluted with EtOAc and washed with 0.5 N
aq. HCl solution (15 mL), 10% aq. LiCl solution (25 mL, 3.times.),
water (930 mL, 2.times.), brine, dried (MgSO.sub.4), filtered and
concentrated. The residue was chromatographed on a silica gel
column and eluted with 50% EtOAc in hexanes, followed by 75% EtOAc
in hexanes and 2% MeOH in EtOAc to obtain the title compound (19
mg, 13%) as a white solid.
Example 313
Preparation of
4-Methyl-2-[[(phenylamino)thiocarbonyl]amino)-N-(2,4,6-trimethylphenyl)-5-
-thiazolecarboxamide
##STR00331##
[0331] A solution of 2 (45 mg, 0.16 mmol) and phenylisothiocyanate
(43 mg, 0.32 mmol) in pyridine (2 mL) was heated to 80.degree. C.
for 20 h. The mixture was cooled, diluted with dichloromethane-THF
mixture (80 mL, 3:1) and washed with 2 N aq. HCl solution (15 mL,
2.times.). The organic extract was dried (MgSO.sub.4), filtered and
concentrated. The residue was diluted with EtOAc (20 mL) and the
solid was filtered, washed with ether (10 mL, 3.times.), and dried
in vacuo to obtain the title compound (35 mg, 52%) as an off-white
solid.
Example 314
Preparation of
2-[[(Ethylamino)carbonyl]amino]-4-methyl-N-(2,4,6-trimethylphenyl)-5-thia-
zolecarboxamide
##STR00332##
[0333] Compound 314 was prepared by an analogous method as that of
compounds 171-180, using ethylisocyanate to give the title compound
314 as a white solid (65%).
Example 315
Preparation of
N-(2-Chloro-6-methylphenyl)-2-[(cyclopropylcarbonyl)amino]-5-thiazolecarb-
oxamide
##STR00333##
[0334] A.
Ethyl-2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxyl-
ate
[0335] A suspension of ethyl-2-amino-thiazole-5-carboxylate (972
mg, 6 mmol, B. Plouvler, C. Bailly, R. Houssin, j-P. Henlchart
Heterocyles 32(4), 693-701, 1991 and H. J. Becker, J. de Jonge Rec.
Trav. Chim, 61, 463, 1942), di-t-butyldicarbonate (1.94 g, 9 mmol)
and 4-dimethylaminopyridine (73 mg, 0.6 mmol) in dry
tetrahydrofuran (75 mL) was stirred under nitrogen for 24 h. The
solvent was evaporated in vacuo. The residue was suspended in ether
(50 mL). The solid was washed with ether (10 mL, 3.times.), and
dried in vacuo to obtain the title compound (1.1 g, 70%).
B. 2-tert-butoxycarbonyloxyamino-thiazole-5-carboxylic acid
[0336] A stirred solution of
ethyl-2-tert-butoxycarbonyloxyamino-4-methyl-thiazole-5-carboxylate
(1.1 g, 4.2 mmol) in tetrahydrofuran-methanol (80 mL, 1:1) was
treated with a 6N aq. NaOH solution (20 mL, 120 mmol). The mixture
was stirred at rt for 24 h. Most of THF and methanol were removed
by distillation under reduced pressure and the aq. Solution was
acidified with 6 N aq. HCl solution (22 mL). The precipitated solid
was filtered, washed with water and ether, air dried followed by
drying in vacuo to obtain the title acid (940 mg, 96%) as an
off-white solid.
C.
[5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
[0337] A 2 M solution of oxalyl chloride in dichloromethane (1 mL,
2 mmol) was added dropwise to a stirred solution of
2-tert-butoxycarbonyloxyamino-thiazole-5-carboxylic acid (234 mg, 1
mmol) in THF (10 mL) and N,N-dimethyl formamide (few drops). The
solution was stirred at rt for 4 h. The solvent was evaporated
under reduced pressure, and in vacuo to obtain the crude acid
chloride.
[0338] 2-Chloro-6-methyl aniline (212 mg, 1.5 mmol) was added
dropwise to a stirred solution of crude
2-tert-butoxycarbonyloxyamino-thiazole-5-carboxylic acid chloride
(1 mmol) in dichloromethane (10 mL) at 0.degree. C.
[0339] Diisopropylethylamine (516 mg, 4 mmol) was added. The
solution was allowed to warm to rt and stirred for 24 h, diluted
with dichloromethane (60 mL) and washed with 2 N aq. HCl solution
(15 mL). The organic extract was dried (MgSO.sub.4), filtered and
concentrated. The residue was diluted with EtOAc-ether (25 mL, 1:4)
and the solid was filtered and washed with ether (5 mL, 4.times.),
and dried in vacuo to obtain the title compound (175 mg, 48%) as a
tan solid.
D. 2-Amino-N-(2-chloro-6-methylphenyl)-5-thiazolecarboxamide
[0340] Compound 315D was prepared by an analogous method as that of
2, except using compound 315C to give the title compound 315D as a
tan solid.
E.
2-[(Cyclopropylcarbonyl)amino]-N-(2-chloro-6-methylphenyl)-5-thiazoleca-
rboxamide
[0341] A solution of 315D (50.6 mg, 0.19 mmol) and
cyclopropanecarboxylic acid anhydride (302 mg, 1.96 mmol) in
dioxane (2 mL) was heated to 93.degree. C. overnight. The mixture
was concentrated in vacuo, diluted with EtOAc and washed with satd.
aq. KHCO.sub.3 solution (2.times.). The organic extract was dried
(Na.sub.2SO.sub.4), filtered and concentrated. The residue was
triturated with ether to obtain the title compound (11 mg, 17%) as
a white solid.
Example 316
Preparation of
2-[[[(1,1-Dimethylethyl)amino]carbonyl]amino]-N-(2-chloro-6-methylphenyl)-
-5-thiazolecarboxamide
##STR00334##
[0343] Sodium hydride (19.2 mg, 0.8 mmol) was added to a solution
of 315D (48.3 mg, 0.18 mmol) and t-butylisocyanate (41 .mu.L, 0.36
mmol) in THF (5 mL) at 0.degree. C. After 1 h, the mixture was
diluted with EtOAc and washed with cold satd. aq. ammonium chloride
solution. The aqueous layer was separated and extracted with EtOAc.
The EtOAc extracts were combined, dried (Na.sub.2SO.sub.4),
filtered and concentrated. The residue was purified by automatic
preparative HPLC (conditions: YMC S5 ODS A 20.times.100 mm Column,
10 min gradient starting from 10% solvent B (90% MeOH, 10%
H.sub.2O, 0.1% TFA) and 90% solvent A (10% MeOH, 90% H.sub.2O, 0.1%
TFA) to 100% solvent B, flow rate 20 mL/min, .lamda.=220 nM to
obtain the title compound (18 mg, 28%) as an off-white solid.
Example 317
Preparation of
2-[[(1,1-Dimethylethoxy)carbonyl]amino]-4-methyl-N-(2,4,6-trimethylphenyl-
)-5-thiazoleacetamide
##STR00335##
[0345] Compound 317 was prepared by an analogous method as that of
1, except using methyl-2-amino-4-methyl-thiazole-5-acetate to give
the title compound 317 as an off-white solid.
Example 318
Preparation of
2-Amino-4-methyl-N-(2,4,6-trimethylphenyl)-5-thiazoleacetamide
##STR00336##
[0347] Compound 318 was prepared by an analogous method as that of
2, except using 317 to give the title compound 318 as a light brown
solid.
Example 319
Preparation of N-(2-Chloro-6-methylphenyl)-2-[(4,
6-dimethyl-2-pyridinyl)amino]-5-thiazolecarboxamide
##STR00337##
[0348] A.
2-Bromo-N-(2-chloro-6-methylphenyl)-5-thiazolecarboxamide
[0349] A solution of copper (II) bromide (2.68 g, 12 mmol) in
acetonitrile (50 mL) was purged with nitrogen and cooled to
0.degree. C. t-Butyl nitrite (2 mL, 15 mmol) was added, followed by
a solution of compound 315D (2.68 g, 10 mmol) in acetonitrile (50
mL), The mixture was stirred at rt overnight and concentrated in
vacuo. The residue was dissolved in EtOAc, washed with satd. aq.
NaHCO.sub.3 solution and the precipitate was removed by filtration.
The organic extract was dried (Na.sub.2SO.sub.4), filtered and
concentrated. The residue was crystallized from EtOAc/ether/hexanes
mixture to obtain the title compound (1.68 g, 51%) as a yellow
solid.
B. N-(2-Chloro-6-methylphenyl)-2-[(4,
6-dimethyl-2-pyridinyl)amino]-5-thiazolecarboxamide
[0350] 95% Sodium hydride (15 mg) was added to a mixture of 319A
(25 mg, 0.075 mmol) and 4,6-dimethyl-2-aminopyridine (37 mg, 0.302
mmol) in THF (1 mL). The mixture was heated to 60.degree. C.
overnight, cooled to rt and diluted with satd. aq. ammonium
chloride solution. The mixture was extracted with EtOAc (2.times.).
Organic extracts were combined, washed with water and dried
(Na.sub.2SO.sub.4), filtered and concentrated. The residue was
triturated with ether to obtain the title compound (17.5 mg, 63%)
as a tan solid.
Example 320
Preparation of
N-(2-Chloro-6-methylphenyl)-2-[(4-ethyl-2-pyridinyl)amino]-5-thiazolecarb-
oxamide
##STR00338##
[0352] Compound 320 was prepared by an analogous method as that of
319B, except using 4-ethyl-2-aminopyridine to give the title
compound 320.
Example 321
Preparation of
N-(2-Chloro-6-methylphenyl)-2-[(2,6-dimethyl-4-pyrimidinyl)amino]-5-thiaz-
olecarboxamide
##STR00339##
[0354] Compound 321 was prepared by an analogous method as that of
319B, except using 2,6-dimethyl-4-aminopyrimidine to give the title
compound 321.
Example 322
Preparation of
N-(2-Chloro-6-methylphenyl)-2-(3-pyridazinylamino)-5-thiazolecarboxamide
##STR00340##
[0356] Compound 322 was prepared by an analogous method as that of
319B, except using 3-aminopyridazine to give the title compound
322.
Examples 323 to 335
General Procedure
[0357] Compounds 323 to 335 were prepared following the procedure
described below. Diisopropylethyl amine (60 .mu.L, 0.34 mmol) was
added to a mixture of amine 144 (31 mg, 0.11 mmol), appropriate
carboxylic acid (0.13 mmol), 1-hydroxy-7-azabenzotriazole (19.5 mg,
0.14 mmol), and ethyl-3-(3-dimethylamino)-propyl carbodiimide
hydrochloride (26.8 mg, 0.14 mmol) in THF (0.4 mL). The mixture was
heated in a sealed tube under argon at 50.degree. C. for 24 h. The
reaction mixture was diluted with dichloromethane (4 mL) and washed
with 1 N aq. HCl solution. The dichloromethane solution was passed
through a Varian Mega Bond Elut SCX cation exchange column
(prewashed with methanol and equilibrated with
acetonitrile-methanol (4:1). The column was eluted sequentially
with acetonitrile-methanol (4:1), methanol-2M methanolic ammonia
(4:1). Fractions containing the product were combined and
concentrated in vacuo. "HPLC Ret Time" is the HPLC retention time
under the following conditions: YMC S5 ODS 4.6.times.50 mm
Ballastic Column, 4 min gradient starting from 100% solvent A (10%
MeOH, 90% H.sub.2O, 0.2% H3PO4) to 100% solvent B (90% MeOH, 10%
H.sub.2O, 0.2% H3P04), flow rate 4 mL/min, .lamda.=220 nM.
TABLE-US-00008 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 323 ##STR00341## N-(2-Chloro-6-methylphenyl)-4-
methyl-2-[(2-thienyl- carbonyl)amino]-5- thiazolecarboxamide 3.70
324 ##STR00342## N-(2-Chloro-6-methylphenyl)-2-
[(cyclopropylcarbonyl)amino]-4- methyl-5-thiazolecarboxamide 3.41
325 ##STR00343## N-(2-Chloro-6-methylphenyl)-4-
methyl-2-[(2-furanyl- carbonyl)amino]-5- thiazolecarboxamide 3.49
326 ##STR00344## N-(2-Chloro-6-methylphenyl)-4-
methyl-2-[(3-thienylcar- bonyl)amino]-5-thiazole- carboxamide 3.71
327 ##STR00345## N-(2-Chloro-6-methylphenyl)-4- methyl-2-[(3-
furanylcarbonyl)amino]-5- thiazolecarboxamide 3.57 328 ##STR00346##
trans-N-(2-Chloro-6- methylphenyl)-4-methyl-2-[[(2-
phenylcyclopropyl)carbonyl]amino]- 5-thiazolecarboxamide 4.09 329
##STR00347## N-(2-Chloro-6-methylphenyl)-4-
methyl-2-[[(2-methylcyclo- propyl)carbonyl]amino]-5-
thiazolecarboxamide 3.65 330 ##STR00348##
N-(2-Chloro-6-methylphenyl)-2- [(cyclobutylcarbonyl)amino]-4-
methyl-5-thiazolecarboxamide 3.63 331 ##STR00349## N
N-(2-Chloro-6-methylphenyl)- 2-[(cyclopentylcarbonyl)amino]-4-
methyl-5-thiazolecarboxamide 3.82 332 ##STR00350##
N-(2-Chloro-6-methylphenyl)-4- methyl-2-[(2-methyl-1-
oxopropyl)amino]-5- thiazolecarboxamide 3.50 333 ##STR00351##
N-(2-Chloro-6-methylphenyl)-4- methyl-2-[(1-oxopentyl)amino]-5-
thiazolecarboxamide 3.79 334 ##STR00352##
N-(2-Chloro-6-methylphenyl)-4- methyl-2-[(2-methyl-1-
oxopentyl)amino]-5- thiazolecarboxamide 3.90 335 ##STR00353##
2-(Benzoylamino)-N-(2-chloro-6- methylphenyl)-4-methyl-5-
thiazolecarboxamide 3.79
Examples 336 to 362
General Procedure
[0358] Compounds 336 to 362 were prepared by an analogous method as
that of 323-335, except using 315D in place of 144. The crude
products were purified by automatic preparative HPLC (conditions:
YMC S5 ODS A 20.times.100 mm Column, 10 min gradient starting from
10% solvent B (90% MeOH, 10% H.sub.2O, 0.1% TFA) and 90% solvent A
(10% MeOH, 90% H.sub.2O, 0.1% TFA) to 100% solvent B, flow rate 20
mL/min, .lamda.=220 nM to obtain the title compounds 336-362.
[0359] "HPLC Ret Time" is the HPLC retention time under the
following conditions: YMC S5 ODS 4.6.times.50 mm Ballastic Column,
4 min gradient starting from 100% solvent A (10% MeOH, 90%
H.sub.2O, 0.2% H3PO.sub.4) to 100% solvent B (90% MeOH, 10%
H.sub.2O, 0.2% H3PO.sub.4), flow rate 4 mL/min, .lamda.=220 nM.
TABLE-US-00009 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 336 ##STR00354## N-(2-Chloro-6-methylphenyl)-2-
[(1-oxopropyl)amino]-5- thiazolecarboxamide 3.53 337 ##STR00355##
N-(2-Chloro-6-methylphenyl)- [(1-oxobutyl)amino]-5-
thiazolecarboxamide 3.61 338 ##STR00356##
N-(2-Chloro-6-methylphenyl)- [(2-ethyl-1-oxobutyl)amino]-
5-thiazolecarboxamide 3.54 339 ##STR00357##
N-(2-Chloro-6-methylphenyl)-2- [[(1-phenylcyclo-
propyl)carbonyl]amino]-5- thiazolecarboxamide 3.86 340 ##STR00358##
N-(2-Chloro-6-methylphenyl)-2- [[(1-methylcyclo-
propyl)carbonyl]amino]-5- thiazolecarboxamide 3.53 341 ##STR00359##
N-(2-Chloro-6-methylphenyl)-2- [[(2,2-dichloro-1-methylcyclo-
propyl)carbonyl]amino]-5- thiazolecarboxamide 3.53 342 ##STR00360##
N-(2-Chloro-6-methylphenyl)-2- [[(2-methylcyclo-
propyl)carbonyl]amino]-5- thiazolecarboxamide 3.53 343 ##STR00361##
N-(2-Chloro-6-methylphenyl)-2- [[(1-hydroxycyclopropyl)-
carbonyl]amino]-5-thiazole- carboxamide 3.58 344 ##STR00362##
N-(2-Chloro-6-methylphenyl)-2- [[(2,2.3,3-tetramethylcyclo-
propyl)carbonyl]amino]-5- thiazolecarboxamide 3.69 345 ##STR00363##
N-(2-Chloro-6-methylphenyl)-2- [[(1-cyanocyclopropyl)-
carbonyl]amino]-5-thiazole- carboxamide 3.53 346 ##STR00364##
N-(2-Chloro-6-methylphenyl)-2- [(cyclobutylcarbonyl)amino]-5-
thiazolecarboxamide 3.52 347 ##STR00365##
N-(2-Chloro-6-methylphenyl)-2- [(cyclopentylcarbonyl)amino]-5-
thiazolecarboxamide 3.59 348 ##STR00366##
N-(2-Chloro-6-methylphenyl)-2- [(cyclohexylcarbonyl)amino]-5-
thiazolecarboxamide 3.78 349 ##STR00367##
N-(2-Chloro-6-methylphenyl)-2- [(phenylacetyl)amino]-5-
thiazolecarboxamide 3.62 350 ##STR00368##
N-(2-Chloro-6-methylphenyl)-2- [(cyclohexylacetyl)amino]-5-
thiazolecarboxamide 4.07 351 ##STR00369##
N-(2-Chloro-6-methylphenyl)-2- [(4-pyridinylacetyl)amino]-5-
thiazolecarboxamide 3.75 352 ##STR00370##
N-(2-Chloro-6-methylphenyl)-2- [[(2,5-dimethyl-1H-pyrrol-3-
yl)carbonyl]amino]-5- thiazolecarboxamide 3.17 353 ##STR00371##
N-(2-Chloro-6-methylphenyl)-2- [(2-pyridinylcarbonyl)amino]-5-
thiazolecarboxamide 3.07 354 ##STR00372##
N-(2-Chloro-6-methylphenyl)-2- [(3-pyridinylcarbonyl)amino]-5-
thiazolecarboxamide 3.07 355 ##STR00373##
N-(2-Chloro-6-methylphenyl)-2- [(4-pyridinylcarbonyl)amino]-5-
thiazolecarboxamide 3.61 356 ##STR00374##
N-(2-Chloro-6-methylphenyl)-2- [(3-thienylcarbonyl)amino]-5-
thiazolecarboxamide 3.60 357 ##STR00375##
N-(2-Chloro-6-methylphenyl)-2- [(2-thienylcarbonyl)amino]-5-
thiazolecarboxamide 3.61 358 ##STR00376##
N-(2-Chloro-6-methylphenyl)-2- [(2-furanylcarbonyl)amino]-5-
thiazolecarboxamide 3.61 359 ##STR00377##
N-(2-Chloro-6-methylphenyl)-2- [(3-furanylcarbonyl)amino]-5-
thiazolecarboxamide 3.69 360 ##STR00378## trans-N-(2-Chloro-6-
methylphenyl)-2-[[(2- phenylcyclopropyl)carbonyl]
amino]-5-thiazolecarboxamide 3.98 361 ##STR00379##
N-(2-Chloro-6-methylphenyl)-2- [(2-methyl-1-oxopentyl)amino]-5-
thiazolecarboxamide 3.90 362 ##STR00380##
2-(Benzoylamino)-N-(2-chloro-6- methylphenyl)-5-
thiazolecarboxamide 3.61
Example 363
Preparation of
2-[(Cyclopropylcarbonyl)amino]-N-(2,6-dimethylphenyl)-5-thiazolecarboxami-
de
##STR00381##
[0361] Compound 363 was prepared by an analogous method as that of
315, except using 2,6-dimethylaniline to give the title compound
363.
Example 364
Preparation of
2-[(Cyclopropylcarbonyl)amino]-N-(2,4,6-trimethylphenyl)-5-thiazolecarbox-
amide
##STR00382##
[0363] Compound 364 was prepared by an analogous method as that of
315, except using 2,4,6-trimethylaniline to give the title compound
364.
Example 365
Preparation of N-(2-Chloro-4,
6-dimethlphenyl)-2-[(cyclopropylcarbonyl)amino]-5-thiazolecarboxamide
##STR00383##
[0365] Compound 365 was prepared by an analogous method as that of
315, except using 2-chloro-4,6-dimethylaniline to give the title
compound 365.
Example 366
Preparation of
[4-[2-Oxo-2-[(2,4,6-trimethylphenyl)amino]ethyl]-2-thiazolyl]carbamic
acid 1,1-dimethylethyl ester
##STR00384##
[0367] Compound 366 was prepared by an analogous method as that of
1 except, using 2-tert-butoxycarbonyloxyamino-thiazole-4-acetic
acid to give the title compound 366 as a white solid.
Example 367
Preparation of
2-Amino-N-(2,4,6-trimethylphenyl)-4-thiazoleacetamide
##STR00385##
[0369] Compound 367 was prepared by an analogous method as that of
4, except using 365 to give the title compound 367 as a white
solid.
Example 368
Preparation of
2-Methyl-5-nitro-N-(2,4,6-trimethylphenyl)benzamide
##STR00386##
[0371] Compound 368 was prepared by an analogous method as that of
3, except using 2-methyl-5-nitrobenzoic acid to give the title
compound 368 as a white solid.
Example 369
Preparation of
5-Amino-2-methyl-N-(2,4,6-trimethylphenyl)benzamide
##STR00387##
[0373] 10% Palladium on charcoal (30 mg) was added to a stirred
solution of 368 (149 mg, 0.5 mmol) in EtOAc (50 mL). The reaction
flask was equipped with a hydrogen filled balloon via a three-way
stopcock. Air inside the flask was evacuated under reduced pressure
and the flask filled with hydrogen from the balloon. After 4 h, the
catalyst was filtered, washed with EtOAc (5 mL, 5.times.). The
filtrate was concentrated to obtain the title compound (133 mg,
99%) as a white solid.
Example 370
Preparation of
2-Amino-5-chloro-N-(2,4,6-trimethylphenyl)-4-pyrimidinecarboxamide
##STR00388##
[0375] Compound 370 was prepared by an analogous method as that of
3, except using 2-amino-5-chloro-pyrimidine-4-carboxylic acid to
give the title compound 370 as a white solid.
Example 371
Preparation of
[4-Methyl-5-[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-oxazolyl]carbamic
acid 1,1-dimethylethyl ester
##STR00389##
[0377] Compound 371 was prepared by an analogous method as that of
1, except using
2-tert-butoxycarbonyloxyamino-4-methyl-5-oxazolecarboxylic acid to
give the title compound 371 as a light yellow foam.
Example 372
Preparation of
2-Amino-4-(methyl)-N-(2,4,6-trimethylphenyl)-5-oxazolecarboxamide,
trifluoroacetate (1:1)
##STR00390##
[0379] Compound 372 was prepared by an analogous method as that of
4, except using 369 to give the title compound 372 as a white
solid.
Example 373
Preparation of
2-Amino-N-(2,4,6-trimethylphenyl)-5-pyridinecarboxamide
##STR00391##
[0381] Compound 373 was prepared by an analogous method as that of
3, except using 6-aminonicotinic acid to give the title compound
373 as a white solid.
Example 374
Preparation
3-Amino-N-(2,4,6-trimethylphenyl)-4-pyridinecarboxamide
##STR00392##
[0383] Compound 374 was prepared by an analogous method as that of
3, except using 3-amino-4-pyridinecarboxylic acid to give the title
compound 374 as a white solid.
Example 375
Preparation
2-Amino-4-methyl-N-(2,4,6-trimethylphenyl)-5-pyrimidinecarboxamide
##STR00393##
[0385] Compound 375 was prepared by an analogous method as that of
3, except using 2-amino-4-methyl-5-pyrimidinecarboxylic acid to
give the title compound 375 as a white solid.
Example 376
Preparation of
N-(2-Chloro-6-methylphenyl)-2-[(4-methyl-2-pyridinyl)amino]-5-thiazolecar-
boxamide
##STR00394##
[0387] Compound 376 was prepared by an analogous method as that of
319B, except using 2-amino-4-methyl-pyridine to give the title
compound 376 as an off-white solid.
Example 377
Preparation of
2-[(6-Amino-2-pyridinyl)amino]l-N-(2-chloro-6-methylphenyl)-5-thiazolecar-
boxamide
##STR00395##
[0389] Compound 377 was prepared by an analogous method as that of
319B, except using 2,6-diaminopyridine to give the title compound
377 as a light brown solid.
Example 378
Preparation of
N-(2-Chloro-6-methylphenyl)-2-[(6-propyl-2-pyridinyl)amino]-5-thiazolecar-
boxamide
##STR00396##
[0391] Compound 378 was prepared by an analogous method as that of
319B, except using 2-amino-6-propyl-pyridine to give the title
compound 378 as an off-white solid.
Example 379
Preparation of
N-(2-Chloro-6-methylphenyl)-2-[(6-ethyl-4-pyrimidinyl)amino]-5-thiazoleca-
rboxamide
##STR00397##
[0393] Compound 379 was prepared by an analogous method as that of
319B, except using 4-amino-6-ethyl-pyrimidine to give the title
compound 379 as a white solid.
Examples 380 to 409
General Procedure
[0394] Compounds 380 to 409 were prepared by an analogous method as
that of 319B. For the following examples 380 to 527 "HPLC Ret Time"
is the HPLC retention time under the following conditions: YMC S5
ODS 4.6.times.50 mm Ballastic Column, 4 min gradient starting from
100% solvent A (10% MeOH, 90% H.sub.2O, 0.2% H.sub.3PO.sub.4) to
100% solvent B (90% MeOH, 10% H.sub.2O, 0.2% H.sub.3PO.sub.4), flow
rate 4 mL/min, .lamda.=220 nM. Where used, "HPLC Ret Time `B`" is
the HPLC retention time under the following conditions: YMC S5 ODS
4.6.times.33 mm Turbo Column, 2 min gradient starting from 100%
solvent A (10% MeOH, 90% H.sub.2O, 0.1% TFA) to 100% solvent B (90%
MeOH, 10% H.sub.2O, 0.1% TFA) with 1 min at 100% solvent B, flow
rate 4 mL/min, .lamda.=220 nM.
TABLE-US-00010 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 380 ##STR00398## 'N-(2-Chloro-6-methylphenyl)-2-
(2-pyridinylamino)-5- thiazolecarboxamide 3.337 381 ##STR00399##
'N-(2-Chloro-6-methylphenyl)-2- [(6-methyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.61 382 ##STR00400##
'N-(2-Chloro-6-methylphenyl)-2- [(5-methyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.487 383 ##STR00401##
'N-(2-Chloro-6-methylphenyl)-2- [(4-methyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.293 384 ##STR00402##
'N-(2-Chloro-6-methylphenyl)-2- [(3-methyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.243 385 ##STR00403## '2-[(5-Bromo-3-methyl-2-
pyridinyl)amino]-N-(2-chloro-6- methylphenyl)-5-
thiazolecarboxamide 4.17 386 ##STR00404##
'2-[(6-Amino-2-pyridinyl)amino]- N-(2-chloro-6-methylphenyl)-5-
thiazolecarboxamide 2.817 387 ##STR00405##
'2-[(5-Bromo-2-pyridinyl)amino]- N-(2-chloro-6-methylphenyl)-5-
thiazolecarboxamide 4.023 388 ##STR00406##
'N-(2-Chloro-6-methylphenyl)-2- [[3-(phenylmethoxy)-2-
pyridinyl]amino]-5- thiazolecarboxamide 4.143 389 ##STR00407##
'N-(2-Chloro-6-methylphenyl)-2- [(5-chloro-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.957 390 ##STR00408##
'N-(2-Chloro-6-methylphenyl)-2- [(6-ethyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.867 391 ##STR00409##
'N-(2-Chloro-6-methylphenyl)-2- [(6-propyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 4.083 392 ##STR00410## '2-[(3-Bromo-5-methyl-2-
pyridinyl)amino]-N-(2-chloro-6- methylphenyl)-5-
thiazolecarboxamide 4.077 393 ##STR00411##
'2-[(2-Amino-3-pyridinyl)amino]- N-(2-chloro-6-methylphenyl)-5-
thiazolecarboxamide 2.343 394 ##STR00412##
'2-[(3-Amino-2-pyridinyl)amino]- N-(2-chloro-6-methylphenyl)-5-
thiazolecarboxamide 2.777 395 ##STR00413##
'N-(2-Chloro-6-methylphenyl)-2- (4-pyridinylamino)-5-
thiazolecarboxamide 2.493 396 ##STR00414##
'N-(2-Chloro-6-methylphenyl)-2- (3-pyridinylamino)-5-
thiazolecarboxamide 2.47 397 ##STR00415##
'N-(2-Chloro-6-methylphenyl)-2- [(6-chloro-3-pyridinyl)amino]-5-
thiazolecarboxamide 3.75 398 ##STR00416##
'N-(2-Chloro-6-methylphenyl)-2- [(2-chloro-3-pyridinyl)amino]-5-
thiazolecarboxamide 3.443 399 ##STR00417##
'N-(2-Chloro-6-methylphenyl)-2- [(6-methoxy-3-pyridinyl)amino]-5-
thiazolecarboxamide 3.517 400 ##STR00418##
'N-(2-Chloro-6-methylphenyl)-2- [(3,5-dimethyl-2-
pyrazinyl)amino]-5- thiazolecarboxamide 3.583 401 ##STR00419##
'N-(2-Chloro-6-methylphenyl)-2- (phenylamino)-5-
thiazolecarboxamide 3.697 402 ##STR00420##
'N-(2-Chloro-6-methylphenyl)-2- [(3-ethylphenyl)amino]-5-
thiazolecarboxamide 4.107 403 ##STR00421##
'N-(2-Chloro-6-methylphenyl)-2- [(3,5-dimethylphenyl)amino]-5-
thiazolecarboxamide 3.98 404 ##STR00422##
'N-(2-Chloro-6-methylphenyl)-2- [(4,6-dimethyl-2-
pyrimidinyl)amino]-5- thiazolecarboxamide 3.51 405 ##STR00423##
'N-(2-Chloro-6-methylphenyl)-2- [(6-ethyl-4-pyrimidinyl)amino]-5-
thiazolecarboxamide 2.943 406 ##STR00424##
'N-(2-Chloro-6-methylphenyl)-2- [(6-chloro-2-pyrazinyl)amino]-5-
thiazolecarboxamide 3.763 407 ##STR00425##
'2-[(3-Aminophenyl)amino]-N-(2- chloro-6-methylphenyl)-5-
thiazolecarboxamide 2.633 408 ##STR00426##
'N-(2-Chloro-6-methylphenyl)-2- [(3-hydroxyphenyl)amino]-5-
thiazolecarboxamide 3.337 409 ##STR00427##
'2-[(3-Bromophenyl)amino]-N-(2- chloro-6-methylphenyl)-5-
thiazolecarboxamide 4.12
Example 410
Preparation of
'N-(2,6-Dimethylphenyl)-2-(phenylamino)-5-thiazolecarboxamide
##STR00428##
[0395] A.
[5-[[(2,6-dimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic acid,
1,1-dimethylethyl ester
[0396] Compound 410A was prepared by an analogous method as that of
315C, except using 2,6-dimethylaniline.
B. 2-Amino-N-(2,6-dimethylphenyl)-5-thiazolecarboxamide
[0397] Compound 410B was prepared by an analogous method as that of
315D, except using compound 410A.
C. Title Compound
[0398] The title compound was prepared by an analogous method as
that of 319B, except using compound 410B and aniline. HPLC Ret.
Time 3.69 min.
Examples 411 to 427
General Procedure
[0399] Compounds 411 to 427 were prepared by an analogous method as
that of 319B.
TABLE-US-00011 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 411 ##STR00429## 'N-(2,6-Dimethylphenyl)-2-
(methylphenylamino)-5- thiazolecarboxamide 3.667 412 ##STR00430##
'N-(2,6-Dimethylphenyl)-2-(2- pyridinylamino)-5-
thiazolecarboxamide 3.297 413 ##STR00431##
'N-(2,6-Dimethylphenyl)-2-[(6- methyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.587 414 ##STR00432##
'N-(2,6-Dimethylphenyl)-2-[(4- methyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.222 415 ##STR00433##
'N-(2,6-Dimethylphenyl)-2-[(4- ethyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.54 416 ##STR00434##
'N-(2,6-Dimethylphenyl)-2-[(4,6- dimethyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.543 417 ##STR00435##
'2-[(6-Amino-2-pyridinyl)amino]- N-(2,6-dimethylphenyl)-5-
thiazolecarboxamide 2.807 418 ##STR00436##
'N-(2,6-Dimethylphenyl)-2-[(6- ethyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 3.847 419 ##STR00437##
'N-(2,6-Dimethylphenyl)-2-[(6- propyl-2-pyridinyl)amino]-5-
thiazolecarboxamide 4.057 420 ##STR00438##
'2-[(2-Amino-3-pyridinyl)amino]- N-(2,6-dimethylphenyl)-5-
thiazolecarboxamide 2.337 421 ##STR00439##
'2-[(3-Amino-2-pyridinyl)amino]- N-(2,6-dimethylphenyl)-5-
thiazolecarboxamide 2.737 422 ##STR00440## '2-[(6-Amino-2-methyl-4-
pyrimidinyl)amino]-N-(2,6- dimethylphenyl)-5- thiazolecarboxamide
2.71 423 ##STR00441## 'N-(2,6-Dimethylphenyl)-2-[[6-(4-
morpholinyl)-3- pyridazinyl]amino]-5- thiazolecarboxamide 2.727 424
##STR00442## '2-[(6-Chloro-3- pyridazinyl)amino]-N-(2,6-
dimethylphenyl)-5- thiazolecarboxamide 3.46 425 ##STR00443##
'N-(2,6-Dimethylphenyl)-2-(3- pyridazinylamino)-5-
thiazolecarboxamide 2.973 426 ##STR00444##
'2-[(3-Aminophenyl)amino]-N- (2,6-dimethylphenyl)-5-
thiazolecarboxamide 2.63 427 ##STR00445##
'2-[(3-Bromophenyl)amino]-N- (2,6-dimethylphenyl)-5-
thiazolecarboxamide 4.143
Example 428
Preparation of
'2-(2-Pyridinylamino)-N-(2,4,6-trimethylphenyl)-5-thiazolecarboxamide
##STR00446##
[0400] A.
[5-[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-thiazolyl]carbamic
acid, 1,1-dimethylethyl ester
[0401] Compound 428A was prepared by an analogous method as that of
315C, except using 2,4,6-trimethylaniline.
B. 2-Amino-N-(2,6-dimethylphenyl)-5-thiazolecarboxamide
[0402] Compound 428B was prepared by an analogous method as that of
315D, except using compound 428A.
C. Title Compound
[0403] The title compound was prepared by an analogous method as
that of 319B, except using compound 428B and 2-aminopyridine. HPLC
Ret. Time 3.66 min.
Examples 429 to 443
General Procedure
[0404] Compounds 429 to 443 were prepared by an analogous method as
that of 319B.
TABLE-US-00012 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 429 ##STR00447## '2-[(6-Methyl-2-pyridinyl)amino]-N-
(2,4,6-trimethylphenyl)-5- thiazolecarboxamide 3.903 430
##STR00448## '2-[(5-Methyl-2-pyridinyl)amino]-N-
(2,4,6-trimethylphenyl)-5- thiazolecarboxamide 3.8 431 ##STR00449##
'2-[(4-Methyl-2-pyridinyl)amino]-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 3.603 432 ##STR00450##
'2-[(3-Methyl-2-pyridinyl)amino]-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 3.56 433 ##STR00451##
'2-[(5-Bromo-2-pyridinyl)amino]-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 4.263 434 ##STR00452##
'2-[(5-Chloro-2-pyridinyl)amino]-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 4.203 435 ##STR00453##
'2-[(6-Methoxy-3-pyridinyl)amino]- N-(2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 3.8 436 ##STR00454##
'2-[(4-Ethyl-2-pyridinyl)amino]-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 3.86 437 ##STR00455##
'2-[(6-Ethyl-2-pyridinyl)amino]-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 4.127 438 ##STR00456##
'2-[(6-Chloro-3-pyridinyl)amino]-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 4.017 439 ##STR00457## '2-[(2,6-Dimethyl-4-
pyrimidinyl)amino]-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 2.943 440 ##STR00458##
'2-[(4-Methyl-2-pyrimidinyl)amino]- N-(2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 3.723 441 ##STR00459##
'2-(2-Pyrazinylamino)-N-(2,4,6- trimethylphenyl)-5-
thiazolecarboxamide 3.65 442 ##STR00460##
'2-[(6-Chloro-2-pyrazinyl)amino]-N- (2,4,6-trimethylphenyl)-5-
thiazolecarboxamide 4.05 443 ##STR00461## '2-[(3,5-Dimethyl-2-
pyrazinyl)amino)-N-(2,4,6- trimethylphenyl)-5- thiazolecarboxamide
3.877
Example 444
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[2-methyl-6-[[2-(4-morpholinyl)ethyl]amin-
o]-4-pyrimidinyl]amino]-5-thiazolecarboxamide
##STR00462##
[0406] To a suspension of NaH (148 mg, 6.17 mmol) in THF (20 mL)
was added a solution of compound 315D (551 mg, 2.06 mmol) in THF
(10 mL) and stirred at RT for 0.5 h. A solution of
4,6-dichloro-2-methylpyrimidine (671.6 mg, 4.12 mmol) in THF (10
mL) and stirred at RT overnight. The reaction was quenched with
acetic acid and the solvent removed in vacuo. Water and saturated
NaHCO.sub.3 were added to the residue and extracted with
CH.sub.2Cl.sub.2. The organic layer was removed in vacuo and the
crude material purified by column chromatography to give 444A (494
mg).
B. Title Compound
[0407] To compound 444A (30 mg) was added
N-(2-aminoethyl)-morpholine (300 .mu.L) and the mixture was heated
at 80.degree. C. for 2 h. Water was added to the reaction and the
product was collected by filtration. HPLC Ret. Time 2.357 min.
Examples 445 to 461
General Procedure
[0408] Compounds 445 to 461 were prepared by an analogous method as
that of 444B by substituting the appropriate amine.
TABLE-US-00013 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 445 ##STR00463## 'N-(2-Chloro-6-methylphenyl)-2-
[[2-methyl-6-[[3-(4- morpholinyl)propyl]amino]-4-
pyrimidinyl]amino]-5- thiazolecarboxamide 2.253 446 ##STR00464##
'N-(2-Chloro-6-methylphenyl)-2-[[2- methyl-6-[methyl[3-(methyl-
amino)propyl]amino]-4-pyrimidinyl] amino]-5-thiazole-carboxamide
2.493 447 ##STR00465## 'N-(2-Chloro-6-methylphenyl)-2-
[[2-methyl-6-[[2-(tetrahydro-2-oxo-
1H-imidazol-1-yl)ethyl]-amino]-4- pyrimidinyl]amino]-5-thiazole-
carboxamide 2.71 448 ##STR00466## 'N-(2-Chloro-6-methylphenyl)-2-
[[2-methyl-6-[(2-1H-imidazol-4- ylethyl)amino]-4-
pyrimidinyl]amino]-5- thiazolecarboxamide 2.303 449 ##STR00467##
'N-(2-Chloro-6-methylphenyl)-2- [[2-methyl-6-(4-morpholinyl)-4-
pyrimidinyl]amino]-5- thiazolecarboxamide 3.337 450 ##STR00468##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[[(2R)-1-ethyl-2-
pyrrolidinyl]methyl]amino]-2- methyl-4-pyrimidinyl]amino]-5-
thiazolecarboxamide 2.703 451 ##STR00469##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[[(2S)-1-ethyl-2-
pyrrolidinyl]methyl]amino]-2- methyl-4-pyrimidinyl]amino]-5-
thiazolecarboxamide 2.717 452 ##STR00470##
'2-[[6-[(2S)-2-(Aminocarbonyl)-1- pyrrolidinyl]-2-methyl-4-
pyrimidinyl]amino]-N-(2-chloro-6- methylphenyl)-5-
thiazolecarboxamide 2.81 453 ##STR00471##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[(2-hydroxyethyl)amino]-2-
methyl-4-pyrimidinyl]amino]-5- thiazolecarboxamide 2.677 454
##STR00472## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[4-(hydroxymethyl)-1- pipendinyl]-2-methyl-4-
pyrimidinyl]amino]-5- thiazolecarboxamide 3.05 455 ##STR00473##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[4-(2-hydroxyethyl)-1-
piperazinyl]-2-methyl-4- pyrimidinyl]amino]-5- thiazolecarboxamide
2.717 456 ##STR00474## '1-[6-[[5-[[(2-Chloro-6-
methylphenyl)amino]carbonyl]-2- thiazolyl]amino]-2-methyl-4-
pyrimidinyl]-4- pipendinecarboxamide 2.863 457 ##STR00475##
'N-(2-Chloro-6-methylphenyl)-2- [[2-methyl-6-[(3S)-3-methyl-1-
piperazinyl]-4-pyrimidinyl]amino]- 5-thiazolecarboxamide 2.823 458
##STR00476## '2-[[6-[3-(Acetylamino)-1- pyrrolidinyl]-2-methyl-4-
pyrimidinyl]amino]-N-(2-chloro-6- methylphenyl)-5-
thiazolecarboxamide 2.78 459 ##STR00477##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[2-(1-methyl-2-
pyrrolidinyl)ethyl]amino]-2-methyl- 4-pyrimidinyl]amino]-5-
thiazolecarboxamide 2.383 460 ##STR00478##
'N-(2-Chloro-6-methylphenyl)-2- [[2-methyl-6-[[(5-methyl-2-
pyrazinyl)methyl]amino]-4- pyrimidinyl]amino]-5-
thiazolecarboxamide 3.027 461 ##STR00479##
'N-(2-Chloro-6-methylphenyl)-2- [[2-methyl-6-[[2-(1H-1,2,3-triazol-
1-yl)ethyl]amino]-4- pyrimidinyl]amino]-5- thiazolecarboxamide
2.78
Example 462
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[6-[[2-(4-morpholinyl)ethyl]amino]-4-pyri-
midinyl]amino]-5-thiazolecarboxamide
##STR00480##
[0410] Compound 462A was prepared by an analogous method as that of
444A, except using 4,6-dichloropyrimidine.
B. Title Compound
[0411] The title compound was prepared by an analogous method as
that of 444B, except using compound 462A in place of compound 444A.
HPLC Ret. Time 2.553 min.
Examples 463 to 472
General Procedure
[0412] Compounds 463 to 472 were prepared by an analogous method as
that of 444B by substituting the appropriate amine. "HPLC Ret Time
`B`" is the HPLC retention time under the following conditions: YMC
S5 ODS 4.6.times.33 mm Turbo Column, 2 min gradient starting from
100% solvent A (10% MeOH, 90% H.sub.2O, 0.1% TFA) to 100% solvent B
(90% MeOH, 10% H.sub.2O, 0.1% TFA) with 1 min at 100% solvent B,
flow rate 4 mL/min, .lamda.=220 nM.
TABLE-US-00014 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 463 ##STR00481## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[[2-(dimethyl-amino)- ethyl]amino]-4-pyrimidinyl]-
amino]-5-thiazolecarboxamide 2.527 464 ##STR00482##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[2-(tetrahydro-2-oxo-1H-
imidazol-1-yl)ethyl]amino]-4- pyrimidinyl]amino]-5-
thiazolecarboxamide 2.797 465 ##STR00483##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[methyl[2-(methylamino)-
ethyl]amino]-4-pyrimidinyl]- amino]-5-thiazolecarboxamide 1.137 B
466 ##STR00484## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[[2-(1-methyl-2- pyrrolidinyl)ethyl]amino]-4-
pyrimidinyl]amino]-5- thiazolecarboxamide 1.113 B 467 ##STR00485##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[2-(1-pyrrolidinyl)-
ethyl]amino]-4-pyrimidinyl]- amino]-5-thiazolecarboxamide 1.150 B
468 ##STR00486## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[[(1-ethyl-2-pyrrolidinyl)- methyl]amino]-4-pyrimidinyl]
amino]-5-thiazole- carboxamide 1.237 B 469 ##STR00487##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[(4-piperidinyl-
methyl)amino]-4-pyrimidinyl] amino]-5-thiazole- carboxamide 1.160 B
470 ##STR00488## '2-[[6-[[2-(Acetylamino)-
ethyl]amino]-4-pyrimidinyl] amino]-N-(2-chloro-6-
methylphenyl)-5-thiazole- carboxamide 2.457 B 471 ##STR00489##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[2-(1H-1,2,3-triazol-1-
yl)ethyl]amino]-4- pyrimidinyl]amino]-5- thiazolecarboxamide 2.897
472 ##STR00490## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-(4-morpholinyl)-4- pyrimidinyl]amino]-5- thiazolecarboxamide
3.437
Example 473
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[6-[[2-(4-morpholinyl)ethyl]amino]-2-pyri-
dinyl]amino]-5-thiazolecarboxamide
##STR00491##
[0414] To a suspension of NaH (2.83 g, 118 mmol) in DMF (350 mL)
cooled to 0.degree. C. was added compound 319A (31 g, 93.5 mmol).
The mixture was stirred for 45 min at 0.degree. C. then Bu.sub.4NI
(6.9 g, 18.7 mmol) was added followed by addition of 4-methoxy
benzylchloride (18 g, 115 mmol). The reaction was allowed to warm
to RT. After stirring overnight at RT the reaction was quenched
slowly with acetic acid then the solvent removed in vacuo. To the
residue was added water and neutralized with saturated aqueous
NaHCO.sub.3. The mixture was extracted 3 times with EtOAc and the
combined organic layers washed with water then washed with
saturated NaCl solution. The EtOAc layer was concentrated in vacuo
and the residue purified by column chromatography to give 473A (35
g).
##STR00492##
[0415] To compound 473A (0.5 g, 1.1 mmol) dissolved in THF (50 mL)
was slowly added NaH (0.13 g, 5.5 mmol) followed by
2-bromo-6-aminopyridine (0.76 g, 4.4 mmol). The reaction was heated
to reflux for 2 h then cooled to RT and quenched with acetic acid.
The solvent was removed in vacuo then water and hexane was added
and stirred at RT. The solid precipitate was collected by
filtration and washed with water and Et.sub.2O to give 473B (0.48
g)
##STR00493##
[0416] To compound 473B (0.48 g) dissolved in TFA (5 mL) was added
anisole (2 mL) followed by triflic acid (1 mL). The reaction was
stirred at RT for 3 h then was slowly added to a rapidly stirred
mixture of ice, saturated NaHCO.sub.3, Et.sub.2O and
CH.sub.2Cl.sub.2. The mixture was stirred cold for 1 h then the
solid precipitate was collected by filtration and washed with water
followed by Et.sub.2O/CH.sub.2Cl.sub.2 mixture to give 473C (0.344
g). HPLC Ret. Time 3.85 min.
D. Title Compound
[0417] The title compound was prepared by an analogous method as
that of 444B, except using compound 473C in place of compound 444A.
HPLC Ret. Time 2.80 min.
Examples 474 to 480
General Procedure
[0418] Compounds 474 to 480 were prepared by an analogous method as
that of 473D by substituting the appropriate amine.
TABLE-US-00015 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 474 ##STR00494## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[[3-(4-morpholinyl)- propyl]amino]-2-pyridinyl]-
amino]-5-thiazolecarboxamide 2.867 475 ##STR00495##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[methyl[3-(methyl-
amino)propyl]amino]-2- pyridinyl]amino]-5-thiazole- carboxamide
3.067 476 ##STR00496## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[(3S)-3-methyl-1-piperazinyl]- 2-pyridinyl]-amino]-5-
thiazolecarboxamide 2.827 477 ##STR00497##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[(3-1H-imidazol-1-
ylpropyl)amino]-2-pyridinyl]- amino]-5-thiazolecarboxamide 2.83 478
##STR00498## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[(2-hydroxyethyl)amino]-2- pyridinyl]amino]-5-
thiazolecarboxamide 3.077 479 ##STR00499##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[(2-1H-imidazol-1-
ylethyl)amino]-2-pyridinyl]- amino]-5-thiazolecarboxamide 2.903 480
##STR00500## 'N-(2-Chloro-6-methylphenyl)-2- [[6-(4-morpholinyl)-2-
pyridinyl]amino]-5- thiazolecarboxamide 3.727
Example 481
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[6-[[2-(4-morpholinyl)ethyl]amino]-2-pyra-
zinyl]amino]-5-thiazolecarboxamide
##STR00501##
[0420] Compound 481A was prepared by an analogous method as that of
473B, except using compound 2-chloro-6-aminopyrazine in place of
compound 2-bromo-6-aminopyridine.
B. (Alternate Synthesis for Compound 406)
##STR00502##
[0422] Compound 406 was prepared by an analogous method as that of
473C, except using compound 481A in place of compound 473B.
C. Title Compound
[0423] The title compound was prepared by an analogous method as
that of 444B, except using compound 406 in place of compound 444A.
HPLC Ret. Time 2.69 min.
Examples 482 to 486
General Procedure
[0424] Compounds 482 to 486 were prepared by an analogous method as
that of 481C by substituting the appropriate amine.
TABLE-US-00016 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 482 ##STR00503## 'N-(2-Chloro-6-methylphenyl)-
2-[[6-[[3-(4-morpholinyl)- propyl]amino]-2-pyrazinyl]-
amino]-5-thiazolecarboxamide 2.783 483 ##STR00504##
'N-(2-Chloro-6-methylphenyl)- 2-[[6-(4-morpholinyl)-2-
pyrazinyl]amino]-5-thiazole- carboxamide 3.57 484 ##STR00505##
'N-(2-Chloro-6-methylphenyl)- 2-[[6-[(3S)-3-methyl-1-
piperazinyl]-2-pyrazinyl]- amino]-5-thiazolecarboxamide 2.743 485
##STR00506## 'N-(2-Chloro-6-methylphenyl)-
2-[[6-(3-hydroxy-1-pyrrolidinyl)- 2-pyrazinyl]-amino]-5-
thiazolecarboxamide 3.327 486 ##STR00507##
'N-(2-Chloro-6-methylphenyl)- 2-[[6-(1H-imidazol-1-yl)-2-
pyrazinyl]amino]-5- thiazolecarboxamide 2.68
Example 487
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[6-(3-hydroxy-1-pyrrolidinyl)-3-pyridazin-
yl]amino]-5-thiazolecarboxamide
##STR00508##
[0426] Compound 487A was prepared by an analogous method as that of
473B, except using compound 3-chloro-5-aminopyridazine in place of
compound 2-bromo-6-aminopyridine.
##STR00509##
[0427] Compound 487B was prepared by an analogous method as that of
473C, except using compound 487A in place of compound 473B.
C. Title Compound
[0428] The title compound was prepared by an analogous method as
that of 444B, except using compound 487B in place of compound 444A,
and 3-hydroxypyrrolidine in place of N-(2-aminoethyl)-morpholine.
HPLC Ret. Time 2.493 min.
Example 488
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[6-(1H-imidazol-1-yl)-3-pyridazinyl]amino-
]-5-thiazolecarboxamide
##STR00510##
[0430] Compound 488 was prepared by an analogous method as that of
487C, except using imidazole in place of 3-hydroxypyrrolidine. HPLC
Ret. Time 2.61 min.
Example 489
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[3-(methylamino)-2-pyrazinyl]amino]-5-thi-
azolecarboxamide
##STR00511##
[0432] Compound 489A was prepared by an analogous method as that of
473B, except using compound 2-chloro-3-aminopyrazine in place of
compound 2-bromo-6-aminopyridine.
##STR00512##
[0433] Compound 489B was prepared by an analogous method as that of
473C, except using compound 489A in place of compound 473B.
C. Title Compound
[0434] The title compound was prepared by an analogous method as
that of 444B, except using compound 489B in place of compound 444A,
and using methylamine in place of N-(2-aminoethyl)-morpholine. HPLC
Ret. Time 2.81 min.
Examples 490 to 494
General Procedure
[0435] Compounds 490 to 494 were prepared by an analogous method as
that of 489C by substituting the appropriate amine.
TABLE-US-00017 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 490 ##STR00513## 'N-(2-Chloro-6-methylphenyl)-2-
[[3-(3-hydroxy-1-pyrrolidinyl)-2- pyrazinyl]amino]-5-
thiazolecarboxamide 2.82 491 ##STR00514##
'N-(2-Chloro-6-methylphenyl)-2- [[3-(cyclopropylamino)-2-
pyrazinyl]amino]-5- thiazolecarboxamide 2.94 492 ##STR00515##
'N-(2-Chloro-6-methylphenyl)-2- [[3-(4-morpholinyl)-2-
pyrazinyl]amino]-5- thiazolecarboxamide 3.643 493 ##STR00516##
'N-(2-Chloro-6-methylphenyl)-2- [[3-[[2-(4-
morpholinyl)ethyl]amino]-2- pyrazinyl]amino]-5- thiazolecarboxamide
2.72 494 ##STR00517## '2-[[3-[[2- (Acetylamino)ethyl]amino]-2-
pyrazinyl]amino]-N-(2-chloro-6- methylphenyl)-5-
thiazolecarboxamide 2.933
Example 495
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-(cyclohexylamino)-5-thiazolecarboxamide
##STR00518##
[0437] Compound 495 was prepared by an analogous method as that of
444B, except using compound 319A in place of compound 444A, and
using cyclohexylamine in place of N-(2-aminoethyl)-morpholine. HPLC
Ret. Time 3.547 min.
Examples 496 to 500
General Procedure
[0438] Compounds 496 to 500 were prepared by an analogous method as
that of 495 by substituting the appropriate amine.
TABLE-US-00018 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 496 ##STR00519## 'N-(2-Chloro-6-methylphenyl)-2-
(methylamino)-5- thiazolecarboxamide 2.357 497 ##STR00520##
'N-(2-Chloro-6-methylphenyl)-2- (cyclopropylamino)-5-
thiazolecarboxamide 2.887 498 ##STR00521##
'N-(2-Chloro-6-methylphenyl)-2- [(phenylmethyl)amino]-5-
thiazolecarboxamide 3.500 499 ##STR00522##
'2-[[2-(Acetylamino)ethyl]amino]- N-(2-chloro-6-methylphenyl)-5-
thiazolecarboxamide 2.483 500 ##STR00523##
'N-(2-Chloro-6-methylphenyl)-2- [[(1R)-1-(hydroxymethyl)-3-
methylbutyl]amino]-5- thiazolecarboxamide 3.407
Example 501
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[6-(methoxymethyl)-4-pyrimidinyl]amino]-5-
-thiazolecarboxamide
##STR00524##
[0440] To the mixture of methyl 4-methoxyacetoacetate (14.6 g, 0.1
moL) and formami-dine hydrogen chloride salt (16.1 g, 0.2 moL) in
70 mL of dry MeOH was added a 25% solution of sodium methoxide (70
mL, 0.3 moL) in MeOH portionwise. A white precipitate was formed
immediately. The reaction mixture was stirred at room temperature
for 1.0 hr. Acetic acid (28.6 mL, 0.5 moL) was added and the
reaction mixture was concentrated in vacuo. Water was added to the
residue and the mixture was supersaturated with NaCl and extracted
with EtOAc (.times.5). Combined extracts were dried over anhydrous
Na.sub.2SO.sub.4 and concentrated in vacuo to give 8.13 g of
compound 501A as a yellow solid.
##STR00525##
[0441] The mixture of compound 501A (5.3 g, 37.8 mmoL) and
POCl.sub.3 (40 mL) was heated to reflux for 2.0 hrs. Concentration
in vacuo and the residue was poured into a mixture of
ice-CH.sub.2Cl.sub.2. The pH was adjusted to 6.5 to 7 using
concentrated NH.sub.4OH. The mixture was extracted with
CH.sub.2Cl.sub.2 (.times.3) and combined extracts were dried over
Na.sub.2SO.sub.4. Concentration in vacuo followed by flash
chromatography (CH.sub.2Cl.sub.2-EtOAc: 9:1) on silica gel gave
5.33 g of compound 501B as a pale yellow oil.
##STR00526##
[0442] The mixture of compound 501B (3.2 g, 20 mmoL) and NH.sub.4OH
(50 mL) was heated to 85.C in a pressure tube for 3.0 hrs. After
cooled to room temperature, the reaction mixture was concentrated
in vacuo and the residue was triturated with ether to give 2.81 g
of compound 501C as a pale yellow solid.
##STR00527##
[0443] Compound 501D was prepared from compound 501C by a method
analogous to that used for the preparation of compound 473B.
E Title Compound
[0444] The title compound was prepared from compound 501D by a
method analogous to that used for the preparation of compound 473C.
HPLC Retention time=3.25 min.
Example 502
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[6-(hydroxymethyl)-4-pyrimidinyl]amino]-5-
-thiazolecarboxamide
##STR00528##
[0446] To a solution of compound 501 (56 mg, 0.144 mmoL) in dry
CH.sub.2Cl.sub.2 (3.0 mL) cooled at 0.C was added neat BBr.sub.3
(0.054 mL, 0.574 mmoL). The mixture was stirred for 1.0 hr at
ambient temperature. MeOH was added slowly with care at 0.C and the
resulting mixture was concentrated in vacuo. Water was added to the
residue and pH was adjusted to 7 with Sat'd NaHCO.sub.3. The white
precipitate was collected by filtration, rinsed with water/ether
and dried under high vacuum to give 52 mg of Compound 502 as an
off-white solid. HPLC Retention time=2.84 min.
Example 503
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[6-(4-morpholinylmethyl)-4-pyrimidinyl]am-
ino]-5-thiazolecarboxamide
##STR00529##
[0448] To a suspension of compound 502 (44.2 mg, 0.118 mmoL) in 0.5
mL of dry CH.sub.2Cl.sub.2 was added thionyl chloride (0.086 mL,
1.18 mmoL). The reaction mixture was stirred for 5.0 hrs.
Concentration in vacuo and the residue was azeotropic evaporated
with CH.sub.2Cl.sub.2 to give 56 mg of 503 as an yellow solid.
B Title Compound
[0449] The mixture of compound 503A (20 mg), morpholine (0.014 mL)
and diisopropylethyl amine (0.09 mL) in 0.5 mL of dry dioxane was
heated to 85.C for 4.0 hrs. Concentration in vacuo followed by
flash chromatography (CH.sub.2Cl.sub.2-MeOH--NH.sub.4OH: 95:5:0.5)
on silica gel gave 15 mg of title compound as an off-white
solid.
[0450] HPLC Retention time=2.52 min.
Examples 504 to 513
General Procedure
[0451] Compounds 504 to 513 were prepared from 503A by a route
analogous to that used for the preparation of 503. The compounds of
these examples have the structure:
TABLE-US-00019 HPLC EX. Ret Time NO. Compound Structure Compound
Name (min) 504 ##STR00530## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[[[2- (dimethylamino)ethyl]amino]
methyl]-4-pyrimidinyl]amino]-5- thiazolecarboxamide 2.083 505
##STR00531## 'N-(2-Chloro-6-methylphenyl)-2- [[6-[[[2-(4-
morpholinypethyl]amino]methyl]- 4-pyrimidinyl]amino]-5-
thiazolecarboxamide 2.593 506 ##STR00532##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[[3-(4-
morpholinyl)propyl]amino]methyl]- 4-pyrimidinyl]amino]-5-
thiazolecarboxamide 2.163 507 ##STR00533##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[[3-(2-oxo-1-
pyrrolidinyl)propyl]amino]methyl]- 4-pyrimidinyl]amino]-5-
thiazolecarboxamide 2.693 508 ##STR00534##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[(2-1H-imidazol-4-
ylethyl)amino]methyl]-4- pyrimidinyl]amino]-5- thiazolecarboxamide
2.143 509 ##STR00535## 'N-(2-Chloro-6-methylphenyl)-2-
[[6-[[(3-1H-imidazol-1- ylpropyl)amino]methyl]-4-
pyrimidinyl]amino]-5- thiazolecarboxamide 1.103 B 510 ##STR00536##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[[2-(2-
pyridinyl)ethyl]amino]methyl]-4- pyrimidinyl]amino]-5-
thiazolecarboxamide 1.113 B 511 ##STR00537##
'N-(2-Chloro-6-methylphenyl)-2- [[6-[[[2-(3-
pyridinyl)ethyl]amino]methyl]-4- pyrimidinyl]amino]-5-
thiazolecarboxamide 1.117 B 512 ##STR00538##
'1-[[6-[[5-[[(2-Chloro-6- methylphenyl)amino]carbonyl]-2-
thiazolyl]amino]-4- pyrimidinyl]methyl]-4- piperidinecarboxamide
1.207 B 513 ##STR00539## '2-[[6-[[[2-
(Acetylamino)ethyl]amino]methyl]- 4-pyrimidinyl]amino]-N-(2-
chloro-6-methylphenyl)-5- thiazolecarboxamide 1.193 B
Example 514
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-(2-naphthalenylamino)-5-thiazolecarboxamid-
e
##STR00540##
[0453] Compound 514A was prepared from 473A by an analogous method
as that of 473B, except using 2-aminonapthaline in place of
2-bromo-6-aminopyridine.
B. Title Compound
[0454] The title compound was prepared by an analogous method as
that of 473C, except using compound 514A in place of compound 473B.
HPLC Ret. Time 4.11 min.
Example 515
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-(2-quinolinylamino)-5-thiazolecarboxamide
##STR00541##
[0456] Compound 515A was prepared from 473A by an analogous method
as that of 473B, except using 2-aminoquinoline in place of
2-bromo-6-aminopyridine.
B. Title Compound
[0457] The title compound was prepared by an analogous method as
that of 473C, except using compound 515A in place of compound 473B.
HPLC Ret. Time 3.94 min.
Example 516
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-(3-isoquinolinylamino)-5-thiazolecarboxami-
de
##STR00542##
[0459] Compound 516A was prepared from 473A by an analogous method
as that of 473B, except using 3-aminoisoquinoline in place of
2-bromo-6-aminopyridine.
B. Title Compound
[0460] The title compound was prepared by an analogous method as
that of 473C, except using compound 516A in place of compound 473B.
HPLC Ret. Time 3.94 min.
Example 517
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-(2-quinoxalinylamino)-5-thiazolecarboxamid-
e
##STR00543##
[0462] Compound 517A was prepared from 473A by an analogous method
as that of 473B, except using 2-aminoquinoxaline in place of
2-bromo-6-aminopyridine.
B. Title Compound
[0463] The title compound was prepared by an analogous method as
that of 473C, except using compound 517A in place of compound 473B.
HPLC Ret. Time 3.927 min.
Example 518
Preparation of
'N-(2-Chloro-6-methylphenyl)-4-methyl-2-[[2-methyl-6-(4-morpholinyl)-4-py-
rimidinyl]amino]-5-thiazolecarboxamide
##STR00544##
[0465] Compound 518A was prepared from 144 by an analogous method
as that of 319A.
##STR00545##
[0466] Compound 518B was prepared by an analogous method as that of
473A, except using 518A in place of 319A.
##STR00546##
[0467] Compound 518C was prepared by an analogous method as that of
473B, except using 518B in place of 473A, and
4-amino-6-chloro-2-methylpyrimidine in place of
2-amino-6-bromopyridine.
##STR00547##
[0468] Compound 518D was prepared by an analogous method as that of
473C, except using 518C in place of 473B.
E. Title Compound
[0469] The title compound was prepared by an analogous method as
that of 444B, except using compound 518D in place of compound 444A,
and morpholine in place of N-(2-aminoethyl)-morpholine. HPLC Ret.
Time 3.397 min.
Example 519
Preparation of
'N-(2-Chloro-6-methylphenyl)-4-methyl-2-[[2-methyl-6-[[2-(4-morpholinyl)e-
thyl]amino]-4-pyrimidinyl]amino]-5-thiazolecarboxamide
##STR00548##
[0471] Compound 519 was prepared by an analogous method as that of
518E, except using N-(2-aminoethyl)-morpholine in place of
morpholine. HPLC Ret. Time 2.493 min.
Example 520
Alternative Preparation of Compound 321
##STR00549##
[0473] Compound 520A was prepared from 2-aminothiazole according to
the procedure described in UK Patent Application GB 2323595A.
##STR00550##
[0474] To a solution of compound 520A (480 mg, 4.0 mmoL) in dry THF
(10 mL) cooled at -78.C was added a 2.5M solution of n-BuLi (1.68
mL, 4.2 mmoL) in hexane dropwise via a syringe while kept the
internal temperature below -75.C. Upon completion of addition, a
beige suspension was obtained. The reaction mixture was stirred for
15 min at -78.C. A solution of 2-chloro-6-methyl phenyl isocyanate
(0.6 mL, 4.4 mmoL) in 5 mL of dry THF was added and the reaction
mixture was stirred for an additional 2.0 hrs at -78.C. Saturated
aq. NH.sub.4Cl solution (10 mL) was added, the mixture was
partitioned between EtOAc-water and extracted with EtOAc
(.times.2). The combined extracts were dried over Na.sub.2SO.sub.4
and concentration in vacuo to give, after recrystalization from
EtOAc-hexane, 0.99 g of title compound as a pale yellow crystalline
material.
##STR00551##
[0475] Compound 520C was prepared by a method analogous to that
used for the preparation of compound 473A, using 520B in place of
319A.
##STR00552##
[0476] Compound 520D was prepared from compound 520C by a method
analogous to that used for the preparation of compound 473B.
E. Title Compound
[0477] Compound 321 was prepared by a method analogous to that used
for the preparation of compound 473C.
Example 521
Preparation of
'2-[(2,6-Dimethyl-4-pyrimidinyl)amino]-N-phenyl-5-thiazolecarboxamide
##STR00553##
[0479] Compound 521A was prepared by an analogous method as that of
520B, except using phenylisocyanate in place of
2-chloro-6-methylphenylisocyanate.
##STR00554##
[0480] Compound 521B was prepared by a method analogous to that
used for the preparation of compound 473A, using 521A in place of
319A.
##STR00555##
[0481] Compound 521C was prepared from compound 521B by a method
analogous to that used for the preparation of compound 473B.
D Title Compound
[0482] The title compound was prepared by a method analogous to
that used for the preparation of compound 473C. HPLC Ret. Time 1.3
min method B
Example 522
Preparation of
'2-[(2,6-Dimethyl-4-pyrimidinyl)methylamino]-N-(2-methylphenyl)-5-thiazol-
ecarboxamide
##STR00556##
[0484] Compound 522A was prepared by an analogous method as that of
520B, except using 2-methylphenylisocyanate in place of
2-chloro-6-methylphenylisocyanate.
##STR00557##
[0485] Compound 522B was prepared by a method analogous to that
used for the preparation of compound 473A, using 522A in place of
319A.
##STR00558##
[0486] Compound 522C was prepared from compound 522B by a method
analogous to that used for the preparation of compound 473B.
##STR00559##
[0487] Sodium hydride (60% in oil; 40 mg; 1 mmol) was added to a
solution of compound 522C (280 mg; 0.61 mmol) in 2 ml of DMF at
room temp. After stirring 30 minutes, iodomethane (0.2 ml; 3 mmol)
was added and the reaction was stirred 4 hr. After the reaction
mixture was partitioned between ethyl acetate (50 ml) and water (50
ml), the organic layer was washed with water (2.times.50 ml) and
brine (50 ml). Drying (MgSO.sub.4) and concentration afforded an
oil that was chromatographed on a 2.5.times.15 cm silica gel column
using 50-75% ethyl acetate/hexane. The pure fractions were
concentrated and the residue was crystallized from ethyl
acetate/hexane to afford 100 mg of 522D as a light yellow
solid.
E Title Compound
[0488] The title compound was prepared by a method analogous to
that used for the preparation of compound 473C. HPLC Ret. Time 1.21
min method B
Example 523
Preparation of
'2-[(2,6-Dimethyl-4-pyrimidinyl)amino]-N-(2-methylphenyl)-5-thiazolecarbo-
xamide
##STR00560##
[0490] Compound 523 was prepared by a method analogous to that used
for the preparation of compound 473C, except using compound 522C in
place of 473B. HPLC Ret. Time 1.24 min method B
Example 524
Preparation of
'N-(3,5-Dimethoxyphenyl)-2-[(2,6-dimethyl-4-pyrimidinyl)amino]-5-thiazole-
carboxamide
##STR00561##
[0492] Compound 524A was prepared by an analogous method as that of
520B, except using 3,5-dimethoxyphenylisocyanate in place of
2-chloro-6-methylphenylisocyanate.
##STR00562##
[0493] Compound 524B was prepared by a method analogous to that
used for the preparation of compound 473A, using 524A in place of
319A.
##STR00563##
[0494] Compound 524C was prepared from compound 524B by a method
analogous to that used for the preparation of compound 473B.
D Title Compound
[0495] The title compound was prepared by a method analogous to
that used for the preparation of compound 473C, except using
compound 524C in place of compound 473B HPLC Ret. Time 1.28 min
method B
Example 525
Preparation of
'N-[2,6-Bis(1-methylethyl)phenyl]-2-[(2,6-dimethyl-4-pyrimidinyl)amino]-5-
-thiazolecarboxamide
##STR00564##
[0497] Compound 525A was prepared by an analogous method as that of
520B, except using 2,2-diisopropylphenylisocyanate in place of
2-chloro-6-methylphenylisocyanate.
##STR00565##
[0498] Compound 525B was prepared by a method analogous to that
used for the preparation of compound 473A, using 525A in place of
319A.
##STR00566##
[0499] Compound 525C was prepared from compound 525B by a method
analogous to that used for the preparation of compound 473B.
D Title Compound
[0500] The title compound was prepared by a method analogous to
that used for the preparation of compound 473C, except using
compound 525C in place of compound 473B. HPLC Ret. Time 1.6 min
method B
Example 526
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[(2,6-dimethyl-4-pyrimidinyl)methylamino]--
5-thiazolecarboxamide
##STR00567##
[0502] A mixture of compound 321 (110 mg; 0.29 mmol), potassium
carbonate (138 mg; 1 mmol) and iodomethane (0.06 ml; 1 mmol) in DMF
was stirred 2 hr at room temperature. After the reaction mixture
was partitioned between ethyl acetate (25 ml) and water (25 ml),
the organic layer was washed with water (2.times.25 ml) and brine
(25 ml). Drying (MgSO.sub.4) and concentration afforded an oil that
was chromatographed on a 2.5.times.15 cm silica gel column using
1-4% MeOH/CH.sub.2Cl.sub.2 and the fractions containing compound
526 were collected to give 20 mg of product. HPLC Ret. Time 1.3 min
method B.
Example 527
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[(2,6-dimethyl-4-pyrimidinyl)amino]-N-meth-
yl-5-thiazolecarboxamide
##STR00568##
[0504] Compound 527 was prepared by a method analogous to that used
for the preparation of compound 526, except the fractions
containing compound 527 were collected to give 60 mg of product.
HPLC Ret. Time 1.23 min method B
Example 528
Preparation of 2-Bromo-N--, N-(2-chloro-6-methylphenyl)-(4-m
ethoxybenzyl)-5-thiazolecarboxamide
##STR00569##
[0506] To a cooled (0.degree. C.) THF solution of 2-chloro-6-methyl
aniline (2.86 mL, 23.3 mmol, 1.10 equiv) was added dropwise a 1.0 M
solution of lithium bis(trimethylsilyl)amide (42.2 mL, 42.2 mmol,
2.00 equiv) via syringe. The homogeneous solution was allowed to
stir for 5 minutes, and then a THF solution of ethyl
2-bromo-5-thiazolecarboxylate (5.00 g, 21.1 mmol, 1.00 equiv,
prepared in a manner analogous to compound 319A) was added via
cannula. The solution was allowed to stir for 15 minutes until TLC
analysis showed no remaining starting material. To the reaction was
then added 4-methoxybenzyl chloride (7.15 mL, 52.7 mmol, 2.5
equiv), followed by a catalytic amount of tetrabutylammonium iodide
(1.56 g, 4.22 mmol, 0.20 equiv). The homogeneous mixture was
allowed to stir overnight at ambient temperature and then
concentrated in vacuo. The residue was partitioned between ethyl
acetate and water, and the organic extracts were washed with brine
and dried over Na.sub.2SO.sub.4. After filtration and removal of
solvent, the product was purified by flash chromatography (10-20%
ethyl acetate in hexanes) to afford the title compound as a tan
solid (47%).
Example 529
Preparation of N--,
N-(2-Chloro-6-methylphenyl)-(4-methoxybenzyl)-2-[(6-bromo-2-pyridinyl)ami-
no]-5-thiazolecarboxamide
##STR00570##
[0508] Compound 529 was prepared in an analogous manner to 319B,
except using 528 and 6-bromo-2-aminopyridine as the reactants.
Example 530
Preparation of
N-(2-Chloro-6-methylphenyl)-2-[(6-bromo-2-pyridinyl)amino]-5-thiazolecarb-
oxamide
##STR00571##
[0510] Compound 529 (0.500 g, 0.919 mmol, 1.00 equiv) was dissolved
in 5 mL trifluoroacetic acid and charged at ambient temperature
with 2 mL anisole followed by 1 mL trifluoromethanesulfonic acid.
The dark red homogeneous solution was allowed to stir overnight,
and then quenched by carefully pouring the solution into an
ice/sodium bicarbonate mixture. A white solid was filtered off and
washed sequentially with water, 1:1 hexane/ether, and ether to
afford the title compound (41%).
Examples 531-538
General Procedure
[0511] Compounds 531 to 538 were prepared to the general procedure
described below. A 1-dram vial was charged with 530 and excess
amine and heated to 90.degree. C. overnight. The residue was then
purified by reverse phase HPLC to afford the pure compound. For the
following examples 531 to 555 "HPLC Ret Time" is the HPLC retention
time under the following conditions: YMC ODS-A C18 S7 3.0.times.50
mm, 2 min gradient starting from 100% solvent A (10% MeOH, 90%
H.sub.2O, 0.1% TFA) to 100% solvent B (90% MeOH, 10% H.sub.2O, 0.1%
TFA), flow rate 5 mL/min, .lamda.=220 nM.
TABLE-US-00020 EX. HPLC Ret NO. Compound Structure Compound Name
time (min) 531 ##STR00572## 'N-(2-Chloro-6- methylphenyl)-2-[[6-[4-
(2-furanylcarbonyl)-1- piperazinyl]-2- pyridinyl]amino]-5-
thiazolecarboxamide 1.56 532 ##STR00573## '2-[[6-[[3-(1H-
Benzimidazol-1- yl)propyl]amino]-2- pyridinyl]amino]-N-(2-
chloro-6-methylphenyl)- 5-thiazolecarboxamide 1.41 533 ##STR00574##
'N-(2-Chloro-6- methylphenyl)-2-[[6-[[4- (1H-imidazol-1-
yl)butyl]amino]-2- pyridinyl]amino]-5- thiazolecarboxamide 1.24 534
##STR00575## 'N-(2-Chloro-6- methylphenyl)-2-[[6-[[5-
(1H-imidazol-1- yl)pentyl]amino]-2- pyridinyl]amino]-5-
thiazolecarboxamide 1.25 535 ##STR00576## 'N-(2-Chloro-6-
methylphenyl)-2-[[6-[[3- (4-methyl-1- piperazinyl)propyl]amino]-
2-pyridinyl]amino]-5- thiazolecarboxamide 1.14 536 ##STR00577##
'N-(2-Chloro-6- methylphenyl)-2-[[6-[[4- (1H-imidazol-1-
yl)phenyl]amino]-2- pyridinyl]amino]-5- thiazolecarboxamide 1.29
537 ##STR00578## 'N-(2-Chloro-6- methylphenyl)-2-[[6-[[6-
(1H-imidazol-1- yl)hexyl]amino]-2- pyridinyl]amino]-5-
thiazolecarboxamide 1.27 538 ##STR00579## 'N-(2-Chloro-6-
methylphenyl)-2-[[6-[(3- 1H-imidazol-1- ylpropyl)amino]-2-
pyridinyl]amino]-5- thiazolecarboxamide 1.24
Example 539
Preparation of
Ethyl-2-[(6-bromo-2-pyridinyl)amino]-5-thiazolecarboxylate
##STR00580##
[0513] Compound 539 was prepared in an analogous manner to 319B,
except using ethyl 2-bromo-5-thiazolecarboxylate and
6-bromo-2-aminopyridine as the reactants.
Examples 540-550
General Procedure
[0514] Compounds 540 to 550 were prepared according to the general
procedure described below. Compound 539 was condensed with the
appropriate aniline according to the procedure for example 528 to
afford the afford the corresponding N-(4-methoxybenzyl)amide. The
intermediate bromopyridine was then reacted with
N-(3-aminopropyl)-imidazole according to the procedure for examples
531 to 538 to afford the corresponding diaminopyridine. Removal of
the 4-methoxybenzyl group according to the procedure described for
example 530 followed by purification by reverse phase preparative
HPLC afforded compounds 540 to 550.
TABLE-US-00021 EX. HPLC Ret NO. Compound Structure Compound Name
time (min) 540 ##STR00581## '2-[[6-[[3-(1H-Imidazol-
1-yl)propyl]amino]-2- pyridinyl]amino]-N-(4- methoxyphenyl)-5-
thiazolecarboxamide 1.12 541 ##STR00582## '2-[[6-[[3-(1H-Imidazol-
1-yl)propyl]amino]-2- pyridinyl]amino]-N-(4- phenoxyphenyl)-5-
thiazolecarboxamide 1.48 542 ##STR00583## 'N-(4-Chlorophenyl)-2-
[[6-[[3-(1H-imidazol-1- yl)propyl]amino]-2- pyridinyl]amino]-5-
thiazolecarboxamide 1.31 543 ##STR00584## '2-[[6-[[3-(1H-Imidazol-
1-yl)propyl]amino]-2- pyridinyl]amino]-N-[1- (phenylmethyl)-1H-
indazol-5-yl]-5- thiazolecarboxamide 1.34 544 ##STR00585##
'N-(2-Ethylphenyl)-2-[[6- [[3-(1H-imidazol-1- yl)propyl]amino]-2-
pyridinyl]amino]-5- thiazolecarboxamide 1.18 545 ##STR00586##
'N-(2,6- Dimethoxyphenyl)-2-[[6- [[3-(1H-imidazol-1-
yl)propyl]amino]-2- pyridinyl]amino]-5- thiazolecarboxamide 1.11
546 ##STR00587## 'N-(2,4- Dimethoxyphenyl)-2-[[6-
[[3-(1H-imidazol-1- yl)propyl]amino]-2- pyridinyl]amino]-5-
thiazolecarboxamide 1.06 547 ##STR00588## '2-[[6-[[3-(1H-Imidazol-
1-yl)propyl]amino]-2- pyridinyl]amino]-N- phenyl-5-
thiazolecarboxamide 1.06 548 ##STR00589## '2-[[6-[[3-(1H-Imidazol-
1-yl)propyl]amino]-2- pyridinyl]amino]-N-(2- methylphenyl)-5-
thiazolecarboxamide 1.11 549 ##STR00590## 'N-(2-Chlorophenyl)-2-
[[6-[[3-(1H-imidazol-1- yl)propyl]amino]-2- pyridinyl]amino]-5-
thiazolecarboxamide 1.16 550 ##STR00591## 'N-(2,6-Diethylphenyl)-
2-[[6-[[3-(1H-imidazol-1- yl)propyl]amino]-2- pyridinyl]amino]-5-
thiazolecarboxamide 1.29
Example 551
Preparation of
Ethyl-2-[(6-bromo-2-pyridinyl)amino]-4-methyl-5-thiazolecarboxylate
##STR00592##
[0516] Compound 551 was prepared in an analogous manner to 319B,
except using ethyl 2-bromo-4-methyl-5-thiazolecarboxylate and
6-bromo-2-aminopyridine as the reactants.
Examples 552 and 553
[0517] Compounds 552 and 553 were prepared using a similar
procedure described for the preparation of compounds 540 to 550,
except using compound 551 as the starting material.
TABLE-US-00022 EX. HPLC Ret NO. Compound Structure Compound Name
time (min) 552 ##STR00593## 'N-(2-Chloro-6-
methylphenyl)-2-[[6-[[3- (1H-imidazol-1- yl)propyl]amino]-2-
pyridinyl]amino]-4- methyl-5- thiazolecarboxamide 1.19 553
##STR00594## '2-[[6-[[3-(1H-Imidazol- 1-yl)propyl]amino]-2-
pyridinyl]amino]-4- methyl-N-[1- (phenylmethyl)-1H-
indazol-5-yl]-5- thiazolecarboxamide 1.35
Example 554
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[3-[[3-(1H-imidazol-1-yl)propyl]amino]phe-
nyl]amino]-5-thiazolecarboxamide
##STR00595##
[0519] A solution of 528 (0.127 g, 0.281 mmol, 1.00 equiv) and
3-[N--,N-(tert-butoxycarbonyl)-(3-aminopropyl)-imidazoyl]-1,3-phenylenedi-
amine (0.178 g, 0.563 mmol, 2.00 equiv) in 0.200 mL DMSO was heated
at 120.degree. C. in a sealed vial overnight. Purification by
reverse phase preparative HPLC followed by deprotection according
to the procedure for compound 530 afforded the title compound.
Example 555
Preparation of
'N-(2-Chloro-6-methylphenyl)-2-[[5-[[3-(1H-imidazol-1-yl)propyl]amino]-2--
nitrophenyl]amino]-5-thiazolecarboxamide
##STR00596##
[0521] A solution of 2,4-difluoronitrobenzene (0.400 mL, 3.65 mmol,
1.00 equiv) in acetonitrile was charged with K.sub.2CO.sub.3 (0.605
g, 4.38 mmol, 1.20 equiv) followed by
ethyl-2-amino-5-thiazolecarboxylate (0.628 g, 3.65 mmol, 1.00
equiv) as a solid. The heterogeneous mixture was sealed and heated
to 120.degree. C. overnight. The solution was filtered and then
concentrated in vacuo.
[0522] Purification by flash chromatography afforded
ethyl-2-[(3-fluoro-6-nitro-1-phenyl)amino]-5-thiazolecarboxylate as
a yellow solid (9%). This intermediate was coupled with
2-chloro-6-methyl aniline according to the procedure for compound
528 to afford
N-(2-Chloro-6-methylphenyl)-2-[3-(fluoro-6-nitro-1-phenyl)amino]-5-thiazo-
lecarboxamide (21%). The title compound was synthesized by reacting
this intermediate with excess N-(3-aminopropyl)-imidazole at
80.degree. C. followed by purification by reverse phase preparative
HPLC.
Examples 556-566
General Procedure
[0523] Compounds 556 to 566 were prepared according to the general
procedure described below. A mixture of
2-bromo-N-[2-chloro-6-methylphenyl]-5-thiazolecarboxamide 319A, an
aniline (1 eq), 1.0 N aqueous HCl (0.5 eq) in n-BuOH was heated
overnight at 120.degree. C. in a sealed vial. This was diluted with
methanol and the product was isolated by preparative HPLC (YMC S5
ODS 30.times.100 mm column eluted with a gradient comprised of two
solvent mixtures (mixture A: 10% MeOH, 90% water, and 0.1% TFA;
mixture B: 90% MeOH, 10% water, and 0.1% TFA). For anilines
substituted with a carboxylic acid group, the reaction mixture was
treated with 1 N aqueous NaOH (5 eq) overnight before final
purification of the product by HPLC. "HPLC Ret Time" is the HPLC
retention time under the following conditions: YMC S5 OSD
4.6.times.30 mm (for 556 to 560) or YMC S7 ODS 3.times.50 mm column
(for 561 to 566), 2 min gradient starting from 100% solvent A (10%
MeOH, 90% H.sub.2O, 0.1% TFA) to 100% solvent B (90% MeOH, 10%
H.sub.2O, 0.1% TFA), flow rate 5 mL/min, .lamda.=220 nM.
TABLE-US-00023 HPLC EX. Ret time NO. Compound Structure Compound
Name (min) 556 ##STR00597## N-(2-Chloro-6- methylphenyl)-2-
[(3,4,5-trimethoxy- phenyl)amino]-5- thiazolecarboxamide 1.63 557
##STR00598## N-(2-Chloro-6-methyl- phenyl)-2-[(4-methoxy-
phenyl)amino]-5- thiazolecarboxamide 1.63 558 ##STR00599##
N-(2-Chloro-6-methyl- phenyl)-2-[(3-methoxy- phenyl)amino]-5-
thiazolecarboxamide 1.70 559 ##STR00600## N-(2-Chloro-6-methyl-
phenyl)-2-[(2-methoxy- phenyl)amino]-5- thiazolecarboxamide 1.65
560 ##STR00601## N-(2-Chloro-6-methyl- phenyl)-2-[(3,5-
dimethoxyphenyl)- amino]-5- thiazolecarboxamide 1.55 561
##STR00602## N-(2-Chloro-6-methyl- phenyl)-2-[[4- (dimethylamino)-
phenyl]amino]-5- thiazolecarboxamide 1.25 562 ##STR00603##
N-(2-Chloro-6- methylphenyl)-2-[[4- (4-morpholinyl)phenyl]
amino]-5- thiazolecarboxamide 1.24 563 ##STR00604## N-(2-Chloro-6-
methylphenyl)-2-[[3- (carboxymethyl)- phenyl]amino]-5-
thiazolecarboxamide 1.36 564 ##STR00605## N-(2-Chloro-6-
methylphenyl)-2-[[3- (3-carboxypropyl)- phenyl]amino]-5-
thiazolecarboxamide 1.48 565 ##STR00606## N-(2-Chloro-6-
methylphenyl)-2-[[4- (carboxymethyl)phenyl] amino]-5-
thiazolecarboxamide 1.35 566 ##STR00607## N-(2-Chloro-6-
methylphenyl)-2-[(2- methyl-1H- benzimidazol-5- yl)amino]-5-
thiazolecarboxamide 1.27
Example 567
N-(2-Chloro-6-methylphenyl)-2-[[1-[3-(1H-imidazol-1-yl)propyl]-1H-benzimid-
azol-4-yl]amino]-5-thiazolecarboxamide
##STR00608##
[0525] A mixture of 1-bromo-3-chloropropane (10 mL, 0.10 mmole),
imidazole (6.81 gm, 0.10 mmole) in ethanolic NaOEt (41.3 mL, 21 wt
%, 1.1 mmole) was heated at reflux for 1 hr. After cooling to RT,
this was filtered and the filter cake was washed with EtOH. The
solvent was removed from the filtrate to afford crude
3-chloro-1-(imidazo-1-yl)-propane as an oil. A portion of the crude
chloride (1.07 gm, 7.40 mmole) was added to a mixture of
4-nitro-benzimidazole (1.09 gm, 6.66 mmole) and NaH (293 mg, 60% in
oil, 8.14 mmole) in DMF (15 mL). After being heated at 60.degree.
C. overnight and then 75.degree. C. for 3 hr, the solvent was
removed. The residue was partitioned between water and a mixture of
10% MeOH in DCM. The organic phase was separated, dried
(Na.sub.2SO.sub.4) and the solvents removed. Radial chromatography
(4 mm silica gel plate that was eluted with a step gradient of DCM
containing 2, 3, 4, . . . 10% MeOH) afforded the major product,
1-[3-imidazo-1-ylpropyl]-4-nitro-benzimidazole as a solid (513 mg,
28%). A mixture of this material (250 mg) and 10% palladium on
charcoal (200 mg) in EtOH (10 mL) under a hydrogen atmosphere
(balloon) was vigorously stirred for 1 hr. Removal of the catalyst
by filtration and the solvent under reduced pressure left the crude
4-amino-1-[3-imidazo-1-ylpropyl]-benzimidazole as a solid. A
portion of this material (46 mg, 0.191 mmole) was added to a
mixture of 319A (63 mg, 1.0 eq), an aqueous solution of HCl (0.24
mL, 1.0 M, 1.25 eq) and n-BuOH (1 mL). This was heated in a sealed
vial at 120.degree. C. for 44 hr. After cooling to RT, 567 (HPLC
retention time (YMC ODS S5 4.6.times.30 mm): 1.20 min) was isolated
by preparative HPLC.
Example 568
N-(2-Chloro-6-methylphenyl)-2-[[1-[2-(1H-imidazol-1-yl)ethyl]-1H-indazol-6-
-yl]amino]-5-thiazolecarboxamide
##STR00609##
[0527] A mixture of 1-bromo-2-chloroethane (4.6 mL, 0.055 mole),
imidazole (3.40 gm, 0.050 mole) in ethanolic NaOEt (19 mL, 21 wt %,
1 eq) was heated at reflux for 2 hr. After cooling to RT, the
reaction was filtered and the filter cake was washed with EtOH. The
solvent was removed from the filtrate to afford crude
2-chloro-1-(imidazo-1-yl)-ethane. A portion of the crude chloride
(2.24 gm, 17.2 mmole) was added to a mixture of 6-nitro-indazole
(1.63 gm, 10.0 mmole), K.sub.2CO.sub.3(1.50 mg, 1.1 eq), and KI
(1.70 gm, 1.1 eq) in DMF (15 mL). After being heated at 70.degree.
C. overnight and then 90.degree. C. for 4 hr, the solvent was
removed. The residue was partitioned between water and a mixture of
5% MeOH in DCM. The organic phase was separated, dried
(Na.sub.2SO.sub.4) and the solvents removed. Radial chromatography
(4 mm silica gel plate that was eluted with a step gradient of DCM
containing 0, 1, 2% MeOH) afforded 659 mg of
1-[2-imidazo-1-ylethyl]-6-nitro-indazole and 450 mg of the isomeric
2-[2-imidazo-1-ylethyl]-6-nitro-indazole. A mixture of
1-[2-imidazo-1-ylethyl]-6-nitro-indazole (650 mg) and 10% palladium
on charcoal (600 mg) in EtOH (10 mL) under a hydrogen atmosphere
(balloon) was vigorously stirred overnight. Removal of the catalyst
by filtration and the solvent under reduced pressure left the crude
6-amino-1-[2-imidazo-1-ylethyl]-indazole as a solid. A portion of
this material (68.1 mg, 1.5 eq) was added to a mixture of 556 (99.3
mg, 0.300 mmole), an aqueous solution of HCl (0.45 mL, 1.0 M, 1.5
eq) and n-BuOH (1.5 mL). This was heated in a sealed vial at
120.degree. C. for 44 hr. After cooling to RT, 568 (HPLC retention
time (YMC ODS S7 3.times.50 mm): 1.31 min) was isolated by
preparative HPLC.
Example 569
N-(2-Chloro-6-methylphenyl)-2-[[2-[2-(1H-imidazol-1-yl)ethyl]-2H-indazol-6-
-yl]amino]-5-thiazolecarboxamide
##STR00610##
[0529] Beginning with the isomeric
2-[2-imidazo-1-ylethyl]-6-nitro-indazole, 569 (HPLC retention time
(YMC ODS S7 3.times.50 mm): 1.28 min) was prepared in the same
manner as 568.
Example 570
N-(2-Chloro-6-methylphenyl)-2-[(1-methyl-1H-benzimidazol-6-yl)amino]-5-thi-
azolecarboxamide
##STR00611##
[0530] and
Example 571
N-(2-Chloro-6-methylphenyl)-2-[(1-methyl-1H-benzimidazol-5-yl)amino]-5-thi-
azolecarboxamide
##STR00612##
[0532] Beginning with 5-nitrobenzimidazole and methyl iodide, 570
(HPLC retention time (YMC ODS S7 3.times.50 mm): 1.23 min) and 571
(HPLC retention time (YMC ODS S7 3.times.50 mm): 1.23 min) were
prepared in the same manner as compounds 557 and 558.
Example 572
N-(2-Chloro-6-methylphenyl)-2-[[2-[3-(1H-imidazol-1-yl)propyl]amino]-1H-be-
nzimidazol-5-yl]amino]-5-thiazolecarboxamide
##STR00613##
[0534] A mixture of 2-chloro-5-nitro-benzimidazole (985 mg, 5.0
mmole) and 1-(3-aminopropyl)-imidazole (1.8 mL, 3 eq) in toluene
(15 mL) was heated at reflux for 5 hr. The reaction was partitioned
between EtOAc and brine to give a precipitate that was collected by
filtration. Flash chromatography of this material (silica gel;
stepwise gradient elution with mixtures of DCM containing 1, 2, 3,
. . . 10% MeOH) afforded
2-[3-[imidazo-1-yl]-propylamino]-5-nitro-benzimidazole (550 mg) as
a solid. This material was combined with 10% Pd on charcoal (500
mg), suspended in EtOH, and stirred under a hydrogen atmosphere
(balloon) overnight. Removal of the catalyst by filtration and the
solvent under reduced pressure left the crude
5-amino-2-[3-imidazo-1-ylpropylamino]-benzimidazole as a solid. A
portion of this material (77 mg, 0.30 mmole) was added to a mixture
of 319A (99 mg, 1.0 eq), an aqueous solution of HCl (0.60 mL, 1.0
M, 2 eq) and n-BuOH (1.5 mL). This was heated in a sealed vial at
120.degree. C. for 20 hr. After cooling to RT, 572 (HPLC retention
time (YMC ODS S7 3.times.50 mm): 1.20 min) was isolated by
preparative HPLC.
Example 573
N-(2-Chloro-6-methylphenyl)-2-[[2-(4-morpholinylmethyl)-1H-benzimidazol-5--
yl]amino]-5-thiazolecarboxamide
##STR00614##
[0536] A mixture of 3,4-diamino-nitrobenzene (15.3 g, 0.10 mole)
and chloroacetic acid (14.18 gm, 1.5 eq) in 5.0 N aqueous HCl (80
mL) was heated at reflux for 1 hr. After cooling to RT, the
reaction was filtered through celite and the filtrate was stored at
0.degree. C. for 2 days. The crystals that formed, were collected
and recrystallized from a mixture of EtOH and water to give 7.2 gm
of the hydrogen chloride salt of
2-chloromethyl-5-nitro-benzimidazole. A portion of this salt (528
mg, 2.13 mmole) and morpholine (1.31 mL, 7 eq) in toluene (15 mL)
were heated at reflux for 4 hr. After cooling to RT, the reaction
was filtered and the filter cake was washed with toluene. The
solvent was removed from the filtrate to leave the crude
2-[N-morpholinylmethyl]-5-nitro-benzimidazole as an oil. A portion
of this material (657 mg) and 10% palladium on charcoal (650 mg) in
EtOH (10 mL) was stirred overnight under a hydrogen atmosphere
(balloon). Removal of the catalyst by filtration and the solvent
left the crude 5-amino-2-[N-morpholinylmethyl]-benzimidazole as an
oil. A portion of this material was coupled with 556 as described
for 570 to afford 573 (HPLC retention time (YMC ODS S7 3.times.50
mm): 0.92 min).
Example 574
N-(2-Chloro-6-methylphenyl)-2-[[2-(1H-imidazol-1-ylmethyl)-1H-benzimidazol-
-5-yl]amino]-5-thiazolecarboxamide
##STR00615##
[0538] Beginning with imidazole and
2-chloromethyl-5-nitro-benzimidazole compound 574 (HPLC retention
time (YMC ODS S7 3.times.50 mm): 1.17 min) was prepared in the same
manner as compounds 570.
Example 575
N-(2-Chloro-6-methylphenyl)-2-[[3-[[5-(1H-imidazol-1-yl)-2-pyridinyl]amino-
]phenyl]amino]-5-thiazolecarboxamide
##STR00616##
[0540] A mixture of 3-nitroaniline (2.91 gm, 21.1 mmole) and
2,5-dibromopyridine (5.0 gm, 1 eq) was heated at 185.degree. C. for
1 hr. After cooling to RT, the solid was broken up and treated with
a mixture of saturated aq. NaHCO.sub.3 and 10% MeOH in DCM. The
suspended solid was collected by filtration and washed with a
little 10% MeOH in DCM and then water to leave, after drying, 3.72
gm of crude N-[5-bromo-pyridin-2-yl]-5-nitroaniline. A portion of
this material (500 mg, 1.70 mmole) was combined with imidazole (116
mg, 1 eq), CuI (81 mg, 0.25 eq), and K.sub.2CO.sub.3 (235 mg, 1 eq)
in DMF (2 mL) and the mixture was heated at 130.degree. C. for 2
days. After cooling to RT, the solvent was removed and the residue
was partitioned between water and a mixture of 20% MeOH in DCM. The
organic phase was removed, dried (Na.sub.2SO.sub.4), and the
solvents removed to leave the crude
N-[5-imidazo-1-yl]-pyridin-2-yl]-5-nitroaniline as a solid. This
was taken and treated with 10% palladium on charcoal (650 mg) in
EtOH under a hydrogen atmosphere for 1.5 hr. Removal of the
catalyst and then the solvent left the crude
N-[5-imidazo-1-yl]-pyridin-2-yl]-5-aminoaniline. It was purified by
radial chromatography (4 mm silica gel plate that was eluted with a
step gradient of DCM containing 1, 2, 3, . . . 6% MeOH). The
aniline was then coupled with 319A as described for 570 to afford
575 (HPLC retention time (YMC ODS S5 4.6.times.30 mm): 1.42
min).
Example 576
N-(2-Chloro-6-methylphenyl)-2-[[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]amin-
o]-5-thiazolecarboxamide
##STR00617##
[0541] and
Example 577
N-(2-Chloro-6-methylphenyl)-2-[[4-[3-(1H-imidazol-1-yl)propoxy]phenyl]amin-
o]-5-thiazolecarboxamide
##STR00618##
[0543] A suspension of 3-nitrophenol (837 mg, 6.02 mmole),
1-chloro-3-[imidazo-1-yl]-propane (871 mg, 1 eq), K.sub.2CO.sub.3
(3.3 gm, 4 eq) and NaI (1.0 gm, 1.1 eq) in DMF was heated at
120.degree. C. for 6 hr. After cooling to RT, the reaction was
filtered and the filter cake was washed with DMF. The solvent was
removed from the filtrate and the residue was chromatographed
(radial chromatography; 4 mm silica gel plate that was eluted with
a step gradient of DCM containing 0, 1, 2.5, 5, 7.5% MeOH) to
afford 400 mg of 3-[3-imidazo-1-ylpropyloxy]]-nitrobenzene. This
was treated with 10% palladium on charcoal (400 mg) in EtOH under a
hydrogen atmosphere for 4 hr. Removal of the catalyst and the
solvent left 3-[3-imidazo-1-ylpropyloxy]]-aniline was then coupled
with 319A as described for 570 to afford 576 (HPLC retention time
(YMC ODS S5 4.6.times.30 mm): 1.33 min). Beginning with
4-nitrophenol and 1-chloro-3-[imidazo-1-yl]-propane 577 (HPLC
retention time (YMC ODS S5 4.6.times.30 mm): 1.42 min) was prepared
in a similar manner as 576.
Example 578
N-(2-Chloro-6-methylphenyl)-2-[[4-[2-(1H-imidazol-1-yl)ethoxy]-3-methoxyph-
enyl]amino]-5-thiazolecarboxamide
##STR00619##
[0545] Beginning with 2-methoxy-4-nitrophenol and
1-chloro-3-[imidazo-1-yl]-ethane, 578 (HPLC retention time (YMC ODS
S5 4.6.times.30 mm): 1.35 min) was prepared in a similar manner as
576.
Example 579
N-(2-Chloro-6-methylphenyl)-2-[[3-[[[3-(1H-imidazol-1-yl)propyl]amino]sulf-
onyl]phenyl]amino]-5-thiazolecarboxamide
##STR00620##
[0546] and
Example 580
N-(2-Chloro-6-methylphenyl)-2-[[4-[[[3-(1H-imidazol-1-yl)propyl]amino]sulf-
onyl]phenyl]amino]-5-thiazolecarboxamide
##STR00621##
[0548] 3-Imidazo-1-yl-propylamine (2.04 mL, 2.5 eq) was added to a
solution of 3-nitro-benzenesulfonyl chloride (1.5 gm, 6.77 mmole)
in THF (20 mL) at RT. After 1 hr, the solvent was removed and the
residue was partitioned between water and a mixture of 10% MeOH in
DCM. The organic phase was separated, washed with water and dried
(Na2SO4). The crude
N-[3-[imidazo-1-yl]-propyl]-3-nitro-benzenesulfonamide was treated
with 10% palladium on charcoal (2 gm) in THF (60 mL) under a
hydrogen atmosphere overnight. Removal of the catalyst and then the
solvent left crude
3-amino-N-[3-[imidazo-1-yl]-propyl]-benzenesulfonamide which was
then coupled with 319A as described for 570 to afford 579 (HPLC
retention time (YMC ODS S7 3.times.50 mm): 1.22 min). Beginning
with 4-nitro-benzenesulfonyl chloride and
3-[imidazo-1-yl]-propylamine, 580 (HPLC retention time (YMC ODS S7
3.times.50 mm): 1.21 min) was prepared in a similar manner as
579.
* * * * *